id	sid	tid	token	lemma	pos
amwa-17	1	1	64	64	NUM
amwa-17	1	2	amwa	amwa	PROPN
amwa-17	1	3	journal	journal	PROPN
amwa-17	1	4	/	/	SYM
amwa-17	1	5	v36	v36	PROPN
amwa-17	1	6	n2	n2	PROPN
amwa-17	1	7	/	/	SYM
amwa-17	1	8	2021	2021	NUM
amwa-17	1	9	/	/	SYM
amwa-17	1	10	amwa.org	amwa.org	X
amwa-17	1	11	abstract	abstract	NOUN
amwa-17	1	12	the	the	DET
amwa-17	1	13	coronavirus	coronavirus	NOUN
amwa-17	1	14	disease	disease	NOUN
amwa-17	1	15	2019	2019	NUM
amwa-17	1	16	(	(	PUNCT
amwa-17	1	17	covid-19	covid-19	PROPN
amwa-17	1	18	)	)	PUNCT
amwa-17	1	19	pandemic	pandemic	NOUN
amwa-17	1	20	has	have	AUX
amwa-17	1	21	necessitated	necessitate	VERB
amwa-17	1	22	that	that	SCONJ
amwa-17	1	23	medical	medical	ADJ
amwa-17	1	24	writers	writer	NOUN
amwa-17	1	25	adapt	adapt	VERB
amwa-17	1	26	their	their	PRON
amwa-17	1	27	work	work	NOUN
amwa-17	1	28	practices	practice	NOUN
amwa-17	1	29	quickly	quickly	ADV
amwa-17	1	30	to	to	PART
amwa-17	1	31	assist	assist	VERB
amwa-17	1	32	with	with	ADP
amwa-17	1	33	the	the	DET
amwa-17	1	34	preparation	preparation	NOUN
amwa-17	1	35	of	of	ADP
amwa-17	1	36	documentation	documentation	NOUN
amwa-17	1	37	related	relate	VERB
amwa-17	1	38	to	to	ADP
amwa-17	1	39	covid-19	covid-19	PROPN
amwa-17	1	40	research	research	NOUN
amwa-17	1	41	and	and	CCONJ
amwa-17	1	42	clinical	clinical	ADJ
amwa-17	1	43	trials	trial	NOUN
amwa-17	1	44	,	,	PUNCT
amwa-17	1	45	as	as	ADV
amwa-17	1	46	well	well	ADV
amwa-17	1	47	as	as	ADP
amwa-17	1	48	to	to	PART
amwa-17	1	49	assess	assess	VERB
amwa-17	1	50	the	the	DET
amwa-17	1	51	impact	impact	NOUN
amwa-17	1	52	of	of	ADP
amwa-17	1	53	the	the	DET
amwa-17	1	54	pandemic	pandemic	NOUN
amwa-17	1	55	on	on	ADP
amwa-17	1	56	other	other	ADJ
amwa-17	1	57	clinical	clinical	ADJ
amwa-17	1	58	trials	trial	NOUN
amwa-17	1	59	.	.	PUNCT
amwa-17	2	1	complexities	complexity	NOUN
amwa-17	2	2	and	and	CCONJ
amwa-17	2	3	challenges	challenge	VERB
amwa-17	2	4	medical	medical	ADJ
amwa-17	2	5	writers	writer	NOUN
amwa-17	2	6	have	have	AUX
amwa-17	2	7	faced	face	VERB
amwa-17	2	8	include	include	VERB
amwa-17	2	9	the	the	DET
amwa-17	2	10	growing	grow	VERB
amwa-17	2	11	scientific	scientific	ADJ
amwa-17	2	12	knowledge	knowledge	NOUN
amwa-17	2	13	of	of	ADP
amwa-17	2	14	the	the	DET
amwa-17	2	15	virus	virus	NOUN
amwa-17	2	16	,	,	PUNCT
amwa-17	2	17	the	the	DET
amwa-17	2	18	burgeoning	burgeon	VERB
amwa-17	2	19	global	global	ADJ
amwa-17	2	20	footprint	footprint	NOUN
amwa-17	2	21	of	of	ADP
amwa-17	2	22	the	the	DET
amwa-17	2	23	pandemic	pandemic	NOUN
amwa-17	2	24	,	,	PUNCT
amwa-17	2	25	and	and	CCONJ
amwa-17	2	26	the	the	DET
amwa-17	2	27	evolving	evolve	VERB
amwa-17	2	28	regulatory	regulatory	ADJ
amwa-17	2	29	landscape	landscape	NOUN
amwa-17	2	30	on	on	ADP
amwa-17	2	31	both	both	CCONJ
amwa-17	2	32	covid-19	covid-19	PROPN
amwa-17	2	33	and	and	CCONJ
amwa-17	2	34	non	non	ADJ
amwa-17	2	35	-	-	ADJ
amwa-17	2	36	covid-19	covid-19	ADJ
amwa-17	2	37	clinical	clinical	ADJ
amwa-17	2	38	trials	trial	NOUN
amwa-17	2	39	.	.	PUNCT
amwa-17	3	1	introduction	introduction	NOUN
amwa-17	3	2	when	when	SCONJ
amwa-17	3	3	cases	case	NOUN
amwa-17	3	4	of	of	ADP
amwa-17	3	5	a	a	DET
amwa-17	3	6	novel	novel	ADJ
amwa-17	3	7	coronavirus	coronavirus	NOUN
amwa-17	3	8	,	,	PUNCT
amwa-17	3	9	severe	severe	ADJ
amwa-17	3	10	acute	acute	ADJ
amwa-17	3	11	respiratory	respiratory	ADJ
amwa-17	3	12	syndrome	syndrome	NOUN
amwa-17	3	13	coronavirus	coronavirus	NOUN
amwa-17	3	14	2	2	NUM
amwa-17	3	15	(	(	PUNCT
amwa-17	3	16	sars	sar	NOUN
amwa-17	3	17	-	-	PUNCT
amwa-17	3	18	cov-2	cov-2	NOUN
amwa-17	3	19	)	)	PUNCT
amwa-17	3	20	,	,	PUNCT
amwa-17	3	21	surfaced	surface	VERB
amwa-17	3	22	in	in	ADP
amwa-17	3	23	the	the	DET
amwa-17	3	24	hubei	hubei	PROPN
amwa-17	3	25	province	province	NOUN
amwa-17	3	26	of	of	ADP
amwa-17	3	27	china	china	PROPN
amwa-17	3	28	in	in	ADP
amwa-17	3	29	december	december	PROPN
amwa-17	3	30	2019	2019	NUM
amwa-17	3	31	,	,	PUNCT
amwa-17	3	32	leading	lead	VERB
amwa-17	3	33	to	to	ADP
amwa-17	3	34	the	the	DET
amwa-17	3	35	outbreak	outbreak	NOUN
amwa-17	3	36	of	of	ADP
amwa-17	3	37	a	a	DET
amwa-17	3	38	complex	complex	ADJ
amwa-17	3	39	respiratory	respiratory	ADJ
amwa-17	3	40	illness	illness	NOUN
amwa-17	3	41	(	(	PUNCT
amwa-17	3	42	later	later	ADV
amwa-17	3	43	coined	coined	ADJ
amwa-17	3	44	coronavirus	coronavirus	NOUN
amwa-17	3	45	disease	disease	NOUN
amwa-17	3	46	2019	2019	NUM
amwa-17	3	47	[	[	X
amwa-17	3	48	covid-19	covid-19	PROPN
amwa-17	3	49	]	]	PUNCT
amwa-17	3	50	)	)	PUNCT
amwa-17	3	51	,	,	PUNCT
amwa-17	3	52	the	the	DET
amwa-17	3	53	world	world	NOUN
amwa-17	3	54	watched	watch	VERB
amwa-17	3	55	to	to	PART
amwa-17	3	56	see	see	VERB
amwa-17	3	57	what	what	PRON
amwa-17	3	58	would	would	AUX
amwa-17	3	59	happen	happen	VERB
amwa-17	3	60	next	next	ADV
amwa-17	3	61	.	.	PUNCT
amwa-17	4	1	many	many	ADJ
amwa-17	4	2	were	be	AUX
amwa-17	4	3	cautiously	cautiously	ADV
amwa-17	4	4	optimistic	optimistic	ADJ
amwa-17	4	5	that	that	SCONJ
amwa-17	4	6	the	the	DET
amwa-17	4	7	virus	virus	NOUN
amwa-17	4	8	would	would	AUX
amwa-17	4	9	remain	remain	VERB
amwa-17	4	10	endemic	endemic	ADJ
amwa-17	4	11	to	to	ADP
amwa-17	4	12	the	the	DET
amwa-17	4	13	region	region	NOUN
amwa-17	4	14	of	of	ADP
amwa-17	4	15	the	the	DET
amwa-17	4	16	outbreak	outbreak	NOUN
amwa-17	4	17	,	,	PUNCT
amwa-17	4	18	as	as	SCONJ
amwa-17	4	19	middle	middle	PROPN
amwa-17	4	20	east	east	PROPN
amwa-17	4	21	respiratory	respiratory	ADJ
amwa-17	4	22	syndrome	syndrome	NOUN
amwa-17	4	23	(	(	PUNCT
amwa-17	4	24	mers	mer	NOUN
amwa-17	4	25	)	)	PUNCT
amwa-17	4	26	had	have	VERB
amwa-17	4	27	in	in	ADP
amwa-17	4	28	2012,1	2012,1	NUM
amwa-17	4	29	or	or	CCONJ
amwa-17	4	30	,	,	PUNCT
amwa-17	4	31	at	at	ADP
amwa-17	4	32	worst	bad	ADJ
amwa-17	4	33	,	,	PUNCT
amwa-17	4	34	that	that	SCONJ
amwa-17	4	35	it	it	PRON
amwa-17	4	36	could	could	AUX
amwa-17	4	37	be	be	AUX
amwa-17	4	38	contained	contain	VERB
amwa-17	4	39	as	as	ADP
amwa-17	4	40	the	the	DET
amwa-17	4	41	severe	severe	ADJ
amwa-17	4	42	acute	acute	ADJ
amwa-17	4	43	respiratory	respiratory	ADJ
amwa-17	4	44	syndrome	syndrome	NOUN
amwa-17	4	45	(	(	PUNCT
amwa-17	4	46	sars	sars	PROPN
amwa-17	4	47	)	)	PUNCT
amwa-17	4	48	epidemic	epidemic	NOUN
amwa-17	4	49	had	have	AUX
amwa-17	4	50	been	be	AUX
amwa-17	4	51	in	in	ADP
amwa-17	4	52	2003.2	2003.2	NUM
amwa-17	4	53	the	the	DET
amwa-17	4	54	challenge	challenge	NOUN
amwa-17	4	55	of	of	ADP
amwa-17	4	56	trying	try	VERB
amwa-17	4	57	to	to	PART
amwa-17	4	58	contain	contain	VERB
amwa-17	4	59	the	the	DET
amwa-17	4	60	novel	novel	ADJ
amwa-17	4	61	coronavirus	coronavirus	NOUN
amwa-17	4	62	was	be	AUX
amwa-17	4	63	complicated	complicate	VERB
amwa-17	4	64	by	by	ADP
amwa-17	4	65	a	a	DET
amwa-17	4	66	lack	lack	NOUN
amwa-17	4	67	of	of	ADP
amwa-17	4	68	clarity	clarity	NOUN
amwa-17	4	69	on	on	ADP
amwa-17	4	70	exactly	exactly	ADV
amwa-17	4	71	how	how	SCONJ
amwa-17	4	72	it	it	PRON
amwa-17	4	73	was	be	AUX
amwa-17	4	74	transmitted3	transmitted3	ADJ
amwa-17	4	75	;	;	PUNCT
amwa-17	4	76	it	it	PRON
amwa-17	4	77	was	be	AUX
amwa-17	4	78	not	not	PART
amwa-17	4	79	until	until	ADP
amwa-17	4	80	january	january	PROPN
amwa-17	4	81	19	19	NUM
amwa-17	4	82	,	,	PUNCT
amwa-17	4	83	2020	2020	NUM
amwa-17	4	84	,	,	PUNCT
amwa-17	4	85	that	that	SCONJ
amwa-17	4	86	the	the	DET
amwa-17	4	87	world	world	PROPN
amwa-17	4	88	health	health	NOUN
amwa-17	4	89	organization	organization	NOUN
amwa-17	4	90	(	(	PUNCT
amwa-17	4	91	who	who	PRON
amwa-17	4	92	)	)	PUNCT
amwa-17	4	93	announced	announce	VERB
amwa-17	4	94	that	that	SCONJ
amwa-17	4	95	there	there	PRON
amwa-17	4	96	was	be	VERB
amwa-17	4	97	evidence	evidence	NOUN
amwa-17	4	98	of	of	ADP
amwa-17	4	99	human	human	ADJ
amwa-17	4	100	-	-	PUNCT
amwa-17	4	101	tohuman	tohuman	NOUN
amwa-17	4	102	transmission	transmission	NOUN
amwa-17	4	103	of	of	ADP
amwa-17	4	104	the	the	DET
amwa-17	4	105	virus.4	virus.4	NOUN
amwa-17	4	106	this	this	DET
amwa-17	4	107	article	article	NOUN
amwa-17	4	108	provides	provide	VERB
amwa-17	4	109	a	a	DET
amwa-17	4	110	brief	brief	ADJ
amwa-17	4	111	overview	overview	NOUN
amwa-17	4	112	of	of	ADP
amwa-17	4	113	the	the	DET
amwa-17	4	114	covid-19	covid-19	PROPN
amwa-17	4	115	pandemic	pandemic	ADJ
amwa-17	4	116	time	time	NOUN
amwa-17	4	117	course	course	NOUN
amwa-17	4	118	,	,	PUNCT
amwa-17	4	119	the	the	DET
amwa-17	4	120	regulatory	regulatory	ADJ
amwa-17	4	121	actions	action	NOUN
amwa-17	4	122	taken	take	VERB
amwa-17	4	123	to	to	PART
amwa-17	4	124	allow	allow	VERB
amwa-17	4	125	for	for	ADP
amwa-17	4	126	unprecedented	unprecedented	ADJ
amwa-17	4	127	rapid	rapid	ADJ
amwa-17	4	128	development	development	NOUN
amwa-17	4	129	of	of	ADP
amwa-17	4	130	diagnostic	diagnostic	ADJ
amwa-17	4	131	and	and	CCONJ
amwa-17	4	132	therapeutic	therapeutic	ADJ
amwa-17	4	133	products	product	NOUN
amwa-17	4	134	in	in	ADP
amwa-17	4	135	the	the	DET
amwa-17	4	136	united	united	PROPN
amwa-17	4	137	states	states	PROPN
amwa-17	4	138	for	for	ADP
amwa-17	4	139	covid-19	covid-19	PROPN
amwa-17	4	140	,	,	PUNCT
amwa-17	4	141	and	and	CCONJ
amwa-17	4	142	the	the	DET
amwa-17	4	143	impact	impact	NOUN
amwa-17	4	144	of	of	ADP
amwa-17	4	145	the	the	DET
amwa-17	4	146	pandemic	pandemic	NOUN
amwa-17	4	147	on	on	ADP
amwa-17	4	148	medical	medical	ADJ
amwa-17	4	149	writers	writer	NOUN
amwa-17	4	150	in	in	ADP
amwa-17	4	151	the	the	DET
amwa-17	4	152	biotech	biotech	ADJ
amwa-17	4	153	and	and	CCONJ
amwa-17	4	154	pharmaceutical	pharmaceutical	NOUN
amwa-17	4	155	industry	industry	NOUN
amwa-17	4	156	.	.	PUNCT
amwa-17	5	1	arrival	arrival	NOUN
amwa-17	5	2	of	of	ADP
amwa-17	5	3	covid-19	covid-19	PROPN
amwa-17	5	4	in	in	ADP
amwa-17	5	5	the	the	DET
amwa-17	5	6	united	united	PROPN
amwa-17	5	7	states	states	PROPN
amwa-17	5	8	and	and	CCONJ
amwa-17	5	9	initial	initial	ADJ
amwa-17	5	10	impact	impact	NOUN
amwa-17	5	11	on	on	ADP
amwa-17	5	12	biotech	biotech	ADJ
amwa-17	5	13	and	and	CCONJ
amwa-17	5	14	pharmaceutical	pharmaceutical	NOUN
amwa-17	5	15	companies	company	NOUN
amwa-17	5	16	a	a	DET
amwa-17	5	17	recent	recent	ADJ
amwa-17	5	18	retrospective	retrospective	ADJ
amwa-17	5	19	analysis	analysis	NOUN
amwa-17	5	20	of	of	ADP
amwa-17	5	21	sars	sar	NOUN
amwa-17	5	22	-	-	PUNCT
amwa-17	5	23	cov-2	cov-2	NOUN
amwa-17	5	24	–	–	PUNCT
amwa-17	5	25	reactive	reactive	ADJ
amwa-17	5	26	antibodies	antibody	NOUN
amwa-17	5	27	in	in	ADP
amwa-17	5	28	archived	archive	VERB
amwa-17	5	29	blood	blood	NOUN
amwa-17	5	30	donation	donation	NOUN
amwa-17	5	31	samples	sample	NOUN
amwa-17	5	32	,	,	PUNCT
amwa-17	5	33	spanning	span	VERB
amwa-17	5	34	9	9	NUM
amwa-17	5	35	states	state	NOUN
amwa-17	5	36	from	from	ADP
amwa-17	5	37	the	the	DET
amwa-17	5	38	east	east	NOUN
amwa-17	5	39	to	to	ADP
amwa-17	5	40	west	west	PROPN
amwa-17	5	41	coasts	coast	NOUN
amwa-17	5	42	,	,	PUNCT
amwa-17	5	43	indicates	indicate	VERB
amwa-17	5	44	that	that	SCONJ
amwa-17	5	45	covid-19	covid-19	PROPN
amwa-17	5	46	may	may	AUX
amwa-17	5	47	have	have	AUX
amwa-17	5	48	been	be	AUX
amwa-17	5	49	widely	widely	ADV
amwa-17	5	50	introduced	introduce	VERB
amwa-17	5	51	into	into	ADP
amwa-17	5	52	the	the	DET
amwa-17	5	53	united	united	PROPN
amwa-17	5	54	states	states	PROPN
amwa-17	5	55	as	as	ADV
amwa-17	5	56	early	early	ADV
amwa-17	5	57	as	as	ADP
amwa-17	5	58	mid	mid	NOUN
amwa-17	5	59	-	-	PROPN
amwa-17	5	60	december	december	PROPN
amwa-17	5	61	2019.5	2019.5	NUM
amwa-17	5	62	despite	despite	SCONJ
amwa-17	5	63	the	the	DET
amwa-17	5	64	first	first	ADJ
amwa-17	5	65	cases	case	NOUN
amwa-17	5	66	of	of	ADP
amwa-17	5	67	covid-19	covid-19	PROPN
amwa-17	5	68	being	be	AUX
amwa-17	5	69	observed	observe	VERB
amwa-17	5	70	in	in	ADP
amwa-17	5	71	the	the	DET
amwa-17	5	72	united	united	PROPN
amwa-17	5	73	states	states	PROPN
amwa-17	5	74	and	and	CCONJ
amwa-17	5	75	europe	europe	PROPN
amwa-17	5	76	on	on	SCONJ
amwa-17	5	77	january	january	PROPN
amwa-17	5	78	19	19	NUM
amwa-17	5	79	and	and	CCONJ
amwa-17	5	80	24	24	NUM
amwa-17	5	81	,	,	PUNCT
amwa-17	5	82	2020	2020	NUM
amwa-17	5	83	,	,	PUNCT
amwa-17	5	84	respectively	respectively	ADV
amwa-17	5	85	(	(	PUNCT
amwa-17	5	86	figure),4,6	figure),4,6	NUM
amwa-17	5	87	operations	operation	NOUN
amwa-17	5	88	for	for	ADP
amwa-17	5	89	biotech	biotech	ADJ
amwa-17	5	90	and	and	CCONJ
amwa-17	5	91	pharmaceutical	pharmaceutical	NOUN
amwa-17	5	92	companies	company	NOUN
amwa-17	5	93	in	in	ADP
amwa-17	5	94	the	the	DET
amwa-17	5	95	united	united	PROPN
amwa-17	5	96	states	states	PROPN
amwa-17	5	97	continued	continue	VERB
amwa-17	5	98	as	as	ADP
amwa-17	5	99	normal	normal	ADJ
amwa-17	5	100	into	into	ADP
amwa-17	5	101	february	february	PROPN
amwa-17	5	102	.	.	PUNCT
amwa-17	6	1	on	on	ADP
amwa-17	6	2	february	february	PROPN
amwa-17	6	3	26	26	NUM
amwa-17	6	4	and	and	CCONJ
amwa-17	6	5	27	27	NUM
amwa-17	6	6	,	,	PUNCT
amwa-17	6	7	a	a	DET
amwa-17	6	8	large	large	ADJ
amwa-17	6	9	conference	conference	NOUN
amwa-17	6	10	was	be	AUX
amwa-17	6	11	hosted	host	VERB
amwa-17	6	12	by	by	ADP
amwa-17	6	13	a	a	DET
amwa-17	6	14	biotech	biotech	ADJ
amwa-17	6	15	company	company	NOUN
amwa-17	6	16	in	in	ADP
amwa-17	6	17	boston	boston	PROPN
amwa-17	6	18	,	,	PUNCT
amwa-17	6	19	massachusetts	massachusetts	PROPN
amwa-17	6	20	,	,	PUNCT
amwa-17	6	21	which	which	PRON
amwa-17	6	22	was	be	AUX
amwa-17	6	23	later	later	ADV
amwa-17	6	24	deemed	deem	VERB
amwa-17	6	25	a	a	DET
amwa-17	6	26	“	"	PUNCT
amwa-17	6	27	superspreader	superspreader	NOUN
amwa-17	6	28	”	"	PUNCT
amwa-17	6	29	event,7	event,7	NOUN
amwa-17	6	30	with	with	ADP
amwa-17	6	31	approximately	approximately	ADV
amwa-17	6	32	100	100	NUM
amwa-17	6	33	diagnosed	diagnose	VERB
amwa-17	6	34	cases	case	NOUN
amwa-17	6	35	after	after	SCONJ
amwa-17	6	36	the	the	DET
amwa-17	6	37	event	event	NOUN
amwa-17	6	38	ultimately	ultimately	ADV
amwa-17	6	39	being	be	AUX
amwa-17	6	40	associated	associate	VERB
amwa-17	6	41	by	by	ADP
amwa-17	6	42	genomic	genomic	ADJ
amwa-17	6	43	analysis	analysis	NOUN
amwa-17	6	44	with	with	ADP
amwa-17	6	45	up	up	ADP
amwa-17	6	46	to	to	PART
amwa-17	6	47	330,000	330,000	NUM
amwa-17	6	48	subsequent	subsequent	ADJ
amwa-17	6	49	cases	case	NOUN
amwa-17	6	50	.	.	PUNCT
amwa-17	7	1	following	follow	VERB
amwa-17	7	2	this	this	DET
amwa-17	7	3	event	event	NOUN
amwa-17	7	4	,	,	PUNCT
amwa-17	7	5	biotech	biotech	NOUN
amwa-17	7	6	and	and	CCONJ
amwa-17	7	7	pharmaceutical	pharmaceutical	NOUN
amwa-17	7	8	companies	company	NOUN
amwa-17	7	9	across	across	ADP
amwa-17	7	10	the	the	DET
amwa-17	7	11	united	united	PROPN
amwa-17	7	12	states	states	PROPN
amwa-17	7	13	,	,	PUNCT
amwa-17	7	14	particularly	particularly	ADV
amwa-17	7	15	those	those	PRON
amwa-17	7	16	in	in	ADP
amwa-17	7	17	states	state	NOUN
amwa-17	7	18	experiencing	experience	VERB
amwa-17	7	19	a	a	DET
amwa-17	7	20	surge	surge	NOUN
amwa-17	7	21	in	in	ADP
amwa-17	7	22	cases	case	NOUN
amwa-17	7	23	,	,	PUNCT
amwa-17	7	24	began	begin	VERB
amwa-17	7	25	enacting	enact	VERB
amwa-17	7	26	business	business	NOUN
amwa-17	7	27	continuity	continuity	NOUN
amwa-17	7	28	plans	plan	NOUN
amwa-17	7	29	per	per	ADP
amwa-17	7	30	local	local	ADJ
amwa-17	7	31	and	and	CCONJ
amwa-17	7	32	state	state	NOUN
amwa-17	7	33	guidelines	guideline	NOUN
amwa-17	7	34	,	,	PUNCT
amwa-17	7	35	including	include	VERB
amwa-17	7	36	sheltering	shelter	VERB
amwa-17	7	37	in	in	ADP
amwa-17	7	38	place	place	NOUN
amwa-17	7	39	to	to	ADP
amwa-17	7	40	the	the	DET
amwa-17	7	41	extent	extent	NOUN
amwa-17	7	42	possible	possible	ADJ
amwa-17	7	43	.	.	PUNCT
amwa-17	8	1	meanwhile	meanwhile	ADV
amwa-17	8	2	,	,	PUNCT
amwa-17	8	3	a	a	DET
amwa-17	8	4	shortage	shortage	NOUN
amwa-17	8	5	of	of	ADP
amwa-17	8	6	personal	personal	ADJ
amwa-17	8	7	protective	protective	ADJ
amwa-17	8	8	equipment	equipment	NOUN
amwa-17	8	9	led	lead	VERB
amwa-17	8	10	many	many	ADJ
amwa-17	8	11	companies	company	NOUN
amwa-17	8	12	to	to	PART
amwa-17	8	13	donate	donate	VERB
amwa-17	8	14	their	their	PRON
amwa-17	8	15	current	current	ADJ
amwa-17	8	16	laboratory	laboratory	NOUN
amwa-17	8	17	supplies	supply	NOUN
amwa-17	8	18	to	to	ADP
amwa-17	8	19	local	local	ADJ
amwa-17	8	20	health	health	NOUN
amwa-17	8	21	care	care	NOUN
amwa-17	8	22	centers	center	NOUN
amwa-17	8	23	in	in	ADP
amwa-17	8	24	surge	surge	NOUN
amwa-17	8	25	states	state	NOUN
amwa-17	8	26	in	in	ADP
amwa-17	8	27	early	early	ADJ
amwa-17	8	28	spring.8	spring.8	PROPN
amwa-17	8	29	for	for	ADP
amwa-17	8	30	those	those	DET
amwa-17	8	31	employees	employee	NOUN
amwa-17	8	32	who	who	PRON
amwa-17	8	33	did	do	AUX
amwa-17	8	34	have	have	VERB
amwa-17	8	35	to	to	PART
amwa-17	8	36	go	go	VERB
amwa-17	8	37	on	on	ADP
amwa-17	8	38	site	site	NOUN
amwa-17	8	39	at	at	ADP
amwa-17	8	40	their	their	PRON
amwa-17	8	41	companies	company	NOUN
amwa-17	8	42	to	to	PART
amwa-17	8	43	perform	perform	VERB
amwa-17	8	44	experiments	experiment	NOUN
amwa-17	8	45	,	,	PUNCT
amwa-17	8	46	a	a	DET
amwa-17	8	47	lack	lack	NOUN
amwa-17	8	48	of	of	ADP
amwa-17	8	49	covid-19	covid-19	PROPN
amwa-17	8	50	testing	testing	NOUN
amwa-17	8	51	supplies	supply	NOUN
amwa-17	8	52	contributed	contribute	VERB
amwa-17	8	53	to	to	ADP
amwa-17	8	54	uncertainty	uncertainty	NOUN
amwa-17	8	55	for	for	ADP
amwa-17	8	56	how	how	SCONJ
amwa-17	8	57	to	to	PART
amwa-17	8	58	continue	continue	VERB
amwa-17	8	59	critical	critical	ADJ
amwa-17	8	60	research	research	NOUN
amwa-17	8	61	while	while	SCONJ
amwa-17	8	62	minimizing	minimize	VERB
amwa-17	8	63	the	the	DET
amwa-17	8	64	risk	risk	NOUN
amwa-17	8	65	for	for	ADP
amwa-17	8	66	virus	virus	NOUN
amwa-17	8	67	spread	spread	VERB
amwa-17	8	68	.	.	PUNCT
amwa-17	9	1	with	with	ADP
amwa-17	9	2	guidelines	guideline	NOUN
amwa-17	9	3	on	on	ADP
amwa-17	9	4	safe	safe	ADJ
amwa-17	9	5	business	business	NOUN
amwa-17	9	6	operation	operation	NOUN
amwa-17	9	7	being	be	AUX
amwa-17	9	8	issued	issue	VERB
amwa-17	9	9	at	at	ADP
amwa-17	9	10	the	the	DET
amwa-17	9	11	state	state	NOUN
amwa-17	9	12	level	level	NOUN
amwa-17	9	13	,	,	PUNCT
amwa-17	9	14	it	it	PRON
amwa-17	9	15	was	be	AUX
amwa-17	9	16	not	not	PART
amwa-17	9	17	immediately	immediately	ADV
amwa-17	9	18	clear	clear	ADJ
amwa-17	9	19	how	how	SCONJ
amwa-17	9	20	planned	planned	ADJ
amwa-17	9	21	research	research	NOUN
amwa-17	9	22	and	and	CCONJ
amwa-17	9	23	development	development	NOUN
amwa-17	9	24	(	(	PUNCT
amwa-17	9	25	r&d	r&d	NOUN
amwa-17	9	26	)	)	PUNCT
amwa-17	9	27	activities	activity	NOUN
amwa-17	9	28	would	would	AUX
amwa-17	9	29	be	be	AUX
amwa-17	9	30	impacted	impact	VERB
amwa-17	9	31	or	or	CCONJ
amwa-17	9	32	for	for	ADP
amwa-17	9	33	how	how	SCONJ
amwa-17	9	34	long	long	ADJ
amwa-17	9	35	.	.	PUNCT
amwa-17	10	1	to	to	PART
amwa-17	10	2	address	address	VERB
amwa-17	10	3	local	local	ADJ
amwa-17	10	4	social	social	ADJ
amwa-17	10	5	distancing	distancing	NOUN
amwa-17	10	6	requirements	requirement	NOUN
amwa-17	10	7	,	,	PUNCT
amwa-17	10	8	some	some	DET
amwa-17	10	9	companies	company	NOUN
amwa-17	10	10	had	have	VERB
amwa-17	10	11	to	to	PART
amwa-17	10	12	prioritize	prioritize	VERB
amwa-17	10	13	laboratory	laboratory	NOUN
amwa-17	10	14	research	research	NOUN
amwa-17	10	15	for	for	ADP
amwa-17	10	16	covid-19	covid-19	PROPN
amwa-17	10	17	and	and	CCONJ
amwa-17	10	18	for	for	ADP
amwa-17	10	19	certain	certain	ADJ
amwa-17	10	20	conditions	condition	NOUN
amwa-17	10	21	with	with	ADP
amwa-17	10	22	unmet	unmet	NOUN
amwa-17	10	23	need.9	need.9	PROPN
amwa-17	10	24	it	it	PRON
amwa-17	10	25	was	be	AUX
amwa-17	10	26	also	also	ADV
amwa-17	10	27	not	not	PART
amwa-17	10	28	immediately	immediately	ADV
amwa-17	10	29	clear	clear	ADJ
amwa-17	10	30	to	to	ADP
amwa-17	10	31	what	what	DET
amwa-17	10	32	extent	extent	NOUN
amwa-17	10	33	biotech	biotech	NOUN
amwa-17	10	34	and	and	CCONJ
amwa-17	10	35	pharmaceutical	pharmaceutical	NOUN
amwa-17	10	36	companies	company	NOUN
amwa-17	10	37	,	,	PUNCT
amwa-17	10	38	and	and	CCONJ
amwa-17	10	39	the	the	DET
amwa-17	10	40	venture	venture	NOUN
amwa-17	10	41	capital	capital	NOUN
amwa-17	10	42	firms	firm	NOUN
amwa-17	10	43	that	that	PRON
amwa-17	10	44	finance	finance	VERB
amwa-17	10	45	their	their	PRON
amwa-17	10	46	r&d	r&d	NOUN
amwa-17	10	47	activities	activity	NOUN
amwa-17	10	48	,	,	PUNCT
amwa-17	10	49	would	would	AUX
amwa-17	10	50	invest	invest	VERB
amwa-17	10	51	in	in	ADP
amwa-17	10	52	developing	develop	VERB
amwa-17	10	53	treatjeanette	treatjeanette	NOUN
amwa-17	10	54	towles	towle	NOUN
amwa-17	10	55	,	,	PUNCT
amwa-17	10	56	ma	ma	PROPN
amwa-17	10	57	/	/	SYM
amwa-17	10	58	synterex	synterex	PROPN
amwa-17	10	59	,	,	PUNCT
amwa-17	10	60	inc	inc	PROPN
amwa-17	10	61	.	.	PROPN
amwa-17	10	62	,	,	PUNCT
amwa-17	10	63	boston	boston	PROPN
amwa-17	10	64	,	,	PUNCT
amwa-17	10	65	ma	ma	PROPN
amwa-17	10	66	a	a	DET
amwa-17	10	67	brief	brief	ADJ
amwa-17	10	68	history	history	NOUN
amwa-17	10	69	of	of	ADP
amwa-17	10	70	the	the	DET
amwa-17	10	71	covid-19	covid-19	PROPN
amwa-17	10	72	pandemic	pandemic	ADJ
amwa-17	10	73	and	and	CCONJ
amwa-17	10	74	current	current	ADJ
amwa-17	10	75	efforts	effort	NOUN
amwa-17	10	76	to	to	PART
amwa-17	10	77	combat	combat	VERB
amwa-17	10	78	it	it	PRON
amwa-17	10	79	r	r	NOUN
amwa-17	10	80	e	e	NOUN
amwa-17	10	81	s	s	X
amwa-17	10	82	e	e	X
amwa-17	10	83	a	a	DET
amwa-17	10	84	r	r	NOUN
amwa-17	10	85	c	c	NOUN
amwa-17	10	86	h	h	NOUN
amwa-17	10	87	amwa	amwa	PROPN
amwa-17	10	88	journal	journal	PROPN
amwa-17	10	89	/	/	SYM
amwa-17	10	90	v36	v36	PROPN
amwa-17	10	91	n2	n2	PROPN
amwa-17	10	92	/	/	SYM
amwa-17	10	93	2021	2021	NUM
amwa-17	10	94	/	/	SYM
amwa-17	10	95	amwa.org	amwa.org	PROPN
amwa-17	10	96	65	65	NUM
amwa-17	10	97	ments	ment	NOUN
amwa-17	10	98	for	for	ADP
amwa-17	10	99	a	a	DET
amwa-17	10	100	novel	novel	ADJ
amwa-17	10	101	virus	virus	NOUN
amwa-17	10	102	that	that	PRON
amwa-17	10	103	might	might	AUX
amwa-17	10	104	not	not	PART
amwa-17	10	105	persist	persist	VERB
amwa-17	10	106	in	in	ADP
amwa-17	10	107	the	the	DET
amwa-17	10	108	long	long	ADJ
amwa-17	10	109	term	term	NOUN
amwa-17	10	110	,	,	PUNCT
amwa-17	10	111	based	base	VERB
amwa-17	10	112	on	on	ADP
amwa-17	10	113	evolving	evolve	VERB
amwa-17	10	114	information	information	NOUN
amwa-17	10	115	on	on	ADP
amwa-17	10	116	sars	sar	NOUN
amwa-17	10	117	-	-	PUNCT
amwa-17	10	118	cov-2	cov-2	NOUN
amwa-17	10	119	as	as	ADV
amwa-17	10	120	well	well	ADV
amwa-17	10	121	as	as	ADP
amwa-17	10	122	prior	prior	ADJ
amwa-17	10	123	sars	sar	NOUN
amwa-17	10	124	/	/	SYM
amwa-17	10	125	mers	mer	NOUN
amwa-17	10	126	experience	experience	NOUN
amwa-17	10	127	.	.	PUNCT
amwa-17	11	1	these	these	DET
amwa-17	11	2	factors	factor	NOUN
amwa-17	11	3	represented	represent	VERB
amwa-17	11	4	an	an	DET
amwa-17	11	5	initial	initial	ADJ
amwa-17	11	6	threat	threat	NOUN
amwa-17	11	7	to	to	ADP
amwa-17	11	8	an	an	DET
amwa-17	11	9	industry	industry	NOUN
amwa-17	11	10	that	that	PRON
amwa-17	11	11	is	be	AUX
amwa-17	11	12	largely	largely	ADV
amwa-17	11	13	dependent	dependent	ADJ
amwa-17	11	14	upon	upon	SCONJ
amwa-17	11	15	the	the	DET
amwa-17	11	16	continuous	continuous	ADJ
amwa-17	11	17	advancement	advancement	NOUN
amwa-17	11	18	of	of	ADP
amwa-17	11	19	research	research	NOUN
amwa-17	11	20	.	.	PUNCT
amwa-17	12	1	declaration	declaration	NOUN
amwa-17	12	2	of	of	ADP
amwa-17	12	3	a	a	DET
amwa-17	12	4	pandemic	pandemic	NOUN
amwa-17	12	5	,	,	PUNCT
amwa-17	12	6	the	the	DET
amwa-17	12	7	us	us	PROPN
amwa-17	12	8	food	food	NOUN
amwa-17	12	9	and	and	CCONJ
amwa-17	12	10	drug	drug	PROPN
amwa-17	12	11	administration	administration	NOUN
amwa-17	12	12	response	response	NOUN
amwa-17	12	13	,	,	PUNCT
amwa-17	12	14	and	and	CCONJ
amwa-17	12	15	the	the	DET
amwa-17	12	16	shift	shift	NOUN
amwa-17	12	17	to	to	PART
amwa-17	12	18	realtime	realtime	VERB
amwa-17	12	19	drug	drug	NOUN
amwa-17	12	20	development	development	NOUN
amwa-17	12	21	pursuant	pursuant	ADJ
amwa-17	12	22	to	to	ADP
amwa-17	12	23	a	a	DET
amwa-17	12	24	rise	rise	NOUN
amwa-17	12	25	in	in	ADP
amwa-17	12	26	the	the	DET
amwa-17	12	27	number	number	NOUN
amwa-17	12	28	,	,	PUNCT
amwa-17	12	29	severity	severity	NOUN
amwa-17	12	30	,	,	PUNCT
amwa-17	12	31	and	and	CCONJ
amwa-17	12	32	location	location	NOUN
amwa-17	12	33	of	of	ADP
amwa-17	12	34	cases	case	NOUN
amwa-17	12	35	,	,	PUNCT
amwa-17	12	36	a	a	DET
amwa-17	12	37	pandemic	pandemic	NOUN
amwa-17	12	38	was	be	AUX
amwa-17	12	39	formally	formally	ADV
amwa-17	12	40	declared	declare	VERB
amwa-17	12	41	on	on	ADP
amwa-17	12	42	march	march	PROPN
amwa-17	12	43	11	11	NUM
amwa-17	12	44	,	,	PUNCT
amwa-17	12	45	2020	2020	NUM
amwa-17	12	46	,	,	PUNCT
amwa-17	12	47	by	by	ADP
amwa-17	12	48	who.10	who.10	ADP
amwa-17	12	49	the	the	DET
amwa-17	12	50	director	director	NOUN
amwa-17	12	51	of	of	ADP
amwa-17	12	52	who	who	PRON
amwa-17	12	53	urged	urge	VERB
amwa-17	12	54	countries	country	NOUN
amwa-17	12	55	worldwide	worldwide	ADV
amwa-17	12	56	to	to	PART
amwa-17	12	57	change	change	VERB
amwa-17	12	58	the	the	DET
amwa-17	12	59	course	course	NOUN
amwa-17	12	60	of	of	ADP
amwa-17	12	61	the	the	DET
amwa-17	12	62	pandemic	pandemic	NOUN
amwa-17	12	63	and	and	CCONJ
amwa-17	12	64	to	to	PART
amwa-17	12	65	“	"	PUNCT
amwa-17	12	66	first	first	ADV
amwa-17	12	67	,	,	PUNCT
amwa-17	12	68	prepare	prepare	VERB
amwa-17	12	69	and	and	CCONJ
amwa-17	12	70	be	be	AUX
amwa-17	12	71	ready	ready	ADJ
amwa-17	12	72	.	.	PUNCT
amwa-17	13	1	second	second	ADJ
amwa-17	13	2	,	,	PUNCT
amwa-17	13	3	detect	detect	NOUN
amwa-17	13	4	,	,	PUNCT
amwa-17	13	5	protect	protect	VERB
amwa-17	13	6	and	and	CCONJ
amwa-17	13	7	treat	treat	NOUN
amwa-17	13	8	.	.	PUNCT
amwa-17	14	1	third	third	ADV
amwa-17	14	2	,	,	PUNCT
amwa-17	14	3	reduce	reduce	VERB
amwa-17	14	4	transmission	transmission	NOUN
amwa-17	14	5	.	.	PUNCT
amwa-17	15	1	fourth	fourth	ADJ
amwa-17	15	2	,	,	PUNCT
amwa-17	15	3	innovate	innovate	VERB
amwa-17	15	4	and	and	CCONJ
amwa-17	15	5	learn	learn	VERB
amwa-17	15	6	.	.	PUNCT
amwa-17	15	7	”	"	PUNCT
amwa-17	16	1	as	as	ADP
amwa-17	16	2	more	more	ADV
amwa-17	16	3	became	became	AUX
amwa-17	16	4	known	know	VERB
amwa-17	16	5	publicly	publicly	ADV
amwa-17	16	6	about	about	ADP
amwa-17	16	7	the	the	DET
amwa-17	16	8	clinical	clinical	ADJ
amwa-17	16	9	course	course	NOUN
amwa-17	16	10	of	of	ADP
amwa-17	16	11	the	the	DET
amwa-17	16	12	virus	virus	NOUN
amwa-17	16	13	,	,	PUNCT
amwa-17	16	14	many	many	ADJ
amwa-17	16	15	global	global	ADJ
amwa-17	16	16	biotech	biotech	NOUN
amwa-17	16	17	and	and	CCONJ
amwa-17	16	18	pharmaceutical	pharmaceutical	NOUN
amwa-17	16	19	companies	company	NOUN
amwa-17	16	20	sprang	spring	VERB
amwa-17	16	21	into	into	ADP
amwa-17	16	22	action	action	NOUN
amwa-17	16	23	to	to	PART
amwa-17	16	24	see	see	VERB
amwa-17	16	25	if	if	SCONJ
amwa-17	16	26	existing	exist	VERB
amwa-17	16	27	technology	technology	NOUN
amwa-17	16	28	or	or	CCONJ
amwa-17	16	29	assets	asset	NOUN
amwa-17	16	30	could	could	AUX
amwa-17	16	31	contribute	contribute	VERB
amwa-17	16	32	to	to	ADP
amwa-17	16	33	a	a	DET
amwa-17	16	34	cure	cure	NOUN
amwa-17	16	35	or	or	CCONJ
amwa-17	16	36	a	a	DET
amwa-17	16	37	treatment	treatment	NOUN
amwa-17	16	38	for	for	ADP
amwa-17	16	39	covid-19	covid-19	PROPN
amwa-17	16	40	or	or	CCONJ
amwa-17	16	41	its	its	PRON
amwa-17	16	42	sequelae	sequelae	NOUN
amwa-17	16	43	.	.	PUNCT
amwa-17	17	1	these	these	DET
amwa-17	17	2	companies	company	NOUN
amwa-17	17	3	included	include	VERB
amwa-17	17	4	those	those	PRON
amwa-17	17	5	already	already	ADV
amwa-17	17	6	developing	develop	VERB
amwa-17	17	7	vaccines	vaccine	NOUN
amwa-17	17	8	,	,	PUNCT
amwa-17	17	9	those	those	DET
amwa-17	17	10	developing	develop	VERB
amwa-17	17	11	therapeutics	therapeutic	NOUN
amwa-17	17	12	who	who	PRON
amwa-17	17	13	entered	enter	VERB
amwa-17	17	14	vaccine	vaccine	NOUN
amwa-17	17	15	development	development	PROPN
amwa-17	17	16	de	de	PROPN
amwa-17	17	17	novo	novo	PROPN
amwa-17	17	18	,	,	PUNCT
amwa-17	17	19	those	those	PRON
amwa-17	17	20	repurposing	repurpose	VERB
amwa-17	17	21	existing	exist	VERB
amwa-17	17	22	antiviral	antiviral	NOUN
amwa-17	17	23	and	and	CCONJ
amwa-17	17	24	other	other	ADJ
amwa-17	17	25	drugs	drug	NOUN
amwa-17	17	26	,	,	PUNCT
amwa-17	17	27	and	and	CCONJ
amwa-17	17	28	those	those	PRON
amwa-17	17	29	developing	develop	VERB
amwa-17	17	30	new	new	ADJ
amwa-17	17	31	drugs	drug	NOUN
amwa-17	17	32	.	.	PUNCT
amwa-17	18	1	several	several	ADJ
amwa-17	18	2	companies	company	NOUN
amwa-17	18	3	partnered	partner	VERB
amwa-17	18	4	with	with	ADP
amwa-17	18	5	other	other	ADJ
amwa-17	18	6	biotech	biotech	ADJ
amwa-17	18	7	companies	company	NOUN
amwa-17	18	8	or	or	CCONJ
amwa-17	18	9	academic	academic	ADJ
amwa-17	18	10	institutions	institution	NOUN
amwa-17	18	11	to	to	PART
amwa-17	18	12	optimize	optimize	VERB
amwa-17	18	13	efficiency	efficiency	NOUN
amwa-17	18	14	.	.	PUNCT
amwa-17	19	1	the	the	DET
amwa-17	19	2	sequence	sequence	NOUN
amwa-17	19	3	of	of	ADP
amwa-17	19	4	the	the	DET
amwa-17	19	5	virus	virus	NOUN
amwa-17	19	6	was	be	AUX
amwa-17	19	7	first	first	ADV
amwa-17	19	8	made	make	VERB
amwa-17	19	9	public	public	ADJ
amwa-17	19	10	in	in	ADP
amwa-17	19	11	early	early	ADJ
amwa-17	19	12	january	january	PROPN
amwa-17	19	13	2020,4,11	2020,4,11	NUM
amwa-17	19	14	and	and	CCONJ
amwa-17	19	15	by	by	ADP
amwa-17	19	16	late	late	ADJ
amwa-17	19	17	january	january	PROPN
amwa-17	19	18	,	,	PUNCT
amwa-17	19	19	the	the	DET
amwa-17	19	20	us	us	PROPN
amwa-17	19	21	food	food	NOUN
amwa-17	19	22	and	and	CCONJ
amwa-17	19	23	drug	drug	PROPN
amwa-17	19	24	administration	administration	PROPN
amwa-17	19	25	(	(	PUNCT
amwa-17	19	26	fda	fda	PROPN
amwa-17	19	27	)	)	PUNCT
amwa-17	19	28	announced	announce	VERB
amwa-17	19	29	that	that	SCONJ
amwa-17	19	30	it	it	PRON
amwa-17	19	31	was	be	AUX
amwa-17	19	32	“	"	PUNCT
amwa-17	19	33	actively	actively	ADV
amwa-17	19	34	leveraging	leverage	VERB
amwa-17	19	35	the	the	DET
amwa-17	19	36	vast	vast	ADJ
amwa-17	19	37	breadth	breadth	NOUN
amwa-17	19	38	of	of	ADP
amwa-17	19	39	the	the	DET
amwa-17	19	40	fda	fda	PROPN
amwa-17	19	41	’s	’s	PART
amwa-17	19	42	expertise	expertise	NOUN
amwa-17	19	43	”	"	PUNCT
amwa-17	19	44	and	and	CCONJ
amwa-17	19	45	had	have	AUX
amwa-17	19	46	“	"	PUNCT
amwa-17	19	47	begun	begin	VERB
amwa-17	19	48	employing	employ	VERB
amwa-17	19	49	the	the	DET
amwa-17	19	50	full	full	ADJ
amwa-17	19	51	range	range	NOUN
amwa-17	19	52	of	of	ADP
amwa-17	19	53	our	our	PRON
amwa-17	19	54	public	public	ADJ
amwa-17	19	55	health	health	NOUN
amwa-17	19	56	authorities	authority	NOUN
amwa-17	19	57	to	to	PART
amwa-17	19	58	facilitate	facilitate	VERB
amwa-17	19	59	the	the	DET
amwa-17	19	60	development	development	NOUN
amwa-17	19	61	and	and	CCONJ
amwa-17	19	62	availability	availability	NOUN
amwa-17	19	63	of	of	ADP
amwa-17	19	64	investigational	investigational	ADJ
amwa-17	19	65	medical	medical	ADJ
amwa-17	19	66	products	product	NOUN
amwa-17	19	67	to	to	PART
amwa-17	19	68	help	help	VERB
amwa-17	19	69	address	address	VERB
amwa-17	19	70	this	this	DET
amwa-17	19	71	urgent	urgent	ADJ
amwa-17	19	72	public	public	ADJ
amwa-17	19	73	health	health	NOUN
amwa-17	19	74	situation	situation	NOUN
amwa-17	19	75	.	.	PUNCT
amwa-17	20	1	”12	”12	PROPN
amwa-17	20	2	on	on	ADP
amwa-17	20	3	january	january	PROPN
amwa-17	20	4	31	31	NUM
amwa-17	20	5	,	,	PUNCT
amwa-17	20	6	2020	2020	NUM
amwa-17	20	7	,	,	PUNCT
amwa-17	20	8	the	the	DET
amwa-17	20	9	us	us	PROPN
amwa-17	20	10	department	department	PROPN
amwa-17	20	11	of	of	ADP
amwa-17	20	12	health	health	PROPN
amwa-17	20	13	and	and	CCONJ
amwa-17	20	14	human	human	PROPN
amwa-17	20	15	services	service	NOUN
amwa-17	20	16	declared	declare	VERB
amwa-17	20	17	that	that	SCONJ
amwa-17	20	18	covid-19	covid-19	PROPN
amwa-17	20	19	constituted	constitute	VERB
amwa-17	20	20	a	a	DET
amwa-17	20	21	us	us	PROPN
amwa-17	20	22	public	public	ADJ
amwa-17	20	23	health	health	NOUN
amwa-17	20	24	emergency	emergency	NOUN
amwa-17	20	25	and	and	CCONJ
amwa-17	20	26	that	that	SCONJ
amwa-17	20	27	an	an	DET
amwa-17	20	28	emergency	emergency	NOUN
amwa-17	20	29	use	use	NOUN
amwa-17	20	30	authorization	authorization	NOUN
amwa-17	20	31	(	(	PUNCT
amwa-17	20	32	eua	eua	PROPN
amwa-17	20	33	)	)	PUNCT
amwa-17	20	34	was	be	AUX
amwa-17	20	35	needed	need	VERB
amwa-17	20	36	to	to	PART
amwa-17	20	37	mitigate	mitigate	VERB
amwa-17	20	38	the	the	DET
amwa-17	20	39	threat	threat	NOUN
amwa-17	20	40	of	of	ADP
amwa-17	20	41	covid-19	covid-19	PROPN
amwa-17	20	42	.	.	PUNCT
amwa-17	21	1	this	this	DET
amwa-17	21	2	action	action	NOUN
amwa-17	21	3	enabled	enable	VERB
amwa-17	21	4	the	the	DET
amwa-17	21	5	fda	fda	PROPN
amwa-17	21	6	,	,	PUNCT
amwa-17	21	7	in	in	ADP
amwa-17	21	8	consultation	consultation	NOUN
amwa-17	21	9	with	with	ADP
amwa-17	21	10	the	the	DET
amwa-17	21	11	national	national	PROPN
amwa-17	21	12	institutes	institutes	PROPN
amwa-17	21	13	of	of	ADP
amwa-17	21	14	health	health	NOUN
amwa-17	21	15	and	and	CCONJ
amwa-17	21	16	centers	center	NOUN
amwa-17	21	17	for	for	ADP
amwa-17	21	18	disease	disease	NOUN
amwa-17	21	19	control	control	NOUN
amwa-17	21	20	and	and	CCONJ
amwa-17	21	21	prevention	prevention	NOUN
amwa-17	21	22	(	(	PUNCT
amwa-17	21	23	cdc	cdc	PROPN
amwa-17	21	24	)	)	PUNCT
amwa-17	21	25	,	,	PUNCT
amwa-17	21	26	to	to	PART
amwa-17	21	27	authorize	authorize	VERB
amwa-17	21	28	the	the	DET
amwa-17	21	29	emergency	emergency	NOUN
amwa-17	21	30	use	use	NOUN
amwa-17	21	31	of	of	ADP
amwa-17	21	32	unapproved	unapproved	ADJ
amwa-17	21	33	medical	medical	ADJ
amwa-17	21	34	products	product	NOUN
amwa-17	21	35	(	(	PUNCT
amwa-17	21	36	table	table	NOUN
amwa-17	21	37	1).13,14	1).13,14	NOUN
amwa-17	21	38	with	with	ADP
amwa-17	21	39	so	so	ADV
amwa-17	21	40	many	many	ADJ
amwa-17	21	41	companies	company	NOUN
amwa-17	21	42	advancing	advance	VERB
amwa-17	21	43	new	new	ADJ
amwa-17	21	44	covid-19	covid-19	PROPN
amwa-17	21	45	pipeline	pipeline	NOUN
amwa-17	21	46	assets	asset	NOUN
amwa-17	21	47	,	,	PUNCT
amwa-17	21	48	many	many	ADJ
amwa-17	21	49	of	of	ADP
amwa-17	21	50	the	the	DET
amwa-17	21	51	biotech	biotech	ADJ
amwa-17	21	52	and	and	CCONJ
amwa-17	21	53	pharmaceutical	pharmaceutical	NOUN
amwa-17	21	54	employees	employee	NOUN
amwa-17	21	55	who	who	PRON
amwa-17	21	56	were	be	AUX
amwa-17	21	57	initially	initially	ADV
amwa-17	21	58	impacted	impact	VERB
amwa-17	21	59	by	by	ADP
amwa-17	21	60	the	the	DET
amwa-17	21	61	halt	halt	NOUN
amwa-17	21	62	of	of	ADP
amwa-17	21	63	other	other	ADJ
amwa-17	21	64	clinical	clinical	ADJ
amwa-17	21	65	trials	trial	NOUN
amwa-17	21	66	eventually	eventually	ADV
amwa-17	21	67	were	be	AUX
amwa-17	21	68	reassigned	reassign	VERB
amwa-17	21	69	to	to	ADP
amwa-17	21	70	covid-19	covid-19	PROPN
amwa-17	21	71	–	–	PUNCT
amwa-17	21	72	related	relate	VERB
amwa-17	21	73	work.9	work.9	DET
amwa-17	21	74	first	first	ADJ
amwa-17	21	75	case	case	NOUN
amwa-17	21	76	of	of	ADP
amwa-17	21	77	“	"	PUNCT
amwa-17	21	78	viral	viral	ADJ
amwa-17	21	79	pneumonia	pneumonia	NOUN
amwa-17	21	80	”	"	PUNCT
amwa-17	21	81	reported	report	VERB
amwa-17	21	82	in	in	ADP
amwa-17	21	83	wuhan	wuhan	PROPN
amwa-17	21	84	,	,	PUNCT
amwa-17	21	85	china	china	PROPN
amwa-17	21	86	sars	sars	PROPN
amwa-17	21	87	-	-	PUNCT
amwa-17	21	88	cov-2	cov-2	PART
amwa-17	21	89	virus	virus	NOUN
amwa-17	21	90	genomic	genomic	NOUN
amwa-17	21	91	sequence	sequence	NOUN
amwa-17	21	92	published	publish	VERB
amwa-17	21	93	and	and	CCONJ
amwa-17	21	94	made	make	VERB
amwa-17	21	95	public	public	ADJ
amwa-17	21	96	via	via	ADP
amwa-17	21	97	who	who	PRON
amwa-17	21	98	;	;	PUNCT
amwa-17	21	99	1st	1st	ADJ
amwa-17	21	100	death	death	NOUN
amwa-17	21	101	from	from	ADP
amwa-17	21	102	covid-19	covid-19	PROPN
amwa-17	21	103	reported	report	VERB
amwa-17	21	104	in	in	ADP
amwa-17	21	105	china	china	PROPN
amwa-17	21	106	1st	1st	PROPN
amwa-17	21	107	vaccine	vaccine	NOUN
amwa-17	21	108	vrbpacs	vrbpac	NOUN
amwa-17	21	109	and	and	CCONJ
amwa-17	21	110	euas	euas	NOUN
amwa-17	21	111	who	who	PRON
amwa-17	21	112	convenes	convene	VERB
amwa-17	21	113	diagnostics/	diagnostics/	PROPN
amwa-17	21	114	laboratories	laboratory	NOUN
amwa-17	21	115	global	global	ADJ
amwa-17	21	116	expert	expert	NOUN
amwa-17	21	117	network	network	NOUN
amwa-17	21	118	,	,	PUNCT
amwa-17	21	119	announces	announce	VERB
amwa-17	21	120	protocol	protocol	NOUN
amwa-17	21	121	for	for	ADP
amwa-17	21	122	rt	rt	NOUN
amwa-17	21	123	-	-	PUNCT
amwa-17	21	124	pcr	pcr	PROPN
amwa-17	21	125	for	for	ADP
amwa-17	21	126	covid-19	covid-19	PROPN
amwa-17	21	127	diagnostic	diagnostic	ADJ
amwa-17	21	128	;	;	PUNCT
amwa-17	21	129	1st	1st	ADJ
amwa-17	21	130	and	and	CCONJ
amwa-17	21	131	2nd	2nd	ADJ
amwa-17	21	132	cases	case	NOUN
amwa-17	21	133	reported	report	VERB
amwa-17	21	134	outside	outside	ADP
amwa-17	21	135	of	of	ADP
amwa-17	21	136	china	china	PROPN
amwa-17	21	137	in	in	ADP
amwa-17	21	138	thailand	thailand	PROPN
amwa-17	21	139	and	and	CCONJ
amwa-17	21	140	japan	japan	PROPN
amwa-17	21	141	,	,	PUNCT
amwa-17	21	142	respectively	respectively	ADV
amwa-17	21	143	1st	1st	ADJ
amwa-17	21	144	covid-19	covid-19	PROPN
amwa-17	21	145	case	case	NOUN
amwa-17	21	146	reported	report	VERB
amwa-17	21	147	in	in	ADP
amwa-17	21	148	us	we	PRON
amwa-17	21	149	;	;	PUNCT
amwa-17	21	150	1st	1st	ADJ
amwa-17	21	151	case	case	NOUN
amwa-17	21	152	reported	report	VERB
amwa-17	21	153	in	in	ADP
amwa-17	21	154	eu	eu	PROPN
amwa-17	21	155	;	;	PUNCT
amwa-17	21	156	guidance	guidance	NOUN
amwa-17	21	157	on	on	ADP
amwa-17	21	158	mask	mask	NOUN
amwa-17	21	159	-	-	PUNCT
amwa-17	21	160	wearing	wear	VERB
amwa-17	21	161	in	in	ADP
amwa-17	21	162	public	public	NOUN
amwa-17	21	163	released	release	VERB
amwa-17	21	164	by	by	ADP
amwa-17	21	165	who	who	PRON
amwa-17	21	166	1st	1st	PROPN
amwa-17	21	167	diagnostic	diagnostic	ADJ
amwa-17	21	168	rt	rt	PROPN
amwa-17	21	169	-	-	PUNCT
amwa-17	21	170	pcr	pcr	ADJ
amwa-17	21	171	tests	test	NOUN
amwa-17	21	172	available	available	ADJ
amwa-17	21	173	,	,	PUNCT
amwa-17	21	174	1st	1st	ADJ
amwa-17	21	175	diagnostic	diagnostic	PROPN
amwa-17	21	176	eua	eua	PROPN
amwa-17	21	177	in	in	ADP
amwa-17	21	178	us	we	PRON
amwa-17	21	179	;	;	PUNCT
amwa-17	21	180	virus	virus	NOUN
amwa-17	21	181	coined	coin	VERB
amwa-17	21	182	“	"	PUNCT
amwa-17	21	183	covid-19	covid-19	PROPN
amwa-17	21	184	”	"	PUNCT
amwa-17	21	185	by	by	ADP
amwa-17	21	186	who	who	PRON
amwa-17	21	187	who	who	PRON
amwa-17	21	188	declares	declare	VERB
amwa-17	21	189	covid-19	covid-19	PROPN
amwa-17	21	190	pandemic	pandemic	ADJ
amwa-17	21	191	eua	eua	PROPN
amwa-17	21	192	for	for	ADP
amwa-17	21	193	hq	hq	PROPN
amwa-17	21	194	/	/	SYM
amwa-17	21	195	cq	cq	PROPN
amwa-17	21	196	issued	issue	VERB
amwa-17	21	197	by	by	ADP
amwa-17	21	198	us	us	PROPN
amwa-17	21	199	fda	fda	PROPN
amwa-17	21	200	,	,	PUNCT
amwa-17	21	201	ows	ows	PROPN
amwa-17	21	202	launches	launch	NOUN
amwa-17	21	203	,	,	PUNCT
amwa-17	21	204	ctap	ctap	PROPN
amwa-17	21	205	announced	announce	VERB
amwa-17	21	206	eua	eua	PROPN
amwa-17	21	207	for	for	ADP
amwa-17	21	208	hq	hq	PROPN
amwa-17	21	209	/	/	SYM
amwa-17	21	210	cq	cq	PROPN
amwa-17	21	211	revoked	revoke	VERB
amwa-17	21	212	;	;	PUNCT
amwa-17	21	213	fda	fda	PROPN
amwa-17	21	214	issues	issue	NOUN
amwa-17	21	215	guidance	guidance	VERB
amwa-17	21	216	on	on	ADP
amwa-17	21	217	vaccine	vaccine	NOUN
amwa-17	21	218	development	development	PROPN
amwa-17	21	219	eua	eua	PROPN
amwa-17	21	220	for	for	ADP
amwa-17	21	221	remdesivir	remdesivir	NOUN
amwa-17	21	222	issued	issue	VERB
amwa-17	21	223	by	by	ADP
amwa-17	21	224	us	we	PRON
amwa-17	21	225	fda	fda	PROPN
amwa-17	21	226	(	(	PUNCT
amwa-17	21	227	severe	severe	ADJ
amwa-17	21	228	covid/	covid/	NUM
amwa-17	21	229	hospitalized	hospitalize	VERB
amwa-17	21	230	patients	patient	NOUN
amwa-17	21	231	)	)	PUNCT
amwa-17	21	232	;	;	PUNCT
amwa-17	21	233	fda	fda	PROPN
amwa-17	21	234	issues	issue	NOUN
amwa-17	21	235	guidance	guidance	VERB
amwa-17	21	236	on	on	ADP
amwa-17	21	237	covid	covid	PROPN
amwa-17	21	238	trials	trial	NOUN
amwa-17	21	239	fda	fda	PROPN
amwa-17	21	240	issues	issue	NOUN
amwa-17	21	241	guidance	guidance	VERB
amwa-17	21	242	on	on	ADP
amwa-17	21	243	conducting	conduct	VERB
amwa-17	21	244	clinical	clinical	ADJ
amwa-17	21	245	trials	trial	NOUN
amwa-17	21	246	during	during	ADP
amwa-17	21	247	pandemic	pandemic	ADJ
amwa-17	21	248	,	,	PUNCT
amwa-17	21	249	announces	announce	VERB
amwa-17	21	250	suspension	suspension	NOUN
amwa-17	21	251	of	of	ADP
amwa-17	21	252	domestic	domestic	ADJ
amwa-17	21	253	and	and	CCONJ
amwa-17	21	254	foreign	foreign	ADJ
amwa-17	21	255	routine	routine	ADJ
amwa-17	21	256	and	and	CCONJ
amwa-17	21	257	bimo	bimo	ADJ
amwa-17	21	258	inspections	inspection	NOUN
amwa-17	21	259	eua	eua	PROPN
amwa-17	21	260	issued	issue	VERB
amwa-17	21	261	for	for	ADP
amwa-17	21	262	convalescent	convalescent	NOUN
amwa-17	21	263	plasma	plasma	NOUN
amwa-17	21	264	;	;	PUNCT
amwa-17	21	265	fda	fda	PROPN
amwa-17	21	266	issues	issue	NOUN
amwa-17	21	267	guidance	guidance	VERB
amwa-17	21	268	on	on	ADP
amwa-17	21	269	supply	supply	NOUN
amwa-17	21	270	chain	chain	NOUN
amwa-17	21	271	and	and	CCONJ
amwa-17	21	272	inspections	inspection	NOUN
amwa-17	21	273	;	;	PUNCT
amwa-17	21	274	eua	eua	PROPN
amwa-17	21	275	for	for	ADP
amwa-17	21	276	remdesivir	remdesivir	NOUN
amwa-17	21	277	broadened	broaden	VERB
amwa-17	21	278	euas	euas	NOUN
amwa-17	21	279	issued	issue	VERB
amwa-17	21	280	for	for	ADP
amwa-17	21	281	3	3	NUM
amwa-17	21	282	mabs	mab	NOUN
amwa-17	21	283	fda	fda	PROPN
amwa-17	21	284	announces	announce	VERB
amwa-17	21	285	plans	plan	NOUN
amwa-17	21	286	to	to	PART
amwa-17	21	287	resume	resume	VERB
amwa-17	21	288	domestic	domestic	ADJ
amwa-17	21	289	inspections	inspection	NOUN
amwa-17	21	290	;	;	PUNCT
amwa-17	21	291	eua	eua	PROPN
amwa-17	21	292	issued	issue	VERB
amwa-17	21	293	for	for	ADP
amwa-17	21	294	1st	1st	PROPN
amwa-17	21	295	covid	covid	PROPN
amwa-17	21	296	testing	testing	NOUN
amwa-17	21	297	of	of	ADP
amwa-17	21	298	asymptomatic	asymptomatic	ADJ
amwa-17	21	299	individuals	individual	NOUN
amwa-17	21	300	nih	nih	PROPN
amwa-17	21	301	announces	announce	VERB
amwa-17	21	302	activ	activ	PROPN
amwa-17	21	303	program	program	PROPN
amwa-17	21	304	fda	fda	PROPN
amwa-17	21	305	issues	issues	PROPN
amwa-17	21	306	eua	eua	PROPN
amwa-17	21	307	guidance	guidance	NOUN
amwa-17	21	308	for	for	ADP
amwa-17	21	309	vaccines	vaccine	NOUN
amwa-17	21	310	;	;	PUNCT
amwa-17	21	311	approval	approval	NOUN
amwa-17	21	312	of	of	ADP
amwa-17	21	313	remdesivir	remdesivir	NOUN
amwa-17	21	314	for	for	ADP
amwa-17	21	315	covid-19	covid-19	PROPN
amwa-17	21	316	treatment	treatment	NOUN
amwa-17	21	317	dec	dec	PROPN
amwa-17	21	318	2020	2020	NUM
amwa-17	21	319	nov	nov	PROPN
amwa-17	21	320	2020	2020	NUM
amwa-17	21	321	oct	oct	PROPN
amwa-17	21	322	2020	2020	NUM
amwa-17	21	323	aug	aug	PROPN
amwa-17	21	324	2020	2020	NUM
amwa-17	21	325	jul	jul	PROPN
amwa-17	21	326	2020	2020	NUM
amwa-17	21	327	jun	jun	PROPN
amwa-17	21	328	2020	2020	NUM
amwa-17	21	329	may	may	AUX
amwa-17	21	330	2020	2020	NUM
amwa-17	21	331	apr	apr	NOUN
amwa-17	21	332	2020	2020	NUM
amwa-17	21	333	mar	mar	PROPN
amwa-17	21	334	2020	2020	NUM
amwa-17	21	335	feb	feb	X
amwa-17	21	336	2020	2020	NUM
amwa-17	21	337	jan	jan	PROPN
amwa-17	21	338	2020	2020	NUM
amwa-17	21	339	31	31	NUM
amwa-17	21	340	dec	dec	PROPN
amwa-17	21	341	2019	2019	NUM
amwa-17	21	342	figure	figure	NOUN
amwa-17	21	343	.	.	PUNCT
amwa-17	22	1	timeline	timeline	NOUN
amwa-17	22	2	of	of	ADP
amwa-17	22	3	key	key	ADJ
amwa-17	22	4	events	event	NOUN
amwa-17	22	5	associated	associate	VERB
amwa-17	22	6	with	with	ADP
amwa-17	22	7	the	the	DET
amwa-17	22	8	covid-19	covid-19	PROPN
amwa-17	22	9	pandemic	pandemic	NOUN
amwa-17	22	10	.	.	PUNCT
amwa-17	23	1	sources	source	NOUN
amwa-17	23	2	:	:	PUNCT
amwa-17	23	3	who,3,4,10	who,3,4,10	X
amwa-17	23	4	genbank,11	genbank,11	PROPN
amwa-17	23	5	fda.15,18	fda.15,18	PROPN
amwa-17	23	6	-	-	PUNCT
amwa-17	23	7	22,24,33,47	22,24,33,47	NUM
amwa-17	23	8	-	-	PUNCT
amwa-17	23	9	49	49	NUM
amwa-17	23	10	abbreviations	abbreviation	NOUN
amwa-17	23	11	:	:	PUNCT
amwa-17	23	12	activ	activ	NOUN
amwa-17	23	13	,	,	PUNCT
amwa-17	23	14	accelerating	accelerate	VERB
amwa-17	23	15	covid-19	covid-19	PROPN
amwa-17	23	16	therapeutic	therapeutic	ADJ
amwa-17	23	17	interventions	intervention	NOUN
amwa-17	23	18	and	and	CCONJ
amwa-17	23	19	vaccines	vaccine	NOUN
amwa-17	23	20	;	;	PUNCT
amwa-17	23	21	bimo	bimo	ADJ
amwa-17	23	22	,	,	PUNCT
amwa-17	23	23	biomedical	biomedical	ADJ
amwa-17	23	24	research	research	NOUN
amwa-17	23	25	monitoring	monitoring	NOUN
amwa-17	23	26	;	;	PUNCT
amwa-17	23	27	covid-19	covid-19	PROPN
amwa-17	23	28	,	,	PUNCT
amwa-17	23	29	novel	novel	ADJ
amwa-17	23	30	coronavirus	coronavirus	NOUN
amwa-17	23	31	2019	2019	NUM
amwa-17	23	32	;	;	PUNCT
amwa-17	23	33	cq	cq	PROPN
amwa-17	23	34	,	,	PUNCT
amwa-17	23	35	chloroquine	chloroquine	NOUN
amwa-17	23	36	;	;	PUNCT
amwa-17	23	37	ctap	ctap	NOUN
amwa-17	23	38	,	,	PUNCT
amwa-17	23	39	coronavirus	coronavirus	NOUN
amwa-17	23	40	treatment	treatment	NOUN
amwa-17	23	41	acceleration	acceleration	NOUN
amwa-17	23	42	program	program	NOUN
amwa-17	23	43	;	;	PUNCT
amwa-17	23	44	eu	eu	PROPN
amwa-17	23	45	,	,	PUNCT
amwa-17	23	46	european	european	PROPN
amwa-17	23	47	union	union	PROPN
amwa-17	23	48	;	;	PUNCT
amwa-17	23	49	eua	eua	PROPN
amwa-17	23	50	,	,	PUNCT
amwa-17	23	51	emergency	emergency	NOUN
amwa-17	23	52	use	use	NOUN
amwa-17	23	53	authorization	authorization	NOUN
amwa-17	23	54	;	;	PUNCT
amwa-17	23	55	fda	fda	PROPN
amwa-17	23	56	,	,	PUNCT
amwa-17	23	57	food	food	NOUN
amwa-17	23	58	and	and	CCONJ
amwa-17	23	59	drug	drug	NOUN
amwa-17	23	60	administration	administration	NOUN
amwa-17	23	61	;	;	PUNCT
amwa-17	23	62	hq	hq	NOUN
amwa-17	23	63	,	,	PUNCT
amwa-17	23	64	hydroxychloroquine	hydroxychloroquine	PROPN
amwa-17	23	65	;	;	PUNCT
amwa-17	23	66	mab	mab	X
amwa-17	23	67	,	,	PUNCT
amwa-17	23	68	monoclonal	monoclonal	NOUN
amwa-17	23	69	antibody	antibody	NOUN
amwa-17	23	70	;	;	PUNCT
amwa-17	23	71	nih	nih	PROPN
amwa-17	23	72	,	,	PUNCT
amwa-17	23	73	national	national	PROPN
amwa-17	23	74	institutes	institutes	PROPN
amwa-17	23	75	of	of	ADP
amwa-17	23	76	health	health	PROPN
amwa-17	23	77	;	;	PUNCT
amwa-17	23	78	ows	ow	NOUN
amwa-17	23	79	,	,	PUNCT
amwa-17	23	80	operation	operation	NOUN
amwa-17	23	81	warp	warp	NOUN
amwa-17	23	82	speed	speed	NOUN
amwa-17	23	83	;	;	PUNCT
amwa-17	23	84	rt	rt	NOUN
amwa-17	23	85	,	,	PUNCT
amwa-17	23	86	reverse	reverse	ADJ
amwa-17	23	87	transcription	transcription	NOUN
amwa-17	23	88	polymerase	polymerase	NOUN
amwa-17	23	89	chain	chain	NOUN
amwa-17	23	90	reaction	reaction	NOUN
amwa-17	23	91	;	;	PUNCT
amwa-17	23	92	sars	sar	NOUN
amwa-17	23	93	-	-	PUNCT
amwa-17	23	94	cov-2	cov-2	NOUN
amwa-17	23	95	,	,	PUNCT
amwa-17	23	96	virus	virus	NOUN
amwa-17	23	97	that	that	PRON
amwa-17	23	98	causes	cause	VERB
amwa-17	23	99	coronavirus	coronavirus	NOUN
amwa-17	23	100	2019	2019	NUM
amwa-17	23	101	disease	disease	NOUN
amwa-17	23	102	;	;	PUNCT
amwa-17	23	103	us	we	PRON
amwa-17	23	104	,	,	PUNCT
amwa-17	23	105	united	united	PROPN
amwa-17	23	106	states	states	PROPN
amwa-17	23	107	;	;	PUNCT
amwa-17	23	108	vrbpac	vrbpac	ADJ
amwa-17	23	109	,	,	PUNCT
amwa-17	23	110	vaccines	vaccine	NOUN
amwa-17	23	111	and	and	CCONJ
amwa-17	23	112	related	related	ADJ
amwa-17	23	113	biological	biological	ADJ
amwa-17	23	114	products	product	NOUN
amwa-17	23	115	advisory	advisory	NOUN
amwa-17	23	116	committee	committee	NOUN
amwa-17	23	117	;	;	PUNCT
amwa-17	23	118	who	who	PRON
amwa-17	23	119	,	,	PUNCT
amwa-17	23	120	world	world	NOUN
amwa-17	23	121	health	health	NOUN
amwa-17	23	122	organization	organization	NOUN
amwa-17	23	123	.	.	PUNCT
amwa-17	24	1	66	66	NUM
amwa-17	24	2	amwa	amwa	PROPN
amwa-17	24	3	journal	journal	PROPN
amwa-17	24	4	/	/	SYM
amwa-17	24	5	v36	v36	PROPN
amwa-17	24	6	n2	n2	PROPN
amwa-17	24	7	/	/	SYM
amwa-17	24	8	2021	2021	NUM
amwa-17	24	9	/	/	SYM
amwa-17	24	10	amwa.org	amwa.org	NOUN
amwa-17	24	11	as	as	SCONJ
amwa-17	24	12	the	the	DET
amwa-17	24	13	author	author	NOUN
amwa-17	24	14	experienced	experience	VERB
amwa-17	24	15	,	,	PUNCT
amwa-17	24	16	and	and	CCONJ
amwa-17	24	17	based	base	VERB
amwa-17	24	18	on	on	ADP
amwa-17	24	19	personal	personal	ADJ
amwa-17	24	20	communication	communication	NOUN
amwa-17	24	21	of	of	ADP
amwa-17	24	22	the	the	DET
amwa-17	24	23	author	author	NOUN
amwa-17	24	24	with	with	ADP
amwa-17	24	25	industry	industry	NOUN
amwa-17	24	26	colleagues	colleague	NOUN
amwa-17	24	27	,	,	PUNCT
amwa-17	24	28	medical	medical	ADJ
amwa-17	24	29	writers	writer	NOUN
amwa-17	24	30	set	set	VERB
amwa-17	24	31	to	to	PART
amwa-17	24	32	work	work	VERB
amwa-17	24	33	alongside	alongside	ADP
amwa-17	24	34	researchers	researcher	NOUN
amwa-17	24	35	on	on	ADP
amwa-17	24	36	manuscripts	manuscript	NOUN
amwa-17	24	37	for	for	ADP
amwa-17	24	38	covid19	covid19	NOUN
amwa-17	24	39	research	research	NOUN
amwa-17	24	40	,	,	PUNCT
amwa-17	24	41	many	many	ADJ
amwa-17	24	42	times	time	NOUN
amwa-17	24	43	resulting	result	VERB
amwa-17	24	44	in	in	ADP
amwa-17	24	45	unprecedented	unprecedented	ADJ
amwa-17	24	46	rapid	rapid	ADJ
amwa-17	24	47	review	review	NOUN
amwa-17	24	48	and	and	CCONJ
amwa-17	24	49	release	release	NOUN
amwa-17	24	50	of	of	ADP
amwa-17	24	51	results	result	NOUN
amwa-17	24	52	in	in	ADP
amwa-17	24	53	journals	journal	NOUN
amwa-17	24	54	ahead	ahead	ADV
amwa-17	24	55	of	of	ADP
amwa-17	24	56	peer	peer	NOUN
amwa-17	24	57	review	review	NOUN
amwa-17	24	58	to	to	PART
amwa-17	24	59	allow	allow	VERB
amwa-17	24	60	for	for	ADP
amwa-17	24	61	real	real	ADJ
amwa-17	24	62	-	-	PUNCT
amwa-17	24	63	time	time	NOUN
amwa-17	24	64	dissemination	dissemination	NOUN
amwa-17	24	65	.	.	PUNCT
amwa-17	25	1	regulatory	regulatory	ADJ
amwa-17	25	2	medical	medical	ADJ
amwa-17	25	3	writers	writer	NOUN
amwa-17	25	4	collaborated	collaborate	VERB
amwa-17	25	5	with	with	ADP
amwa-17	25	6	cross	cross	ADJ
amwa-17	25	7	-	-	ADJ
amwa-17	25	8	functional	functional	ADJ
amwa-17	25	9	colleagues	colleague	NOUN
amwa-17	25	10	on	on	ADP
amwa-17	25	11	investigational	investigational	ADJ
amwa-17	25	12	new	new	ADJ
amwa-17	25	13	drug	drug	NOUN
amwa-17	25	14	(	(	PUNCT
amwa-17	25	15	ind	ind	NOUN
amwa-17	25	16	)	)	PUNCT
amwa-17	25	17	application	application	NOUN
amwa-17	25	18	and	and	CCONJ
amwa-17	25	19	eua	eua	PROPN
amwa-17	25	20	documentation	documentation	NOUN
amwa-17	25	21	to	to	PART
amwa-17	25	22	enable	enable	VERB
amwa-17	25	23	clinical	clinical	ADJ
amwa-17	25	24	evaluation	evaluation	NOUN
amwa-17	25	25	of	of	ADP
amwa-17	25	26	diagnostic	diagnostic	ADJ
amwa-17	25	27	,	,	PUNCT
amwa-17	25	28	therapeutic	therapeutic	ADJ
amwa-17	25	29	,	,	PUNCT
amwa-17	25	30	and	and	CCONJ
amwa-17	25	31	preventive	preventive	ADJ
amwa-17	25	32	products	product	NOUN
amwa-17	25	33	;	;	PUNCT
amwa-17	25	34	others	other	NOUN
amwa-17	25	35	participated	participate	VERB
amwa-17	25	36	in	in	ADP
amwa-17	25	37	conversations	conversation	NOUN
amwa-17	25	38	with	with	ADP
amwa-17	25	39	contract	contract	NOUN
amwa-17	25	40	research	research	NOUN
amwa-17	25	41	organizations	organization	NOUN
amwa-17	25	42	(	(	PUNCT
amwa-17	25	43	cro	cro	NOUN
amwa-17	25	44	)	)	PUNCT
amwa-17	25	45	and	and	CCONJ
amwa-17	25	46	sites	site	NOUN
amwa-17	25	47	,	,	PUNCT
amwa-17	25	48	balancing	balance	VERB
amwa-17	25	49	operational	operational	ADJ
amwa-17	25	50	feasibility	feasibility	NOUN
amwa-17	25	51	and	and	CCONJ
amwa-17	25	52	cost	cost	NOUN
amwa-17	25	53	while	while	SCONJ
amwa-17	25	54	implementing	implement	VERB
amwa-17	25	55	evolving	evolve	VERB
amwa-17	25	56	regulatory	regulatory	ADJ
amwa-17	25	57	guidance	guidance	NOUN
amwa-17	25	58	,	,	PUNCT
amwa-17	25	59	to	to	PART
amwa-17	25	60	determine	determine	VERB
amwa-17	25	61	if	if	SCONJ
amwa-17	25	62	certain	certain	ADJ
amwa-17	25	63	non	non	ADJ
amwa-17	25	64	-	-	ADJ
amwa-17	25	65	covid-19	covid-19	ADJ
amwa-17	25	66	trials	trial	NOUN
amwa-17	25	67	would	would	AUX
amwa-17	25	68	be	be	AUX
amwa-17	25	69	able	able	ADJ
amwa-17	25	70	to	to	PART
amwa-17	25	71	continue	continue	VERB
amwa-17	25	72	during	during	ADP
amwa-17	25	73	the	the	DET
amwa-17	25	74	pandemic	pandemic	NOUN
amwa-17	25	75	.	.	PUNCT
amwa-17	26	1	although	although	SCONJ
amwa-17	26	2	medical	medical	ADJ
amwa-17	26	3	writers	writer	NOUN
amwa-17	26	4	have	have	AUX
amwa-17	26	5	connected	connect	VERB
amwa-17	26	6	with	with	ADP
amwa-17	26	7	colleagues	colleague	NOUN
amwa-17	26	8	remotely	remotely	ADV
amwa-17	26	9	via	via	ADP
amwa-17	26	10	various	various	ADJ
amwa-17	26	11	electronic	electronic	ADJ
amwa-17	26	12	media	medium	NOUN
amwa-17	26	13	for	for	ADP
amwa-17	26	14	a	a	DET
amwa-17	26	15	long	long	ADJ
amwa-17	26	16	time	time	NOUN
amwa-17	26	17	,	,	PUNCT
amwa-17	26	18	many	many	ADJ
amwa-17	26	19	recently	recently	ADV
amwa-17	26	20	have	have	AUX
amwa-17	26	21	had	have	VERB
amwa-17	26	22	to	to	PART
amwa-17	26	23	cope	cope	VERB
amwa-17	26	24	with	with	ADP
amwa-17	26	25	a	a	DET
amwa-17	26	26	new	new	ADJ
amwa-17	26	27	shift	shift	NOUN
amwa-17	26	28	in	in	ADP
amwa-17	26	29	their	their	PRON
amwa-17	26	30	workload	workload	NOUN
amwa-17	26	31	and	and	CCONJ
amwa-17	26	32	priorities	priority	NOUN
amwa-17	26	33	.	.	PUNCT
amwa-17	27	1	in	in	ADP
amwa-17	27	2	addition	addition	NOUN
amwa-17	27	3	,	,	PUNCT
amwa-17	27	4	medical	medical	ADJ
amwa-17	27	5	writers	writer	NOUN
amwa-17	27	6	have	have	AUX
amwa-17	27	7	had	have	VERB
amwa-17	27	8	to	to	PART
amwa-17	27	9	change	change	VERB
amwa-17	27	10	how	how	SCONJ
amwa-17	27	11	and	and	CCONJ
amwa-17	27	12	how	how	SCONJ
amwa-17	27	13	often	often	ADV
amwa-17	27	14	they	they	PRON
amwa-17	27	15	communicate	communicate	VERB
amwa-17	27	16	during	during	ADP
amwa-17	27	17	the	the	DET
amwa-17	27	18	writing	writing	NOUN
amwa-17	27	19	process	process	NOUN
amwa-17	27	20	to	to	PART
amwa-17	27	21	meet	meet	VERB
amwa-17	27	22	the	the	DET
amwa-17	27	23	demand	demand	NOUN
amwa-17	27	24	of	of	ADP
amwa-17	27	25	real	real	ADJ
amwa-17	27	26	-	-	PUNCT
amwa-17	27	27	time	time	NOUN
amwa-17	27	28	drug	drug	NOUN
amwa-17	27	29	development	development	NOUN
amwa-17	27	30	,	,	PUNCT
amwa-17	27	31	oftentimes	oftentime	VERB
amwa-17	27	32	working	work	VERB
amwa-17	27	33	in	in	ADP
amwa-17	27	34	coauthoring	coauthore	VERB
amwa-17	27	35	environments	environment	NOUN
amwa-17	27	36	or	or	CCONJ
amwa-17	27	37	live	live	ADJ
amwa-17	27	38	meetings	meeting	NOUN
amwa-17	27	39	rather	rather	ADV
amwa-17	27	40	than	than	ADP
amwa-17	27	41	iteratively	iteratively	ADV
amwa-17	27	42	.	.	PUNCT
amwa-17	28	1	table	table	NOUN
amwa-17	28	2	1	1	NUM
amwa-17	28	3	.	.	X
amwa-17	29	1	global	global	ADJ
amwa-17	29	2	and	and	CCONJ
amwa-17	29	3	united	united	PROPN
amwa-17	29	4	states	states	PROPN
amwa-17	29	5	covid-19	covid-19	PROPN
amwa-17	29	6	preventive	preventive	ADJ
amwa-17	29	7	and	and	CCONJ
amwa-17	29	8	therapeutic	therapeutic	ADJ
amwa-17	29	9	initiatives	initiative	NOUN
amwa-17	29	10	initiative	initiative	NOUN
amwa-17	29	11	owner(s	owner(s	NOUN
amwa-17	29	12	)	)	PUNCT
amwa-17	29	13	initiative	initiative	NOUN
amwa-17	29	14	purpose	purpose	NOUN
amwa-17	29	15	various	various	ADJ
amwa-17	29	16	governments	government	NOUN
amwa-17	29	17	,	,	PUNCT
amwa-17	29	18	scientists	scientist	NOUN
amwa-17	29	19	,	,	PUNCT
amwa-17	29	20	businesses	business	NOUN
amwa-17	29	21	,	,	PUNCT
amwa-17	29	22	civil	civil	ADJ
amwa-17	29	23	societies	society	NOUN
amwa-17	29	24	,	,	PUNCT
amwa-17	29	25	philanthropists	philanthropist	NOUN
amwa-17	29	26	,	,	PUNCT
amwa-17	29	27	and	and	CCONJ
amwa-17	29	28	global	global	ADJ
amwa-17	29	29	health	health	NOUN
amwa-17	29	30	organizations	organization	NOUN
amwa-17	29	31	the	the	DET
amwa-17	29	32	act	act	NOUN
amwa-17	29	33	accelerator	accelerator	NOUN
amwa-17	29	34	global	global	ADJ
amwa-17	29	35	collaboration	collaboration	NOUN
amwa-17	29	36	to	to	PART
amwa-17	29	37	accelerate	accelerate	VERB
amwa-17	29	38	the	the	DET
amwa-17	29	39	development	development	NOUN
amwa-17	29	40	,	,	PUNCT
amwa-17	29	41	production	production	NOUN
amwa-17	29	42	,	,	PUNCT
amwa-17	29	43	and	and	CCONJ
amwa-17	29	44	equitable	equitable	ADJ
amwa-17	29	45	access	access	NOUN
amwa-17	29	46	to	to	ADP
amwa-17	29	47	covid-19	covid-19	PROPN
amwa-17	29	48	tests	test	NOUN
amwa-17	29	49	,	,	PUNCT
amwa-17	29	50	treatments	treatment	NOUN
amwa-17	29	51	,	,	PUNCT
amwa-17	29	52	and	and	CCONJ
amwa-17	29	53	vaccines.38,39,a	vaccines.38,39,a	NOUN
amwa-17	29	54	who	who	PRON
amwa-17	29	55	+	+	CCONJ
amwa-17	29	56	global	global	ADJ
amwa-17	29	57	experts	expert	NOUN
amwa-17	29	58	r&d	r&d	NOUN
amwa-17	29	59	blueprint	blueprint	NOUN
amwa-17	29	60	a	a	DET
amwa-17	29	61	global	global	ADJ
amwa-17	29	62	strategy	strategy	NOUN
amwa-17	29	63	and	and	CCONJ
amwa-17	29	64	preparedness	preparedness	NOUN
amwa-17	29	65	plan	plan	NOUN
amwa-17	29	66	to	to	PART
amwa-17	29	67	fast	fast	ADJ
amwa-17	29	68	-	-	PUNCT
amwa-17	29	69	track	track	VERB
amwa-17	29	70	the	the	DET
amwa-17	29	71	availability	availability	NOUN
amwa-17	29	72	of	of	ADP
amwa-17	29	73	effective	effective	ADJ
amwa-17	29	74	tests	test	NOUN
amwa-17	29	75	,	,	PUNCT
amwa-17	29	76	vaccines	vaccine	NOUN
amwa-17	29	77	,	,	PUNCT
amwa-17	29	78	and	and	CCONJ
amwa-17	29	79	medicines	medicine	NOUN
amwa-17	29	80	that	that	PRON
amwa-17	29	81	can	can	AUX
amwa-17	29	82	be	be	AUX
amwa-17	29	83	used	use	VERB
amwa-17	29	84	to	to	PART
amwa-17	29	85	save	save	VERB
amwa-17	29	86	lives	life	NOUN
amwa-17	29	87	and	and	CCONJ
amwa-17	29	88	avert	avert	VERB
amwa-17	29	89	large	large	ADJ
amwa-17	29	90	-	-	PUNCT
amwa-17	29	91	scale	scale	NOUN
amwa-17	29	92	crises	crisis	NOUN
amwa-17	29	93	.	.	PUNCT
amwa-17	30	1	global	global	ADJ
amwa-17	30	2	research	research	NOUN
amwa-17	30	3	roadmap	roadmap	NOUN
amwa-17	30	4	released	release	VERB
amwa-17	30	5	in	in	ADP
amwa-17	30	6	march	march	PROPN
amwa-17	30	7	2020.40,41	2020.40,41	PROPN
amwa-17	30	8	who	who	PRON
amwa-17	30	9	solidarity	solidarity	PROPN
amwa-17	30	10	ii	ii	PROPN
amwa-17	30	11	international	international	PROPN
amwa-17	30	12	clinical	clinical	PROPN
amwa-17	30	13	trial25,b	trial25,b	DET
amwa-17	30	14	covid-19	covid-19	PROPN
amwa-17	30	15	technical	technical	ADJ
amwa-17	30	16	guidance	guidance	NOUN
amwa-17	30	17	:	:	PUNCT
amwa-17	30	18	the	the	DET
amwa-17	30	19	unity	unity	NOUN
amwa-17	30	20	studies	study	NOUN
amwa-17	30	21	:	:	PUNCT
amwa-17	30	22	early	early	ADJ
amwa-17	30	23	investigation	investigation	NOUN
amwa-17	30	24	protocols	protocol	NOUN
amwa-17	30	25	global	global	ADJ
amwa-17	30	26	collaboration	collaboration	NOUN
amwa-17	30	27	led	lead	VERB
amwa-17	30	28	by	by	ADP
amwa-17	30	29	who	who	PRON
amwa-17	30	30	that	that	PRON
amwa-17	30	31	promotes	promote	VERB
amwa-17	30	32	the	the	DET
amwa-17	30	33	implementation	implementation	NOUN
amwa-17	30	34	of	of	ADP
amwa-17	30	35	serological	serological	ADJ
amwa-17	30	36	surveys	survey	NOUN
amwa-17	30	37	of	of	ADP
amwa-17	30	38	sars	sar	NOUN
amwa-17	30	39	-	-	PUNCT
amwa-17	30	40	cov-2	cov-2	NOUN
amwa-17	30	41	.	.	PUNCT
amwa-17	30	42	promotes	promote	VERB
amwa-17	30	43	standardized	standardized	ADJ
amwa-17	30	44	epidemiological	epidemiological	ADJ
amwa-17	30	45	,	,	PUNCT
amwa-17	30	46	molecular	molecular	ADJ
amwa-17	30	47	,	,	PUNCT
amwa-17	30	48	and	and	CCONJ
amwa-17	30	49	serological	serological	ADJ
amwa-17	30	50	methods	method	NOUN
amwa-17	30	51	to	to	PART
amwa-17	30	52	facilitate	facilitate	VERB
amwa-17	30	53	international	international	ADJ
amwa-17	30	54	comparisons	comparison	NOUN
amwa-17	30	55	so	so	SCONJ
amwa-17	30	56	that	that	SCONJ
amwa-17	30	57	both	both	DET
amwa-17	30	58	countries	country	NOUN
amwa-17	30	59	and	and	CCONJ
amwa-17	30	60	the	the	DET
amwa-17	30	61	global	global	ADJ
amwa-17	30	62	community	community	NOUN
amwa-17	30	63	can	can	AUX
amwa-17	30	64	collectively	collectively	ADV
amwa-17	30	65	address	address	VERB
amwa-17	30	66	knowledge	knowledge	NOUN
amwa-17	30	67	gaps	gap	NOUN
amwa-17	30	68	and	and	CCONJ
amwa-17	30	69	inform	inform	VERB
amwa-17	30	70	an	an	DET
amwa-17	30	71	evidence	evidence	NOUN
amwa-17	30	72	-	-	PUNCT
amwa-17	30	73	based	base	VERB
amwa-17	30	74	covid-19	covid-19	PROPN
amwa-17	30	75	response.42	response.42	VERB
amwa-17	30	76	us	we	PRON
amwa-17	30	77	dhhs	dhhs	PROPN
amwa-17	30	78	ows	ows	PROPN
amwa-17	30	79	partnership	partnership	PROPN
amwa-17	30	80	among	among	ADP
amwa-17	30	81	components	component	NOUN
amwa-17	30	82	of	of	ADP
amwa-17	30	83	the	the	DET
amwa-17	30	84	dhhs	dhhs	PROPN
amwa-17	30	85	,	,	PUNCT
amwa-17	30	86	including	include	VERB
amwa-17	30	87	the	the	DET
amwa-17	30	88	cdc	cdc	PROPN
amwa-17	30	89	,	,	PUNCT
amwa-17	30	90	nih	nih	PROPN
amwa-17	30	91	,	,	PUNCT
amwa-17	30	92	barda	barda	NOUN
amwa-17	30	93	,	,	PUNCT
amwa-17	30	94	and	and	CCONJ
amwa-17	30	95	dod	dod	PROPN
amwa-17	30	96	with	with	ADP
amwa-17	30	97	private	private	ADJ
amwa-17	30	98	firms	firm	NOUN
amwa-17	30	99	and	and	CCONJ
amwa-17	30	100	other	other	ADJ
amwa-17	30	101	federal	federal	ADJ
amwa-17	30	102	agencies	agency	NOUN
amwa-17	30	103	.	.	PUNCT
amwa-17	31	1	coordinates	coordinate	NOUN
amwa-17	31	2	existing	exist	VERB
amwa-17	31	3	dhhs	dhhs	NOUN
amwa-17	31	4	-	-	PUNCT
amwa-17	31	5	wide	wide	ADJ
amwa-17	31	6	efforts	effort	NOUN
amwa-17	31	7	,	,	PUNCT
amwa-17	31	8	including	include	VERB
amwa-17	31	9	the	the	DET
amwa-17	31	10	nih	nih	PROPN
amwa-17	31	11	’s	’s	PART
amwa-17	31	12	activ	activ	PROPN
amwa-17	31	13	partnership	partnership	PROPN
amwa-17	31	14	,	,	PUNCT
amwa-17	31	15	nih	nih	PROPN
amwa-17	31	16	’s	’s	PART
amwa-17	31	17	radx	radx	PROPN
amwa-17	31	18	initiative	initiative	NOUN
amwa-17	31	19	,	,	PUNCT
amwa-17	31	20	and	and	CCONJ
amwa-17	31	21	work	work	VERB
amwa-17	31	22	by	by	ADP
amwa-17	31	23	barda	barda	PROPN
amwa-17	31	24	.	.	PUNCT
amwa-17	32	1	vaccine	vaccine	NOUN
amwa-17	32	2	candidates	candidate	NOUN
amwa-17	32	3	from	from	ADP
amwa-17	32	4	3	3	NUM
amwa-17	32	5	companies	company	NOUN
amwa-17	32	6	are	be	AUX
amwa-17	32	7	part	part	NOUN
amwa-17	32	8	of	of	ADP
amwa-17	32	9	this	this	DET
amwa-17	32	10	initiative.43	initiative.43	PROPN
amwa-17	32	11	fnih	fnih	PROPN
amwa-17	32	12	activ	activ	PROPN
amwa-17	32	13	public	public	ADJ
amwa-17	32	14	-	-	PUNCT
amwa-17	32	15	private	private	ADJ
amwa-17	32	16	partnership	partnership	NOUN
amwa-17	32	17	to	to	PART
amwa-17	32	18	speed	speed	VERB
amwa-17	32	19	covid-19	covid-19	PROPN
amwa-17	32	20	vaccine	vaccine	NOUN
amwa-17	32	21	and	and	CCONJ
amwa-17	32	22	treatment	treatment	NOUN
amwa-17	32	23	options.44	options.44	NOUN
amwa-17	32	24	us	us	PROPN
amwa-17	32	25	dhhs	dhhs	PROPN
amwa-17	32	26	,	,	PUNCT
amwa-17	32	27	nih	nih	PROPN
amwa-17	32	28	covpn	covpn	PROPN
amwa-17	32	29	merged	merge	VERB
amwa-17	32	30	4	4	NUM
amwa-17	32	31	existing	exist	VERB
amwa-17	32	32	niaid	niaid	NOUN
amwa-17	32	33	-	-	PUNCT
amwa-17	32	34	funded	fund	VERB
amwa-17	32	35	clinical	clinical	ADJ
amwa-17	32	36	trials	trial	NOUN
amwa-17	32	37	networks	network	NOUN
amwa-17	32	38	:	:	PUNCT
amwa-17	32	39	the	the	DET
amwa-17	32	40	hiv	hiv	PROPN
amwa-17	32	41	vaccine	vaccine	NOUN
amwa-17	32	42	trials	trial	NOUN
amwa-17	32	43	network	network	NOUN
amwa-17	32	44	,	,	PUNCT
amwa-17	32	45	hiv	hiv	PROPN
amwa-17	32	46	prevention	prevention	NOUN
amwa-17	32	47	trials	trial	NOUN
amwa-17	32	48	network	network	NOUN
amwa-17	32	49	,	,	PUNCT
amwa-17	32	50	infectious	infectious	ADJ
amwa-17	32	51	diseases	disease	NOUN
amwa-17	32	52	clinical	clinical	ADJ
amwa-17	32	53	research	research	NOUN
amwa-17	32	54	consortium	consortium	NOUN
amwa-17	32	55	,	,	PUNCT
amwa-17	32	56	and	and	CCONJ
amwa-17	32	57	aids	aid	VERB
amwa-17	32	58	clinical	clinical	ADJ
amwa-17	32	59	trials	trial	NOUN
amwa-17	32	60	group.45	group.45	VERB
amwa-17	32	61	us	we	PRON
amwa-17	32	62	dhhs	dhhs	PROPN
amwa-17	32	63	,	,	PUNCT
amwa-17	32	64	fda	fda	PROPN
amwa-17	32	65	ctap	ctap	PROPN
amwa-17	32	66	special	special	ADJ
amwa-17	32	67	emergency	emergency	NOUN
amwa-17	32	68	program	program	NOUN
amwa-17	32	69	for	for	ADP
amwa-17	32	70	possible	possible	ADJ
amwa-17	32	71	covid-19	covid-19	PROPN
amwa-17	32	72	therapies.46	therapies.46	NOUN
amwa-17	32	73	provides	provide	VERB
amwa-17	32	74	fda	fda	PROPN
amwa-17	32	75	subject	subject	ADJ
amwa-17	32	76	matter	matter	NOUN
amwa-17	32	77	expertise	expertise	NOUN
amwa-17	32	78	for	for	ADP
amwa-17	32	79	activ	activ	ADJ
amwa-17	32	80	initiatives	initiative	NOUN
amwa-17	32	81	,	,	PUNCT
amwa-17	32	82	including	include	VERB
amwa-17	32	83	for	for	ADP
amwa-17	32	84	clinical	clinical	ADJ
amwa-17	32	85	trial	trial	NOUN
amwa-17	32	86	design	design	NOUN
amwa-17	32	87	/	/	SYM
amwa-17	32	88	conduct	conduct	NOUN
amwa-17	32	89	and	and	CCONJ
amwa-17	32	90	regulatory	regulatory	ADJ
amwa-17	32	91	standards	standard	NOUN
amwa-17	32	92	.	.	PUNCT
amwa-17	33	1	act	act	PROPN
amwa-17	33	2	,	,	PUNCT
amwa-17	33	3	access	access	NOUN
amwa-17	33	4	to	to	ADP
amwa-17	33	5	covid-19	covid-19	PROPN
amwa-17	33	6	tools	tool	NOUN
amwa-17	33	7	;	;	PUNCT
amwa-17	33	8	activ	activ	NOUN
amwa-17	33	9	,	,	PUNCT
amwa-17	33	10	accelerating	accelerate	VERB
amwa-17	33	11	covid-19	covid-19	PROPN
amwa-17	33	12	therapeutic	therapeutic	ADJ
amwa-17	33	13	interventions	intervention	NOUN
amwa-17	33	14	and	and	CCONJ
amwa-17	33	15	vaccines	vaccine	NOUN
amwa-17	33	16	;	;	PUNCT
amwa-17	33	17	aids	aid	NOUN
amwa-17	33	18	,	,	PUNCT
amwa-17	33	19	acquired	acquire	VERB
amwa-17	33	20	immunodeficiency	immunodeficiency	NOUN
amwa-17	33	21	syndrome	syndrome	NOUN
amwa-17	33	22	;	;	PUNCT
amwa-17	33	23	barda	barda	NOUN
amwa-17	33	24	,	,	PUNCT
amwa-17	33	25	biomedical	biomedical	ADJ
amwa-17	33	26	advanced	advanced	ADJ
amwa-17	33	27	research	research	NOUN
amwa-17	33	28	and	and	CCONJ
amwa-17	33	29	development	development	NOUN
amwa-17	33	30	authority	authority	NOUN
amwa-17	33	31	;	;	PUNCT
amwa-17	33	32	covpn	covpn	NOUN
amwa-17	33	33	,	,	PUNCT
amwa-17	33	34	covid-19	covid-19	PROPN
amwa-17	33	35	prevention	prevention	NOUN
amwa-17	33	36	trials	trial	NOUN
amwa-17	33	37	network	network	NOUN
amwa-17	33	38	;	;	PUNCT
amwa-17	33	39	ctap	ctap	NOUN
amwa-17	33	40	,	,	PUNCT
amwa-17	33	41	coronavirus	coronavirus	NOUN
amwa-17	33	42	treatment	treatment	NOUN
amwa-17	33	43	acceleration	acceleration	NOUN
amwa-17	33	44	program	program	NOUN
amwa-17	33	45	;	;	PUNCT
amwa-17	33	46	dhhs	dhhs	PROPN
amwa-17	33	47	,	,	PUNCT
amwa-17	33	48	department	department	PROPN
amwa-17	33	49	of	of	ADP
amwa-17	33	50	health	health	PROPN
amwa-17	33	51	and	and	CCONJ
amwa-17	33	52	human	human	PROPN
amwa-17	33	53	services	service	NOUN
amwa-17	33	54	;	;	PUNCT
amwa-17	33	55	dod	dod	PROPN
amwa-17	33	56	,	,	PUNCT
amwa-17	33	57	department	department	PROPN
amwa-17	33	58	of	of	ADP
amwa-17	33	59	defense	defense	PROPN
amwa-17	33	60	;	;	PUNCT
amwa-17	33	61	fnih	fnih	PROPN
amwa-17	33	62	,	,	PUNCT
amwa-17	33	63	foundation	foundation	NOUN
amwa-17	33	64	of	of	ADP
amwa-17	33	65	the	the	DET
amwa-17	33	66	national	national	PROPN
amwa-17	33	67	institutes	institutes	PROPN
amwa-17	33	68	of	of	ADP
amwa-17	33	69	health	health	NOUN
amwa-17	33	70	;	;	PUNCT
amwa-17	33	71	hiv	hiv	PROPN
amwa-17	33	72	,	,	PUNCT
amwa-17	33	73	human	human	ADJ
amwa-17	33	74	immunodeficiency	immunodeficiency	NOUN
amwa-17	33	75	virus	virus	NOUN
amwa-17	33	76	;	;	PUNCT
amwa-17	33	77	niaid	niaid	PROPN
amwa-17	33	78	,	,	PUNCT
amwa-17	33	79	national	national	PROPN
amwa-17	33	80	institute	institute	PROPN
amwa-17	33	81	of	of	ADP
amwa-17	33	82	allergy	allergy	PROPN
amwa-17	33	83	and	and	CCONJ
amwa-17	33	84	infectious	infectious	ADJ
amwa-17	33	85	diseases	disease	NOUN
amwa-17	33	86	;	;	PUNCT
amwa-17	33	87	nih	nih	PROPN
amwa-17	33	88	,	,	PUNCT
amwa-17	33	89	national	national	PROPN
amwa-17	33	90	institutes	institutes	PROPN
amwa-17	33	91	of	of	ADP
amwa-17	33	92	health	health	PROPN
amwa-17	33	93	;	;	PUNCT
amwa-17	33	94	ows	ow	NOUN
amwa-17	33	95	,	,	PUNCT
amwa-17	33	96	operation	operation	NOUN
amwa-17	33	97	warp	warp	NOUN
amwa-17	33	98	speed	speed	NOUN
amwa-17	33	99	;	;	PUNCT
amwa-17	33	100	radx	radx	NOUN
amwa-17	33	101	,	,	PUNCT
amwa-17	33	102	rapid	rapid	ADJ
amwa-17	33	103	acceleration	acceleration	NOUN
amwa-17	33	104	of	of	ADP
amwa-17	33	105	diagnostics	diagnostic	NOUN
amwa-17	33	106	.	.	PUNCT
amwa-17	34	1	acovax	acovax	PROPN
amwa-17	34	2	is	be	AUX
amwa-17	34	3	the	the	DET
amwa-17	34	4	vaccines	vaccine	NOUN
amwa-17	34	5	pillar	pillar	NOUN
amwa-17	34	6	of	of	ADP
amwa-17	34	7	the	the	DET
amwa-17	34	8	act	act	NOUN
amwa-17	34	9	accelerator	accelerator	NOUN
amwa-17	34	10	.	.	PUNCT
amwa-17	35	1	more	more	ADJ
amwa-17	35	2	information	information	NOUN
amwa-17	35	3	on	on	ADP
amwa-17	35	4	the	the	DET
amwa-17	35	5	nonvaccine	nonvaccine	ADJ
amwa-17	35	6	pillars	pillar	NOUN
amwa-17	35	7	of	of	ADP
amwa-17	35	8	the	the	DET
amwa-17	35	9	act	act	NOUN
amwa-17	35	10	accelerator	accelerator	NOUN
amwa-17	35	11	is	be	AUX
amwa-17	35	12	available	available	ADJ
amwa-17	35	13	at	at	ADP
amwa-17	35	14	https://www.who.int/initiatives/	https://www.who.int/initiatives/	PROPN
amwa-17	35	15	act	act	PROPN
amwa-17	35	16	-	-	PUNCT
amwa-17	35	17	accelerator	accelerator	NOUN
amwa-17	35	18	.	.	PUNCT
amwa-17	36	1	on	on	ADP
amwa-17	36	2	december	december	PROPN
amwa-17	36	3	31	31	NUM
amwa-17	36	4	,	,	PUNCT
amwa-17	36	5	2020	2020	NUM
amwa-17	36	6	,	,	PUNCT
amwa-17	36	7	the	the	DET
amwa-17	36	8	first	first	ADJ
amwa-17	36	9	vaccine	vaccine	NOUN
amwa-17	36	10	received	receive	VERB
amwa-17	36	11	emergency	emergency	NOUN
amwa-17	36	12	use	use	NOUN
amwa-17	36	13	validation	validation	NOUN
amwa-17	36	14	from	from	ADP
amwa-17	36	15	who.39	who.39	NOUN
amwa-17	36	16	bthe	bthe	DET
amwa-17	36	17	results	result	NOUN
amwa-17	36	18	of	of	ADP
amwa-17	36	19	the	the	DET
amwa-17	36	20	solidarity	solidarity	NOUN
amwa-17	36	21	i	i	PRON
amwa-17	36	22	adaptive	adaptive	ADJ
amwa-17	36	23	treatment	treatment	NOUN
amwa-17	36	24	trial	trial	NOUN
amwa-17	36	25	became	become	VERB
amwa-17	36	26	available	available	ADJ
amwa-17	36	27	october	october	PROPN
amwa-17	36	28	15	15	NUM
amwa-17	36	29	,	,	PUNCT
amwa-17	36	30	2020	2020	NUM
amwa-17	36	31	,	,	PUNCT
amwa-17	36	32	and	and	CCONJ
amwa-17	36	33	concluded	conclude	VERB
amwa-17	36	34	that	that	SCONJ
amwa-17	36	35	the	the	DET
amwa-17	36	36	4	4	NUM
amwa-17	36	37	treatments	treatment	NOUN
amwa-17	36	38	studied	study	VERB
amwa-17	36	39	(	(	PUNCT
amwa-17	36	40	remdesivir	remdesivir	PROPN
amwa-17	36	41	,	,	PUNCT
amwa-17	36	42	hydroxychloroquine	hydroxychloroquine	PROPN
amwa-17	36	43	,	,	PUNCT
amwa-17	36	44	lopinavir	lopinavir	PROPN
amwa-17	36	45	/	/	SYM
amwa-17	36	46	ritonavir	ritonavir	PROPN
amwa-17	36	47	,	,	PUNCT
amwa-17	36	48	and	and	CCONJ
amwa-17	36	49	interferon	interferon	NOUN
amwa-17	36	50	)	)	PUNCT
amwa-17	36	51	had	have	VERB
amwa-17	36	52	little	little	ADJ
amwa-17	36	53	or	or	CCONJ
amwa-17	36	54	no	no	PRON
amwa-17	36	55	effect	effect	NOUN
amwa-17	36	56	compared	compare	VERB
amwa-17	36	57	with	with	ADP
amwa-17	36	58	standard	standard	NOUN
amwa-17	36	59	of	of	ADP
amwa-17	36	60	care	care	NOUN
amwa-17	36	61	on	on	ADP
amwa-17	36	62	overall	overall	ADJ
amwa-17	36	63	mortality	mortality	NOUN
amwa-17	36	64	,	,	PUNCT
amwa-17	36	65	initiation	initiation	NOUN
amwa-17	36	66	of	of	ADP
amwa-17	36	67	ventilation	ventilation	NOUN
amwa-17	36	68	,	,	PUNCT
amwa-17	36	69	and	and	CCONJ
amwa-17	36	70	duration	duration	NOUN
amwa-17	36	71	of	of	ADP
amwa-17	36	72	hospital	hospital	NOUN
amwa-17	36	73	stay	stay	VERB
amwa-17	36	74	in	in	ADP
amwa-17	36	75	hospitalized	hospitalize	VERB
amwa-17	36	76	patients	patient	NOUN
amwa-17	36	77	.	.	PUNCT
amwa-17	37	1	additional	additional	ADJ
amwa-17	37	2	agents	agent	NOUN
amwa-17	37	3	to	to	PART
amwa-17	37	4	be	be	AUX
amwa-17	37	5	evaluated	evaluate	VERB
amwa-17	37	6	per	per	ADP
amwa-17	37	7	who	who	PRON
amwa-17	37	8	.	.	PUNCT
amwa-17	38	1	https://www.who.int/initiatives/act-accelerator	https://www.who.int/initiatives/act-accelerator	ADJ
amwa-17	38	2	amwa	amwa	PROPN
amwa-17	38	3	journal	journal	PROPN
amwa-17	38	4	/	/	SYM
amwa-17	38	5	v36	v36	PROPN
amwa-17	38	6	n2	n2	PROPN
amwa-17	38	7	/	/	SYM
amwa-17	38	8	2021	2021	NUM
amwa-17	38	9	/	/	SYM
amwa-17	38	10	amwa.org	amwa.org	PROPN
amwa-17	38	11	67	67	NUM
amwa-17	38	12	diagnostics	diagnostic	NOUN
amwa-17	38	13	and	and	CCONJ
amwa-17	38	14	medical	medical	ADJ
amwa-17	38	15	equipment	equipment	NOUN
amwa-17	38	16	for	for	ADP
amwa-17	38	17	covid-19	covid-19	PROPN
amwa-17	38	18	under	under	ADP
amwa-17	38	19	eua	eua	PROPN
amwa-17	38	20	in	in	ADP
amwa-17	38	21	early	early	ADJ
amwa-17	38	22	february	february	PROPN
amwa-17	38	23	2020	2020	NUM
amwa-17	38	24	,	,	PUNCT
amwa-17	38	25	the	the	DET
amwa-17	38	26	first	first	ADJ
amwa-17	38	27	eua	eua	PROPN
amwa-17	38	28	for	for	ADP
amwa-17	38	29	a	a	DET
amwa-17	38	30	reverse	reverse	ADJ
amwa-17	38	31	transcription	transcription	NOUN
amwa-17	38	32	polymerase	polymerase	NOUN
amwa-17	38	33	chain	chain	NOUN
amwa-17	38	34	reaction	reaction	NOUN
amwa-17	38	35	covid-19	covid-19	PROPN
amwa-17	38	36	diagnostic	diagnostic	NOUN
amwa-17	38	37	was	be	AUX
amwa-17	38	38	issued	issue	VERB
amwa-17	38	39	for	for	ADP
amwa-17	38	40	use	use	NOUN
amwa-17	38	41	at	at	ADP
amwa-17	38	42	cdc	cdc	PROPN
amwa-17	38	43	laboratories.15	laboratories.15	PROPN
amwa-17	38	44	emergency	emergency	NOUN
amwa-17	38	45	use	use	NOUN
amwa-17	38	46	authorizations	authorization	NOUN
amwa-17	38	47	were	be	AUX
amwa-17	38	48	also	also	ADV
amwa-17	38	49	subsequently	subsequently	ADV
amwa-17	38	50	issued	issue	VERB
amwa-17	38	51	for	for	ADP
amwa-17	38	52	equipment	equipment	NOUN
amwa-17	38	53	needed	need	VERB
amwa-17	38	54	to	to	PART
amwa-17	38	55	protect	protect	VERB
amwa-17	38	56	health	health	NOUN
amwa-17	38	57	care	care	NOUN
amwa-17	38	58	workers	worker	NOUN
amwa-17	38	59	and	and	CCONJ
amwa-17	38	60	treat	treat	VERB
amwa-17	38	61	patients	patient	NOUN
amwa-17	38	62	with	with	ADP
amwa-17	38	63	covid-19	covid-19	PROPN
amwa-17	38	64	as	as	ADV
amwa-17	38	65	well	well	ADV
amwa-17	38	66	as	as	ADP
amwa-17	38	67	for	for	ADP
amwa-17	38	68	additional	additional	ADJ
amwa-17	38	69	diagnostics	diagnostic	NOUN
amwa-17	38	70	at	at	ADP
amwa-17	38	71	non	non	ADJ
amwa-17	38	72	-	-	ADJ
amwa-17	38	73	cdc	cdc	ADJ
amwa-17	38	74	laboratories	laboratory	NOUN
amwa-17	38	75	that	that	PRON
amwa-17	38	76	would	would	AUX
amwa-17	38	77	reduce	reduce	VERB
amwa-17	38	78	the	the	DET
amwa-17	38	79	time	time	NOUN
amwa-17	38	80	to	to	ADP
amwa-17	38	81	and	and	CCONJ
amwa-17	38	82	accuracy	accuracy	NOUN
amwa-17	38	83	of	of	ADP
amwa-17	38	84	results	result	NOUN
amwa-17	38	85	,	,	PUNCT
amwa-17	38	86	including	include	VERB
amwa-17	38	87	home	home	NOUN
amwa-17	38	88	testing	testing	NOUN
amwa-17	38	89	kits	kit	NOUN
amwa-17	38	90	most	most	ADV
amwa-17	38	91	recently.13,16	recently.13,16	VERB
amwa-17	38	92	the	the	DET
amwa-17	38	93	issuance	issuance	NOUN
amwa-17	38	94	of	of	ADP
amwa-17	38	95	fda	fda	PROPN
amwa-17	38	96	guidance	guidance	NOUN
amwa-17	38	97	on	on	ADP
amwa-17	38	98	diagnostic	diagnostic	ADJ
amwa-17	38	99	testing	testing	NOUN
amwa-17	38	100	in	in	ADP
amwa-17	38	101	may	may	PROPN
amwa-17	38	102	202016	202016	NUM
amwa-17	38	103	enabled	enable	VERB
amwa-17	38	104	the	the	DET
amwa-17	38	105	subsequent	subsequent	ADJ
amwa-17	38	106	availability	availability	NOUN
amwa-17	38	107	of	of	ADP
amwa-17	38	108	additional	additional	ADJ
amwa-17	38	109	testing	testing	NOUN
amwa-17	38	110	options	option	NOUN
amwa-17	38	111	(	(	PUNCT
amwa-17	38	112	for	for	ADP
amwa-17	38	113	example	example	NOUN
amwa-17	38	114	,	,	PUNCT
amwa-17	38	115	rapid	rapid	ADJ
amwa-17	38	116	antigen	antigen	ADJ
amwa-17	38	117	testing	testing	NOUN
amwa-17	38	118	)	)	PUNCT
amwa-17	38	119	.	.	PUNCT
amwa-17	39	1	upon	upon	SCONJ
amwa-17	39	2	availability	availability	NOUN
amwa-17	39	3	of	of	ADP
amwa-17	39	4	such	such	ADJ
amwa-17	39	5	testing	testing	NOUN
amwa-17	39	6	options	option	NOUN
amwa-17	39	7	,	,	PUNCT
amwa-17	39	8	medical	medical	ADJ
amwa-17	39	9	writers	writer	NOUN
amwa-17	39	10	began	begin	VERB
amwa-17	39	11	incorporating	incorporate	VERB
amwa-17	39	12	covid-19	covid-19	PROPN
amwa-17	39	13	testing	testing	NOUN
amwa-17	39	14	strategies	strategy	NOUN
amwa-17	39	15	into	into	ADP
amwa-17	39	16	study	study	NOUN
amwa-17	39	17	protocols	protocol	NOUN
amwa-17	39	18	and	and	CCONJ
amwa-17	39	19	amendments	amendment	NOUN
amwa-17	39	20	,	,	PUNCT
amwa-17	39	21	with	with	ADP
amwa-17	39	22	built	build	VERB
amwa-17	39	23	-	-	PUNCT
amwa-17	39	24	in	in	ADP
amwa-17	39	25	flexibility	flexibility	NOUN
amwa-17	39	26	in	in	ADP
amwa-17	39	27	language	language	NOUN
amwa-17	39	28	to	to	PART
amwa-17	39	29	allow	allow	VERB
amwa-17	39	30	for	for	ADP
amwa-17	39	31	regional	regional	ADJ
amwa-17	39	32	differences	difference	NOUN
amwa-17	39	33	in	in	ADP
amwa-17	39	34	testing	testing	NOUN
amwa-17	39	35	availability	availability	NOUN
amwa-17	39	36	or	or	CCONJ
amwa-17	39	37	adoption	adoption	NOUN
amwa-17	39	38	of	of	ADP
amwa-17	39	39	cdc	cdc	PROPN
amwa-17	39	40	recommendations	recommendation	NOUN
amwa-17	39	41	—	—	PUNCT
amwa-17	39	42	a	a	DET
amwa-17	39	43	critical	critical	ADJ
amwa-17	39	44	step	step	NOUN
amwa-17	39	45	toward	toward	ADP
amwa-17	39	46	the	the	DET
amwa-17	39	47	restart	restart	NOUN
amwa-17	39	48	of	of	ADP
amwa-17	39	49	early	early	ADJ
amwa-17	39	50	-	-	PUNCT
amwa-17	39	51	phase	phase	NOUN
amwa-17	39	52	trials	trial	NOUN
amwa-17	39	53	,	,	PUNCT
amwa-17	39	54	which	which	PRON
amwa-17	39	55	often	often	ADV
amwa-17	39	56	have	have	VERB
amwa-17	39	57	an	an	DET
amwa-17	39	58	in	in	ADP
amwa-17	39	59	-	-	PUNCT
amwa-17	39	60	residence	residence	NOUN
amwa-17	39	61	component	component	NOUN
amwa-17	39	62	at	at	ADP
amwa-17	39	63	the	the	DET
amwa-17	39	64	phase	phase	NOUN
amwa-17	39	65	1	1	NUM
amwa-17	39	66	unit	unit	NOUN
amwa-17	39	67	.	.	PUNCT
amwa-17	40	1	preventive	preventive	ADJ
amwa-17	40	2	and	and	CCONJ
amwa-17	40	3	therapeutic	therapeutic	ADJ
amwa-17	40	4	products	product	NOUN
amwa-17	40	5	,	,	PUNCT
amwa-17	40	6	including	include	VERB
amwa-17	40	7	vaccines	vaccine	NOUN
amwa-17	40	8	,	,	PUNCT
amwa-17	40	9	for	for	ADP
amwa-17	40	10	covid-19	covid-19	PROPN
amwa-17	40	11	under	under	ADP
amwa-17	40	12	eua	eua	PROPN
amwa-17	40	13	the	the	DET
amwa-17	40	14	writing	writing	NOUN
amwa-17	40	15	of	of	ADP
amwa-17	40	16	clinical	clinical	ADJ
amwa-17	40	17	trial	trial	NOUN
amwa-17	40	18	protocols	protocol	NOUN
amwa-17	40	19	for	for	ADP
amwa-17	40	20	covid-19	covid-19	PROPN
amwa-17	40	21	studies	study	NOUN
amwa-17	40	22	began	begin	VERB
amwa-17	40	23	in	in	ADP
amwa-17	40	24	the	the	DET
amwa-17	40	25	context	context	NOUN
amwa-17	40	26	of	of	ADP
amwa-17	40	27	the	the	DET
amwa-17	40	28	burgeoning	burgeon	VERB
amwa-17	40	29	geographic	geographic	ADJ
amwa-17	40	30	footprint	footprint	NOUN
amwa-17	40	31	of	of	ADP
amwa-17	40	32	the	the	DET
amwa-17	40	33	pandemic	pandemic	NOUN
amwa-17	40	34	,	,	PUNCT
amwa-17	40	35	with	with	SCONJ
amwa-17	40	36	health	health	NOUN
amwa-17	40	37	care	care	NOUN
amwa-17	40	38	centers	center	NOUN
amwa-17	40	39	in	in	ADP
amwa-17	40	40	some	some	DET
amwa-17	40	41	regions	region	NOUN
amwa-17	40	42	too	too	ADV
amwa-17	40	43	overwhelmed	overwhelmed	ADJ
amwa-17	40	44	by	by	ADP
amwa-17	40	45	critically	critically	ADV
amwa-17	40	46	ill	ill	ADJ
amwa-17	40	47	patients	patient	NOUN
amwa-17	40	48	to	to	PART
amwa-17	40	49	contribute	contribute	VERB
amwa-17	40	50	to	to	ADP
amwa-17	40	51	research	research	NOUN
amwa-17	40	52	while	while	SCONJ
amwa-17	40	53	simultaneously	simultaneously	ADV
amwa-17	40	54	in	in	ADP
amwa-17	40	55	dire	dire	ADJ
amwa-17	40	56	need	need	NOUN
amwa-17	40	57	of	of	ADP
amwa-17	40	58	experimental	experimental	ADJ
amwa-17	40	59	treatments	treatment	NOUN
amwa-17	40	60	,	,	PUNCT
amwa-17	40	61	leading	lead	VERB
amwa-17	40	62	to	to	ADP
amwa-17	40	63	an	an	DET
amwa-17	40	64	added	add	VERB
amwa-17	40	65	layer	layer	NOUN
amwa-17	40	66	of	of	ADP
amwa-17	40	67	volatility	volatility	NOUN
amwa-17	40	68	in	in	ADP
amwa-17	40	69	an	an	DET
amwa-17	40	70	already	already	ADV
amwa-17	40	71	dynamic	dynamic	ADJ
amwa-17	40	72	process	process	NOUN
amwa-17	40	73	.	.	PUNCT
amwa-17	41	1	accordingly	accordingly	ADV
amwa-17	41	2	,	,	PUNCT
amwa-17	41	3	regulatory	regulatory	ADJ
amwa-17	41	4	advice	advice	NOUN
amwa-17	41	5	on	on	ADP
amwa-17	41	6	the	the	DET
amwa-17	41	7	conduct	conduct	NOUN
amwa-17	41	8	of	of	ADP
amwa-17	41	9	such	such	ADJ
amwa-17	41	10	studies	study	NOUN
amwa-17	41	11	developed	develop	VERB
amwa-17	41	12	over	over	ADP
amwa-17	41	13	time	time	NOUN
amwa-17	41	14	.	.	PUNCT
amwa-17	42	1	medical	medical	ADJ
amwa-17	42	2	writers	writer	NOUN
amwa-17	42	3	worked	work	VERB
amwa-17	42	4	in	in	ADP
amwa-17	42	5	concert	concert	NOUN
amwa-17	42	6	with	with	ADP
amwa-17	42	7	their	their	PRON
amwa-17	42	8	cross	cross	ADJ
amwa-17	42	9	-	-	ADJ
amwa-17	42	10	functional	functional	ADJ
amwa-17	42	11	partners	partner	NOUN
amwa-17	42	12	,	,	PUNCT
amwa-17	42	13	regulators	regulator	NOUN
amwa-17	42	14	,	,	PUNCT
amwa-17	42	15	and	and	CCONJ
amwa-17	42	16	other	other	ADJ
amwa-17	42	17	stakeholders	stakeholder	NOUN
amwa-17	42	18	to	to	PART
amwa-17	42	19	overcome	overcome	VERB
amwa-17	42	20	these	these	DET
amwa-17	42	21	challenges	challenge	NOUN
amwa-17	42	22	and	and	CCONJ
amwa-17	42	23	produce	produce	VERB
amwa-17	42	24	protocols	protocol	NOUN
amwa-17	42	25	for	for	ADP
amwa-17	42	26	evaluation	evaluation	NOUN
amwa-17	42	27	of	of	ADP
amwa-17	42	28	a	a	DET
amwa-17	42	29	novel	novel	ADJ
amwa-17	42	30	virus	virus	NOUN
amwa-17	42	31	and	and	CCONJ
amwa-17	42	32	to	to	PART
amwa-17	42	33	interpret	interpret	VERB
amwa-17	42	34	and	and	CCONJ
amwa-17	42	35	convey	convey	VERB
amwa-17	42	36	the	the	DET
amwa-17	42	37	results	result	NOUN
amwa-17	42	38	of	of	ADP
amwa-17	42	39	those	those	DET
amwa-17	42	40	studies	study	NOUN
amwa-17	42	41	in	in	ADP
amwa-17	42	42	record	record	NOUN
amwa-17	42	43	time	time	NOUN
amwa-17	42	44	.	.	PUNCT
amwa-17	43	1	the	the	DET
amwa-17	43	2	first	first	ADJ
amwa-17	43	3	eua	eua	PROPN
amwa-17	43	4	for	for	ADP
amwa-17	43	5	a	a	DET
amwa-17	43	6	covid-19	covid-19	PROPN
amwa-17	43	7	therapeutic	therapeutic	NOUN
amwa-17	43	8	was	be	AUX
amwa-17	43	9	granted	grant	VERB
amwa-17	43	10	in	in	ADP
amwa-17	43	11	march	march	PROPN
amwa-17	43	12	2020	2020	NUM
amwa-17	43	13	for	for	ADP
amwa-17	43	14	antimalarial	antimalarial	ADJ
amwa-17	43	15	agents	agent	NOUN
amwa-17	43	16	hydroxychloroquine	hydroxychloroquine	ADJ
amwa-17	43	17	and	and	CCONJ
amwa-17	43	18	chloroquine	chloroquine	NOUN
amwa-17	43	19	(	(	PUNCT
amwa-17	43	20	table	table	NOUN
amwa-17	43	21	2).13	2).13	NUM
amwa-17	43	22	the	the	DET
amwa-17	43	23	fda	fda	PROPN
amwa-17	43	24	issued	issue	VERB
amwa-17	43	25	several	several	ADJ
amwa-17	43	26	guidance	guidance	NOUN
amwa-17	43	27	documents	document	NOUN
amwa-17	43	28	in	in	ADP
amwa-17	43	29	may	may	PROPN
amwa-17	43	30	2020	2020	NUM
amwa-17	43	31	toward	toward	ADP
amwa-17	43	32	expediting	expedite	VERB
amwa-17	43	33	development	development	NOUN
amwa-17	43	34	of	of	ADP
amwa-17	43	35	covid-19	covid-19	PROPN
amwa-17	43	36	products,17	products,17	NOUN
amwa-17	43	37	including	include	VERB
amwa-17	43	38	information	information	NOUN
amwa-17	43	39	on	on	ADP
amwa-17	43	40	the	the	DET
amwa-17	43	41	process	process	NOUN
amwa-17	43	42	for	for	ADP
amwa-17	43	43	initiating	initiate	VERB
amwa-17	43	44	discussions	discussion	NOUN
amwa-17	43	45	with	with	ADP
amwa-17	43	46	the	the	DET
amwa-17	43	47	fda	fda	PROPN
amwa-17	43	48	(	(	PUNCT
amwa-17	43	49	pre	pre	VERB
amwa-17	43	50	-	-	ADJ
amwa-17	43	51	ind)18	ind)18	PRON
amwa-17	43	52	and	and	CCONJ
amwa-17	43	53	study	study	VERB
amwa-17	43	54	design	design	NOUN
amwa-17	43	55	recommendations	recommendation	NOUN
amwa-17	43	56	,	,	PUNCT
amwa-17	43	57	including	include	VERB
amwa-17	43	58	patient	patient	ADJ
amwa-17	43	59	selection	selection	NOUN
amwa-17	43	60	,	,	PUNCT
amwa-17	43	61	endpoints	endpoint	NOUN
amwa-17	43	62	,	,	PUNCT
amwa-17	43	63	and	and	CCONJ
amwa-17	43	64	analyses.19,20	analyses.19,20	NOUN
amwa-17	43	65	guidelines	guideline	NOUN
amwa-17	43	66	on	on	ADP
amwa-17	43	67	vaccine	vaccine	NOUN
amwa-17	43	68	development	development	NOUN
amwa-17	43	69	were	be	AUX
amwa-17	43	70	issued	issue	VERB
amwa-17	43	71	the	the	DET
amwa-17	43	72	following	follow	VERB
amwa-17	43	73	month	month	NOUN
amwa-17	43	74	and	and	CCONJ
amwa-17	43	75	updated	update	VERB
amwa-17	43	76	in	in	ADP
amwa-17	43	77	october	october	PROPN
amwa-17	43	78	and	and	CCONJ
amwa-17	43	79	most	most	ADV
amwa-17	43	80	recently	recently	ADV
amwa-17	43	81	in	in	ADP
amwa-17	43	82	february	february	PROPN
amwa-17	43	83	of	of	ADP
amwa-17	43	84	2021	2021	NUM
amwa-17	43	85	to	to	PART
amwa-17	43	86	outline	outline	VERB
amwa-17	43	87	the	the	DET
amwa-17	43	88	vaccine	vaccine	NOUN
amwa-17	43	89	eua	eua	PROPN
amwa-17	43	90	process.21,22	process.21,22	PROPN
amwa-17	43	91	subsequent	subsequent	PROPN
amwa-17	43	92	euas	euas	PROPN
amwa-17	43	93	were	be	AUX
amwa-17	43	94	granted	grant	VERB
amwa-17	43	95	for	for	ADP
amwa-17	43	96	9	9	NUM
amwa-17	43	97	additional	additional	ADJ
amwa-17	43	98	products	product	NOUN
amwa-17	43	99	,	,	PUNCT
amwa-17	43	100	including	include	VERB
amwa-17	43	101	an	an	DET
amwa-17	43	102	antiviral	antiviral	NOUN
amwa-17	43	103	in	in	ADP
amwa-17	43	104	may	may	PROPN
amwa-17	43	105	,	,	PUNCT
amwa-17	43	106	convalescent	convalescent	NOUN
amwa-17	43	107	plasma	plasma	NOUN
amwa-17	43	108	in	in	ADP
amwa-17	43	109	august	august	PROPN
amwa-17	43	110	,	,	PUNCT
amwa-17	43	111	monoclonal	monoclonal	NOUN
amwa-17	43	112	antibody	antibody	NOUN
amwa-17	43	113	regimens	regimen	NOUN
amwa-17	43	114	in	in	ADP
amwa-17	43	115	november	november	PROPN
amwa-17	43	116	,	,	PUNCT
amwa-17	43	117	and	and	CCONJ
amwa-17	43	118	the	the	DET
amwa-17	43	119	first	first	ADJ
amwa-17	43	120	vaccines	vaccine	NOUN
amwa-17	43	121	in	in	ADP
amwa-17	43	122	december	december	PROPN
amwa-17	43	123	2020	2020	NUM
amwa-17	43	124	(	(	PUNCT
amwa-17	43	125	table	table	NOUN
amwa-17	43	126	2).13,23	2).13,23	NUM
amwa-17	43	127	monitoring	monitoring	NOUN
amwa-17	43	128	of	of	ADP
amwa-17	43	129	previously	previously	ADV
amwa-17	43	130	issued	issue	VERB
amwa-17	43	131	euas	euas	NOUN
amwa-17	43	132	continues	continue	VERB
amwa-17	43	133	and	and	CCONJ
amwa-17	43	134	,	,	PUNCT
amwa-17	43	135	in	in	ADP
amwa-17	43	136	some	some	DET
amwa-17	43	137	cases	case	NOUN
amwa-17	43	138	,	,	PUNCT
amwa-17	43	139	has	have	AUX
amwa-17	43	140	led	lead	VERB
amwa-17	43	141	to	to	ADP
amwa-17	43	142	the	the	DET
amwa-17	43	143	withdrawal	withdrawal	NOUN
amwa-17	43	144	of	of	ADP
amwa-17	43	145	the	the	DET
amwa-17	43	146	eua	eua	PROPN
amwa-17	43	147	,	,	PUNCT
amwa-17	43	148	such	such	ADJ
amwa-17	43	149	as	as	ADP
amwa-17	43	150	that	that	PRON
amwa-17	43	151	which	which	PRON
amwa-17	43	152	occurred	occur	VERB
amwa-17	43	153	for	for	ADP
amwa-17	43	154	hydroxychloroquine	hydroxychloroquine	NOUN
amwa-17	43	155	and	and	CCONJ
amwa-17	43	156	chloroquine	chloroquine	VERB
amwa-17	43	157	upon	upon	SCONJ
amwa-17	43	158	analysis	analysis	NOUN
amwa-17	43	159	of	of	ADP
amwa-17	43	160	conflicting	conflicting	ADJ
amwa-17	43	161	data	datum	NOUN
amwa-17	43	162	(	(	PUNCT
amwa-17	43	163	including	include	VERB
amwa-17	43	164	results	result	NOUN
amwa-17	43	165	from	from	ADP
amwa-17	43	166	a	a	DET
amwa-17	43	167	randomized	randomized	ADJ
amwa-17	43	168	,	,	PUNCT
amwa-17	43	169	controlled	control	VERB
amwa-17	43	170	trial	trial	NOUN
amwa-17	43	171	)	)	PUNCT
amwa-17	43	172	that	that	PRON
amwa-17	43	173	brought	bring	VERB
amwa-17	43	174	into	into	ADP
amwa-17	43	175	question	question	NOUN
amwa-17	43	176	the	the	DET
amwa-17	43	177	benefit	benefit	NOUN
amwa-17	43	178	-	-	PUNCT
amwa-17	43	179	risk	risk	NOUN
amwa-17	43	180	profile	profile	NOUN
amwa-17	43	181	of	of	ADP
amwa-17	43	182	this	this	DET
amwa-17	43	183	regimen	regimen	NOUN
amwa-17	43	184	for	for	ADP
amwa-17	43	185	treatment	treatment	NOUN
amwa-17	43	186	of	of	ADP
amwa-17	43	187	covid-19.13,24,25	covid-19.13,24,25	PROPN
amwa-17	43	188	the	the	DET
amwa-17	43	189	eua	eua	PROPN
amwa-17	43	190	issued	issue	VERB
amwa-17	43	191	for	for	ADP
amwa-17	43	192	antiviral	antiviral	ADJ
amwa-17	43	193	remdesivir	remdesivir	NOUN
amwa-17	43	194	in	in	ADP
amwa-17	43	195	may	may	AUX
amwa-17	43	196	led	lead	VERB
amwa-17	43	197	to	to	ADP
amwa-17	43	198	approval	approval	NOUN
amwa-17	43	199	of	of	ADP
amwa-17	43	200	the	the	DET
amwa-17	43	201	drug	drug	NOUN
amwa-17	43	202	as	as	ADP
amwa-17	43	203	the	the	DET
amwa-17	43	204	first	first	ADJ
amwa-17	43	205	treatment	treatment	NOUN
amwa-17	43	206	for	for	ADP
amwa-17	43	207	covid-19	covid-19	PROPN
amwa-17	43	208	under	under	ADP
amwa-17	43	209	the	the	DET
amwa-17	43	210	coronavirus	coronavirus	NOUN
amwa-17	43	211	treatment	treatment	NOUN
amwa-17	43	212	acceleration	acceleration	NOUN
amwa-17	43	213	program	program	NOUN
amwa-17	43	214	(	(	PUNCT
amwa-17	43	215	see	see	VERB
amwa-17	43	216	table	table	NOUN
amwa-17	43	217	1	1	NUM
amwa-17	43	218	)	)	PUNCT
amwa-17	43	219	in	in	ADP
amwa-17	43	220	october	october	PROPN
amwa-17	43	221	2020	2020	NUM
amwa-17	43	222	.	.	PUNCT
amwa-17	44	1	as	as	ADP
amwa-17	44	2	of	of	ADP
amwa-17	44	3	january	january	PROPN
amwa-17	44	4	2021	2021	NUM
amwa-17	44	5	,	,	PUNCT
amwa-17	44	6	a	a	DET
amwa-17	44	7	search	search	NOUN
amwa-17	44	8	on	on	ADP
amwa-17	44	9	the	the	DET
amwa-17	44	10	us	us	PROPN
amwa-17	44	11	national	national	PROPN
amwa-17	44	12	library	library	NOUN
amwa-17	44	13	of	of	ADP
amwa-17	44	14	medicine	medicine	NOUN
amwa-17	44	15	’s	’s	PART
amwa-17	44	16	clinicaltrials.gov	clinicaltrials.gov	NOUN
amwa-17	44	17	(	(	PUNCT
amwa-17	44	18	search	search	NOUN
amwa-17	44	19	terms	term	NOUN
amwa-17	44	20	of	of	ADP
amwa-17	44	21	covid-19	covid-19	PROPN
amwa-17	44	22	and	and	CCONJ
amwa-17	44	23	sars	sar	NOUN
amwa-17	44	24	-	-	PUNCT
amwa-17	44	25	cov-2	cov-2	NOUN
amwa-17	44	26	,	,	PUNCT
amwa-17	44	27	with	with	ADP
amwa-17	44	28	a	a	DET
amwa-17	44	29	recruitment	recruitment	NOUN
amwa-17	44	30	status	status	NOUN
amwa-17	44	31	of	of	ADP
amwa-17	44	32	not	not	PART
amwa-17	44	33	yet	yet	ADV
amwa-17	44	34	recruiting	recruit	VERB
amwa-17	44	35	,	,	PUNCT
amwa-17	44	36	recruiting	recruiting	NOUN
amwa-17	44	37	,	,	PUNCT
amwa-17	44	38	enrolling	enrolling	NOUN
amwa-17	44	39	by	by	ADP
amwa-17	44	40	invitation	invitation	NOUN
amwa-17	44	41	,	,	PUNCT
amwa-17	44	42	active	active	ADJ
amwa-17	44	43	,	,	PUNCT
amwa-17	44	44	or	or	CCONJ
amwa-17	44	45	not	not	PART
amwa-17	44	46	recruiting	recruit	VERB
amwa-17	44	47	)	)	PUNCT
amwa-17	44	48	returns	return	NOUN
amwa-17	44	49	results	result	VERB
amwa-17	44	50	for	for	ADP
amwa-17	44	51	over	over	ADP
amwa-17	44	52	3,500	3,500	NUM
amwa-17	44	53	covid-19	covid-19	PROPN
amwa-17	44	54	clinical	clinical	ADJ
amwa-17	44	55	trials	trial	NOUN
amwa-17	44	56	that	that	PRON
amwa-17	44	57	are	be	AUX
amwa-17	44	58	ongoing	ongoing	ADJ
amwa-17	44	59	or	or	CCONJ
amwa-17	44	60	in	in	ADP
amwa-17	44	61	start	start	NOUN
amwa-17	44	62	-	-	PUNCT
amwa-17	44	63	up.26	up.26	ADJ
amwa-17	44	64	clinical	clinical	ADJ
amwa-17	44	65	trials	trial	NOUN
amwa-17	44	66	during	during	ADP
amwa-17	44	67	the	the	DET
amwa-17	44	68	covid-19	covid-19	PROPN
amwa-17	44	69	pandemic	pandemic	NOUN
amwa-17	44	70	between	between	ADP
amwa-17	44	71	approximately	approximately	ADV
amwa-17	44	72	march	march	PROPN
amwa-17	44	73	and	and	CCONJ
amwa-17	44	74	may	may	PROPN
amwa-17	44	75	2020	2020	NUM
amwa-17	44	76	,	,	PUNCT
amwa-17	44	77	thousands	thousand	NOUN
amwa-17	44	78	of	of	ADP
amwa-17	44	79	clinical	clinical	ADJ
amwa-17	44	80	trials	trial	NOUN
amwa-17	44	81	(	(	PUNCT
amwa-17	44	82	or	or	CCONJ
amwa-17	44	83	around	around	ADP
amwa-17	44	84	80	80	NUM
amwa-17	44	85	%	%	NOUN
amwa-17	44	86	of	of	ADP
amwa-17	44	87	non	non	ADJ
amwa-17	44	88	-	-	ADJ
amwa-17	44	89	covid-19	covid-19	ADJ
amwa-17	44	90	trials	trial	NOUN
amwa-17	44	91	)	)	PUNCT
amwa-17	44	92	reported	report	VERB
amwa-17	44	93	a	a	DET
amwa-17	44	94	disruption,27	disruption,27	NOUN
amwa-17	44	95	-	-	SYM
amwa-17	44	96	30	30	NUM
amwa-17	44	97	with	with	ADP
amwa-17	44	98	the	the	DET
amwa-17	44	99	majority	majority	NOUN
amwa-17	44	100	of	of	ADP
amwa-17	44	101	these	these	PRON
amwa-17	44	102	being	be	AUX
amwa-17	44	103	early	early	ADJ
amwa-17	44	104	-	-	PUNCT
amwa-17	44	105	phase	phase	NOUN
amwa-17	44	106	trials	trial	NOUN
amwa-17	44	107	that	that	PRON
amwa-17	44	108	had	have	AUX
amwa-17	44	109	not	not	PART
amwa-17	44	110	yet	yet	ADV
amwa-17	44	111	started	start	VERB
amwa-17	44	112	enrolling	enrol	VERB
amwa-17	44	113	patients.27,29	patients.27,29	NOUN
amwa-17	44	114	the	the	DET
amwa-17	44	115	most	most	ADV
amwa-17	44	116	affected	affected	ADJ
amwa-17	44	117	therapeutic	therapeutic	ADJ
amwa-17	44	118	areas	area	NOUN
amwa-17	44	119	included	include	VERB
amwa-17	44	120	those	those	PRON
amwa-17	44	121	enrolling	enrol	VERB
amwa-17	44	122	participants	participant	NOUN
amwa-17	44	123	with	with	ADP
amwa-17	44	124	advanced	advanced	ADJ
amwa-17	44	125	or	or	CCONJ
amwa-17	44	126	life	life	NOUN
amwa-17	44	127	-	-	PUNCT
amwa-17	44	128	threatening	threaten	VERB
amwa-17	44	129	conditions	condition	NOUN
amwa-17	44	130	such	such	ADJ
amwa-17	44	131	as	as	ADP
amwa-17	44	132	cardiovascular	cardiovascular	ADJ
amwa-17	44	133	disease	disease	NOUN
amwa-17	44	134	or	or	CCONJ
amwa-17	44	135	oncology	oncology	NOUN
amwa-17	44	136	—	—	PUNCT
amwa-17	44	137	indeed	indeed	ADV
amwa-17	44	138	,	,	PUNCT
amwa-17	44	139	the	the	DET
amwa-17	44	140	very	very	ADJ
amwa-17	44	141	patients	patient	NOUN
amwa-17	44	142	who	who	PRON
amwa-17	44	143	are	be	AUX
amwa-17	44	144	most	most	ADV
amwa-17	44	145	at	at	ADP
amwa-17	44	146	risk	risk	NOUN
amwa-17	44	147	for	for	ADP
amwa-17	44	148	covid-1931	covid-1931	ADJ
amwa-17	44	149	—	—	PUNCT
amwa-17	44	150	who	who	PRON
amwa-17	44	151	often	often	ADV
amwa-17	44	152	have	have	VERB
amwa-17	44	153	few	few	ADJ
amwa-17	44	154	other	other	ADJ
amwa-17	44	155	treatment	treatment	NOUN
amwa-17	44	156	options	option	NOUN
amwa-17	44	157	;	;	PUNCT
amwa-17	44	158	the	the	DET
amwa-17	44	159	typical	typical	ADJ
amwa-17	44	160	intravenous	intravenous	PROPN
amwa-17	44	161	administration	administration	PROPN
amwa-17	44	162	route	route	NOUN
amwa-17	44	163	of	of	ADP
amwa-17	44	164	oncologic	oncologic	ADJ
amwa-17	44	165	treatments	treatment	NOUN
amwa-17	44	166	,	,	PUNCT
amwa-17	44	167	which	which	PRON
amwa-17	44	168	require	require	VERB
amwa-17	44	169	patients	patient	NOUN
amwa-17	44	170	to	to	PART
amwa-17	44	171	go	go	VERB
amwa-17	44	172	to	to	ADP
amwa-17	44	173	the	the	DET
amwa-17	44	174	clinical	clinical	ADJ
amwa-17	44	175	site	site	NOUN
amwa-17	44	176	for	for	ADP
amwa-17	44	177	infusions	infusion	NOUN
amwa-17	44	178	,	,	PUNCT
amwa-17	44	179	has	have	AUX
amwa-17	44	180	led	lead	VERB
amwa-17	44	181	to	to	ADP
amwa-17	44	182	additional	additional	ADJ
amwa-17	44	183	logistical	logistical	ADJ
amwa-17	44	184	hurdles.29,32	hurdles.29,32	NOUN
amwa-17	44	185	disruptions	disruption	NOUN
amwa-17	44	186	were	be	AUX
amwa-17	44	187	reported	report	VERB
amwa-17	44	188	as	as	ADP
amwa-17	44	189	delay	delay	NOUN
amwa-17	44	190	or	or	CCONJ
amwa-17	44	191	suspension	suspension	NOUN
amwa-17	44	192	in	in	ADP
amwa-17	44	193	enrollment	enrollment	NOUN
amwa-17	44	194	,	,	PUNCT
amwa-17	44	195	delay	delay	NOUN
amwa-17	44	196	in	in	ADP
amwa-17	44	197	study	study	NOUN
amwa-17	44	198	start	start	VERB
amwa-17	44	199	-	-	PUNCT
amwa-17	44	200	up	up	ADP
amwa-17	44	201	activities	activity	NOUN
amwa-17	44	202	or	or	CCONJ
amwa-17	44	203	initiation	initiation	NOUN
amwa-17	44	204	of	of	ADP
amwa-17	44	205	certain	certain	ADJ
amwa-17	44	206	sites	site	NOUN
amwa-17	44	207	,	,	PUNCT
amwa-17	44	208	delay	delay	NOUN
amwa-17	44	209	in	in	ADP
amwa-17	44	210	dosing	dosing	NOUN
amwa-17	44	211	,	,	PUNCT
amwa-17	44	212	termination	termination	NOUN
amwa-17	44	213	of	of	ADP
amwa-17	44	214	enrollment	enrollment	NOUN
amwa-17	44	215	at	at	ADP
amwa-17	44	216	specific	specific	ADJ
amwa-17	44	217	sites	site	NOUN
amwa-17	44	218	,	,	PUNCT
amwa-17	44	219	early	early	ADJ
amwa-17	44	220	trial	trial	NOUN
amwa-17	44	221	termination	termination	NOUN
amwa-17	44	222	,	,	PUNCT
amwa-17	44	223	and	and	CCONJ
amwa-17	44	224	delay	delay	VERB
amwa-17	44	225	in	in	ADP
amwa-17	44	226	trial	trial	NOUN
amwa-17	44	227	completion	completion	NOUN
amwa-17	44	228	or	or	CCONJ
amwa-17	44	229	availability	availability	NOUN
amwa-17	44	230	of	of	ADP
amwa-17	44	231	data.26,29	data.26,29	NOUN
amwa-17	44	232	in	in	ADP
amwa-17	44	233	many	many	ADJ
amwa-17	44	234	cases	case	NOUN
amwa-17	44	235	,	,	PUNCT
amwa-17	44	236	clinical	clinical	ADJ
amwa-17	44	237	trials	trial	NOUN
amwa-17	44	238	that	that	PRON
amwa-17	44	239	were	be	AUX
amwa-17	44	240	nearly	nearly	ADV
amwa-17	44	241	or	or	CCONJ
amwa-17	44	242	already	already	ADV
amwa-17	44	243	fully	fully	ADV
amwa-17	44	244	enrolled	enrol	VERB
amwa-17	44	245	in	in	ADP
amwa-17	44	246	patient	patient	ADJ
amwa-17	44	247	populations	population	NOUN
amwa-17	44	248	with	with	ADP
amwa-17	44	249	life	life	NOUN
amwa-17	44	250	-	-	PUNCT
amwa-17	44	251	threatening	threaten	VERB
amwa-17	44	252	conditions	condition	NOUN
amwa-17	44	253	continued	continue	VERB
amwa-17	44	254	with	with	ADP
amwa-17	44	255	modifications	modification	NOUN
amwa-17	44	256	to	to	PART
amwa-17	44	257	address	address	VERB
amwa-17	44	258	the	the	DET
amwa-17	44	259	uncertainties	uncertainty	NOUN
amwa-17	44	260	and	and	CCONJ
amwa-17	44	261	challenges	challenge	NOUN
amwa-17	44	262	of	of	ADP
amwa-17	44	263	conducting	conduct	VERB
amwa-17	44	264	clinical	clinical	ADJ
amwa-17	44	265	trials	trial	NOUN
amwa-17	44	266	in	in	ADP
amwa-17	44	267	an	an	DET
amwa-17	44	268	already	already	ADV
amwa-17	44	269	burdened	burden	VERB
amwa-17	44	270	health	health	NOUN
amwa-17	44	271	care	care	NOUN
amwa-17	44	272	system.29	system.29	PROPN
amwa-17	44	273	in	in	ADP
amwa-17	44	274	march	march	PROPN
amwa-17	44	275	2020	2020	NUM
amwa-17	44	276	,	,	PUNCT
amwa-17	44	277	the	the	DET
amwa-17	44	278	fda	fda	PROPN
amwa-17	44	279	issued	issue	VERB
amwa-17	44	280	guidance	guidance	NOUN
amwa-17	44	281	on	on	ADP
amwa-17	44	282	the	the	DET
amwa-17	44	283	conduct	conduct	NOUN
amwa-17	44	284	of	of	ADP
amwa-17	44	285	clinical	clinical	ADJ
amwa-17	44	286	trials	trial	NOUN
amwa-17	44	287	during	during	ADP
amwa-17	44	288	the	the	DET
amwa-17	44	289	covid-19	covid-19	PROPN
amwa-17	44	290	pandemic	pandemic	NOUN
amwa-17	44	291	,	,	PUNCT
amwa-17	44	292	with	with	ADP
amwa-17	44	293	the	the	DET
amwa-17	44	294	goal	goal	NOUN
amwa-17	44	295	of	of	ADP
amwa-17	44	296	ensuring	ensure	VERB
amwa-17	44	297	“	"	PUNCT
amwa-17	44	298	the	the	DET
amwa-17	44	299	safety	safety	NOUN
amwa-17	44	300	of	of	ADP
amwa-17	44	301	trial	trial	NOUN
amwa-17	44	302	participants	participant	NOUN
amwa-17	44	303	,	,	PUNCT
amwa-17	44	304	maintaining	maintain	VERB
amwa-17	44	305	compliance	compliance	NOUN
amwa-17	44	306	with	with	ADP
amwa-17	44	307	good	good	ADJ
amwa-17	44	308	clinical	clinical	ADJ
amwa-17	44	309	practice	practice	NOUN
amwa-17	44	310	and	and	CCONJ
amwa-17	44	311	minimizing	minimize	VERB
amwa-17	44	312	risks	risk	NOUN
amwa-17	44	313	to	to	ADP
amwa-17	44	314	trial	trial	NOUN
amwa-17	44	315	integrity	integrity	NOUN
amwa-17	44	316	.	.	PUNCT
amwa-17	45	1	”33	”33	VERB
amwa-17	45	2	the	the	DET
amwa-17	45	3	guidance	guidance	NOUN
amwa-17	45	4	has	have	AUX
amwa-17	45	5	been	be	AUX
amwa-17	45	6	updated	update	VERB
amwa-17	45	7	on	on	ADP
amwa-17	45	8	a	a	DET
amwa-17	45	9	regular	regular	ADJ
amwa-17	45	10	basis	basis	NOUN
amwa-17	45	11	and	and	CCONJ
amwa-17	45	12	covers	cover	VERB
amwa-17	45	13	key	key	ADJ
amwa-17	45	14	topics	topic	NOUN
amwa-17	45	15	,	,	PUNCT
amwa-17	45	16	such	such	ADJ
amwa-17	45	17	as	as	ADP
amwa-17	45	18	:	:	PUNCT
amwa-17	45	19	•	•	NOUN
amwa-17	45	20	electronic	electronic	ADJ
amwa-17	45	21	and	and	CCONJ
amwa-17	45	22	other	other	ADJ
amwa-17	45	23	remote	remote	ADJ
amwa-17	45	24	informed	inform	VERB
amwa-17	45	25	consent	consent	NOUN
amwa-17	45	26	options	option	NOUN
amwa-17	45	27	•	•	ADP
amwa-17	45	28	alternative	alternative	ADJ
amwa-17	45	29	formats	format	NOUN
amwa-17	45	30	for	for	ADP
amwa-17	45	31	visits	visit	NOUN
amwa-17	45	32	(	(	PUNCT
amwa-17	45	33	eg	eg	NOUN
amwa-17	45	34	,	,	PUNCT
amwa-17	45	35	phone	phone	NOUN
amwa-17	45	36	contact	contact	NOUN
amwa-17	45	37	,	,	PUNCT
amwa-17	45	38	virtual	virtual	ADJ
amwa-17	45	39	visit	visit	NOUN
amwa-17	45	40	,	,	PUNCT
amwa-17	45	41	alternative	alternative	ADJ
amwa-17	45	42	locations	location	NOUN
amwa-17	45	43	,	,	PUNCT
amwa-17	45	44	local	local	ADJ
amwa-17	45	45	laboratory	laboratory	NOUN
amwa-17	45	46	or	or	CCONJ
amwa-17	45	47	imaging	imaging	NOUN
amwa-17	45	48	centers	center	NOUN
amwa-17	45	49	,	,	PUNCT
amwa-17	45	50	home	home	NOUN
amwa-17	45	51	nursing	nursing	NOUN
amwa-17	45	52	)	)	PUNCT
amwa-17	45	53	•	•	ADP
amwa-17	45	54	alternative	alternative	ADJ
amwa-17	45	55	formats	format	NOUN
amwa-17	45	56	for	for	ADP
amwa-17	45	57	clinical	clinical	ADJ
amwa-17	45	58	outcome	outcome	NOUN
amwa-17	45	59	assessments	assessment	NOUN
amwa-17	45	60	(	(	PUNCT
amwa-17	45	61	ie	ie	X
amwa-17	45	62	,	,	PUNCT
amwa-17	45	63	patient	patient	NOUN
amwa-17	45	64	-	-	PUNCT
amwa-17	45	65	reported	report	VERB
amwa-17	45	66	outcomes	outcome	NOUN
amwa-17	45	67	,	,	PUNCT
amwa-17	45	68	clinician	clinician	NOUN
amwa-17	45	69	-	-	PUNCT
amwa-17	45	70	reported	report	VERB
amwa-17	45	71	outcomes	outcome	NOUN
amwa-17	45	72	,	,	PUNCT
amwa-17	45	73	and	and	CCONJ
amwa-17	45	74	observer	observer	NOUN
amwa-17	45	75	-	-	PUNCT
amwa-17	45	76	reported	report	VERB
amwa-17	45	77	outcomes	outcome	NOUN
amwa-17	45	78	)	)	PUNCT
amwa-17	45	79	,	,	PUNCT
amwa-17	45	80	including	include	VERB
amwa-17	45	81	protection	protection	NOUN
amwa-17	45	82	of	of	ADP
amwa-17	45	83	data	datum	NOUN
amwa-17	45	84	privacy	privacy	NOUN
amwa-17	45	85	68	68	NUM
amwa-17	45	86	amwa	amwa	PROPN
amwa-17	45	87	journal	journal	PROPN
amwa-17	45	88	/	/	SYM
amwa-17	45	89	v36	v36	PROPN
amwa-17	45	90	n2	n2	PROPN
amwa-17	45	91	/	/	SYM
amwa-17	45	92	2021	2021	NUM
amwa-17	45	93	/	/	SYM
amwa-17	45	94	amwa.org	amwa.org	NOUN
amwa-17	45	95	table	table	NOUN
amwa-17	45	96	2	2	NUM
amwa-17	45	97	.	.	PUNCT
amwa-17	46	1	covid-19	covid-19	PROPN
amwa-17	46	2	therapeutics	therapeutic	NOUN
amwa-17	46	3	and	and	CCONJ
amwa-17	46	4	biological	biological	ADJ
amwa-17	46	5	products	product	NOUN
amwa-17	46	6	approved	approve	VERB
amwa-17	46	7	under	under	ADP
amwa-17	46	8	eua	eua	PROPN
amwa-17	46	9	date	date	NOUN
amwa-17	46	10	of	of	ADP
amwa-17	46	11	first	first	PROPN
amwa-17	46	12	eua	eua	PROPN
amwa-17	46	13	issuance	issuance	NOUN
amwa-17	46	14	(	(	PUNCT
amwa-17	46	15	reissuance	reissuance	NOUN
amwa-17	46	16	,	,	PUNCT
amwa-17	46	17	if	if	SCONJ
amwa-17	46	18	applicable	applicable	ADJ
amwa-17	46	19	)	)	PUNCT
amwa-17	46	20	approved	approve	VERB
amwa-17	46	21	product	product	NOUN
amwa-17	46	22	under	under	ADP
amwa-17	46	23	eua	eua	PROPN
amwa-17	46	24	therapy	therapy	NOUN
amwa-17	46	25	type	type	NOUN
amwa-17	46	26	authorized	authorize	VERB
amwa-17	46	27	use	use	NOUN
amwa-17	46	28	march	march	PROPN
amwa-17	46	29	29	29	NUM
amwa-17	46	30	,	,	PUNCT
amwa-17	46	31	2021	2021	NUM
amwa-17	46	32	janssen	janssen	PROPN
amwa-17	46	33	covid-19	covid-19	PROPN
amwa-17	46	34	vaccine	vaccine	NOUN
amwa-17	46	35	recombinant	recombinant	NOUN
amwa-17	46	36	,	,	PUNCT
amwa-17	46	37	replicationincompetent	replicationincompetent	NOUN
amwa-17	46	38	human	human	PROPN
amwa-17	46	39	ad26	ad26	PROPN
amwa-17	46	40	vectored	vectore	VERB
amwa-17	46	41	vaccine	vaccine	NOUN
amwa-17	46	42	encoding	encode	VERB
amwa-17	46	43	a	a	DET
amwa-17	46	44	stabilized	stabilize	VERB
amwa-17	46	45	variant	variant	NOUN
amwa-17	46	46	of	of	ADP
amwa-17	46	47	the	the	DET
amwa-17	46	48	sars	sar	NOUN
amwa-17	46	49	-	-	PUNCT
amwa-17	46	50	cov-2	cov-2	NOUN
amwa-17	46	51	s	s	NOUN
amwa-17	46	52	protein	protein	NOUN
amwa-17	46	53	for	for	ADP
amwa-17	46	54	the	the	DET
amwa-17	46	55	prevention	prevention	NOUN
amwa-17	46	56	of	of	ADP
amwa-17	46	57	covid-19	covid-19	PROPN
amwa-17	46	58	for	for	ADP
amwa-17	46	59	individuals	individual	NOUN
amwa-17	46	60	≥18	≥18	NUM
amwa-17	46	61	years	year	NOUN
amwa-17	46	62	old	old	ADJ
amwa-17	46	63	december	december	PROPN
amwa-17	46	64	18	18	NUM
amwa-17	46	65	,	,	PUNCT
amwa-17	46	66	2020	2020	NUM
amwa-17	46	67	(	(	PUNCT
amwa-17	46	68	reissued	reissue	VERB
amwa-17	46	69	february	february	PROPN
amwa-17	46	70	25	25	NUM
amwa-17	46	71	,	,	PUNCT
amwa-17	46	72	2021	2021	NUM
amwa-17	46	73	)	)	PUNCT
amwa-17	46	74	moderna	moderna	PROPN
amwa-17	46	75	covid-19	covid-19	PROPN
amwa-17	46	76	vaccine	vaccine	NOUN
amwa-17	46	77	mrna	mrna	NOUN
amwa-17	46	78	vaccine	vaccine	NOUN
amwa-17	46	79	for	for	ADP
amwa-17	46	80	the	the	DET
amwa-17	46	81	prevention	prevention	NOUN
amwa-17	46	82	of	of	ADP
amwa-17	46	83	covid-19	covid-19	PROPN
amwa-17	46	84	for	for	ADP
amwa-17	46	85	individuals	individual	NOUN
amwa-17	46	86	≥18	≥18	NUM
amwa-17	46	87	years	year	NOUN
amwa-17	46	88	old	old	ADJ
amwa-17	46	89	december	december	PROPN
amwa-17	46	90	11	11	NUM
amwa-17	46	91	,	,	PUNCT
amwa-17	46	92	2020	2020	NUM
amwa-17	46	93	(	(	PUNCT
amwa-17	46	94	reissued	reissue	VERB
amwa-17	46	95	february	february	PROPN
amwa-17	46	96	25	25	NUM
amwa-17	46	97	,	,	PUNCT
amwa-17	46	98	2021	2021	NUM
amwa-17	46	99	)	)	PUNCT
amwa-17	46	100	pfizer	pfizer	NOUN
amwa-17	46	101	-	-	PUNCT
amwa-17	46	102	biontech	biontech	NOUN
amwa-17	46	103	covid-19	covid-19	PROPN
amwa-17	46	104	vaccine	vaccine	NOUN
amwa-17	46	105	mrna	mrna	NOUN
amwa-17	46	106	vaccine	vaccine	NOUN
amwa-17	46	107	for	for	ADP
amwa-17	46	108	the	the	DET
amwa-17	46	109	prevention	prevention	NOUN
amwa-17	46	110	of	of	ADP
amwa-17	46	111	covid-19	covid-19	PROPN
amwa-17	46	112	for	for	ADP
amwa-17	46	113	individuals	individual	NOUN
amwa-17	46	114	≥16	≥16	ADP
amwa-17	46	115	years	year	NOUN
amwa-17	46	116	old	old	ADJ
amwa-17	46	117	february	february	PROPN
amwa-17	46	118	09	09	NUM
amwa-17	46	119	,	,	PUNCT
amwa-17	46	120	2021	2021	NUM
amwa-17	46	121	(	(	PUNCT
amwa-17	46	122	reissued	reissue	VERB
amwa-17	46	123	february	february	PROPN
amwa-17	46	124	25	25	NUM
amwa-17	46	125	,	,	PUNCT
amwa-17	46	126	2021	2021	NUM
amwa-17	46	127	)	)	PUNCT
amwa-17	46	128	bamlanivimab	bamlanivimab	NOUN
amwa-17	46	129	and	and	CCONJ
amwa-17	46	130	etesevimab	etesevimab	NOUN
amwa-17	46	131	antibodies	antibody	NOUN
amwa-17	46	132	for	for	ADP
amwa-17	46	133	the	the	DET
amwa-17	46	134	treatment	treatment	NOUN
amwa-17	46	135	of	of	ADP
amwa-17	46	136	mild	mild	ADJ
amwa-17	46	137	-	-	PUNCT
amwa-17	46	138	to	to	ADP
amwa-17	46	139	-	-	PUNCT
amwa-17	46	140	moderate	moderate	ADJ
amwa-17	46	141	covid-19	covid-19	PROPN
amwa-17	46	142	in	in	ADP
amwa-17	46	143	adult	adult	NOUN
amwa-17	46	144	and	and	CCONJ
amwa-17	46	145	pediatric	pediatric	ADJ
amwa-17	46	146	patients	patient	NOUN
amwa-17	46	147	with	with	ADP
amwa-17	46	148	positive	positive	ADJ
amwa-17	46	149	results	result	NOUN
amwa-17	46	150	of	of	ADP
amwa-17	46	151	direct	direct	ADJ
amwa-17	46	152	sars	sar	NOUN
amwa-17	46	153	-	-	PUNCT
amwa-17	46	154	cov-2	cov-2	NOUN
amwa-17	46	155	viral	viral	ADJ
amwa-17	46	156	testing	testing	NOUN
amwa-17	46	157	who	who	PRON
amwa-17	46	158	are	be	AUX
amwa-17	46	159	≥12	≥12	ADP
amwa-17	46	160	years	year	NOUN
amwa-17	46	161	old	old	ADJ
amwa-17	46	162	,	,	PUNCT
amwa-17	46	163	weigh	weigh	VERB
amwa-17	46	164	at	at	ADV
amwa-17	46	165	least	least	ADV
amwa-17	46	166	40	40	NUM
amwa-17	46	167	kg	kg	NOUN
amwa-17	46	168	,	,	PUNCT
amwa-17	46	169	and	and	CCONJ
amwa-17	46	170	are	be	AUX
amwa-17	46	171	at	at	ADP
amwa-17	46	172	high	high	ADJ
amwa-17	46	173	risk	risk	NOUN
amwa-17	46	174	for	for	ADP
amwa-17	46	175	progressing	progress	VERB
amwa-17	46	176	to	to	PART
amwa-17	46	177	severe	severe	VERB
amwa-17	46	178	covid-19	covid-19	PROPN
amwa-17	46	179	and/or	and/or	CCONJ
amwa-17	46	180	hospitalization	hospitalization	NOUN
amwa-17	46	181	november	november	PROPN
amwa-17	46	182	21	21	NUM
amwa-17	46	183	,	,	PUNCT
amwa-17	46	184	2020	2020	NUM
amwa-17	46	185	(	(	PUNCT
amwa-17	46	186	reissued	reissue	VERB
amwa-17	46	187	february	february	PROPN
amwa-17	46	188	25	25	NUM
amwa-17	46	189	,	,	PUNCT
amwa-17	46	190	2021	2021	NUM
amwa-17	46	191	)	)	PUNCT
amwa-17	46	192	casirivimab	casirivimab	NOUN
amwa-17	46	193	and	and	CCONJ
amwa-17	46	194	imdevimab	imdevimab	NOUN
amwa-17	46	195	antibodies	antibodie	VERB
amwa-17	46	196	for	for	ADP
amwa-17	46	197	the	the	DET
amwa-17	46	198	treatment	treatment	NOUN
amwa-17	46	199	of	of	ADP
amwa-17	46	200	mild	mild	ADJ
amwa-17	46	201	-	-	PUNCT
amwa-17	46	202	to	to	ADP
amwa-17	46	203	-	-	PUNCT
amwa-17	46	204	moderate	moderate	ADJ
amwa-17	46	205	covid-19	covid-19	PROPN
amwa-17	46	206	in	in	ADP
amwa-17	46	207	adults	adult	NOUN
amwa-17	46	208	and	and	CCONJ
amwa-17	46	209	pediatric	pediatric	ADJ
amwa-17	46	210	patients	patient	NOUN
amwa-17	46	211	(	(	PUNCT
amwa-17	46	212	≥12	≥12	ADP
amwa-17	46	213	years	year	NOUN
amwa-17	46	214	old	old	ADJ
amwa-17	46	215	weighing	weigh	VERB
amwa-17	46	216	≥40	≥40	PROPN
amwa-17	46	217	kg	kg	NOUN
amwa-17	46	218	)	)	PUNCT
amwa-17	46	219	with	with	ADP
amwa-17	46	220	positive	positive	ADJ
amwa-17	46	221	results	result	NOUN
amwa-17	46	222	of	of	ADP
amwa-17	46	223	direct	direct	ADJ
amwa-17	46	224	sars	sar	NOUN
amwa-17	46	225	-	-	PUNCT
amwa-17	46	226	cov-2	cov-2	NOUN
amwa-17	46	227	viral	viral	ADJ
amwa-17	46	228	testing	testing	NOUN
amwa-17	46	229	and	and	CCONJ
amwa-17	46	230	who	who	PRON
amwa-17	46	231	are	be	AUX
amwa-17	46	232	at	at	ADP
amwa-17	46	233	high	high	ADJ
amwa-17	46	234	risk	risk	NOUN
amwa-17	46	235	for	for	ADP
amwa-17	46	236	progressing	progress	VERB
amwa-17	46	237	to	to	PART
amwa-17	46	238	severe	severe	VERB
amwa-17	46	239	covid-19	covid-19	PROPN
amwa-17	46	240	and/or	and/or	CCONJ
amwa-17	46	241	hospitalization	hospitalization	NOUN
amwa-17	46	242	november	november	PROPN
amwa-17	46	243	19	19	NUM
amwa-17	46	244	,	,	PUNCT
amwa-17	46	245	2020	2020	NUM
amwa-17	46	246	baricitinib	baricitinib	NOUN
amwa-17	46	247	in	in	ADP
amwa-17	46	248	combination	combination	NOUN
amwa-17	46	249	with	with	ADP
amwa-17	46	250	remdesivir	remdesivir	NOUN
amwa-17	46	251	antibody	antibody	VERB
amwa-17	46	252	+	+	CCONJ
amwa-17	46	253	antiviral	antiviral	ADJ
amwa-17	46	254	for	for	ADP
amwa-17	46	255	emergency	emergency	NOUN
amwa-17	46	256	use	use	NOUN
amwa-17	46	257	by	by	ADP
amwa-17	46	258	health	health	NOUN
amwa-17	46	259	care	care	NOUN
amwa-17	46	260	providers	provider	NOUN
amwa-17	46	261	for	for	ADP
amwa-17	46	262	the	the	DET
amwa-17	46	263	treatment	treatment	NOUN
amwa-17	46	264	of	of	ADP
amwa-17	46	265	suspected	suspect	VERB
amwa-17	46	266	or	or	CCONJ
amwa-17	46	267	laboratoryconfirmed	laboratoryconfirme	VERB
amwa-17	46	268	covid-19	covid-19	PROPN
amwa-17	46	269	in	in	ADP
amwa-17	46	270	hospitalized	hospitalize	VERB
amwa-17	46	271	adults	adult	NOUN
amwa-17	46	272	and	and	CCONJ
amwa-17	46	273	pediatric	pediatric	ADJ
amwa-17	46	274	patients	patient	NOUN
amwa-17	46	275	≥2	≥2	PRON
amwa-17	46	276	years	year	NOUN
amwa-17	46	277	of	of	ADP
amwa-17	46	278	age	age	NOUN
amwa-17	46	279	requiring	require	VERB
amwa-17	46	280	supplemental	supplemental	ADJ
amwa-17	46	281	oxygen	oxygen	NOUN
amwa-17	46	282	,	,	PUNCT
amwa-17	46	283	invasive	invasive	ADJ
amwa-17	46	284	mechanical	mechanical	ADJ
amwa-17	46	285	ventilation	ventilation	NOUN
amwa-17	46	286	,	,	PUNCT
amwa-17	46	287	or	or	CCONJ
amwa-17	46	288	ecmo	ecmo	VERB
amwa-17	46	289	august	august	PROPN
amwa-17	46	290	23	23	NUM
amwa-17	46	291	,	,	PUNCT
amwa-17	46	292	2020	2020	NUM
amwa-17	46	293	(	(	PUNCT
amwa-17	46	294	reissued	reissue	VERB
amwa-17	46	295	march	march	PROPN
amwa-17	46	296	09	09	NUM
amwa-17	46	297	,	,	PUNCT
amwa-17	46	298	2021	2021	NUM
amwa-17	46	299	)	)	PUNCT
amwa-17	46	300	covid-19	covid-19	PROPN
amwa-17	46	301	convalescent	convalescent	NOUN
amwa-17	46	302	plasma	plasma	NOUN
amwa-17	46	303	convalescent	convalescent	NOUN
amwa-17	46	304	plasma	plasma	NOUN
amwa-17	46	305	for	for	ADP
amwa-17	46	306	the	the	DET
amwa-17	46	307	treatment	treatment	NOUN
amwa-17	46	308	of	of	ADP
amwa-17	46	309	hospitalized	hospitalize	VERB
amwa-17	46	310	patients	patient	NOUN
amwa-17	46	311	with	with	ADP
amwa-17	46	312	covid-19	covid-19	PROPN
amwa-17	46	313	august	august	PROPN
amwa-17	46	314	13	13	NUM
amwa-17	46	315	,	,	PUNCT
amwa-17	46	316	2020	2020	NUM
amwa-17	46	317	sodium	sodium	NOUN
amwa-17	46	318	chloride	chloride	NOUN
amwa-17	46	319	and	and	CCONJ
amwa-17	46	320	sodium	sodium	NOUN
amwa-17	46	321	citrate	citrate	NOUN
amwa-17	46	322	renal	renal	ADJ
amwa-17	46	323	replacement	replacement	NOUN
amwa-17	46	324	and	and	CCONJ
amwa-17	46	325	regional	regional	ADJ
amwa-17	46	326	solution	solution	NOUN
amwa-17	46	327	for	for	ADP
amwa-17	46	328	anticoagulation	anticoagulation	NOUN
amwa-17	46	329	of	of	ADP
amwa-17	46	330	the	the	DET
amwa-17	46	331	extracorporeal	extracorporeal	NOUN
amwa-17	46	332	circuit	circuit	NOUN
amwa-17	46	333	replacement	replacement	NOUN
amwa-17	46	334	solution	solution	NOUN
amwa-17	46	335	for	for	ADP
amwa-17	46	336	crrt	crrt	NOUN
amwa-17	46	337	to	to	PART
amwa-17	46	338	be	be	AUX
amwa-17	46	339	used	use	VERB
amwa-17	46	340	as	as	ADP
amwa-17	46	341	a	a	DET
amwa-17	46	342	replacement	replacement	NOUN
amwa-17	46	343	solution	solution	NOUN
amwa-17	46	344	only	only	ADV
amwa-17	46	345	in	in	ADP
amwa-17	46	346	adult	adult	NOUN
amwa-17	46	347	patients	patient	NOUN
amwa-17	46	348	treated	treat	VERB
amwa-17	46	349	with	with	ADP
amwa-17	46	350	crrt	crrt	NOUN
amwa-17	46	351	,	,	PUNCT
amwa-17	46	352	and	and	CCONJ
amwa-17	46	353	for	for	ADP
amwa-17	46	354	whom	whom	PRON
amwa-17	46	355	regional	regional	ADJ
amwa-17	46	356	citrate	citrate	NOUN
amwa-17	46	357	anticoagulation	anticoagulation	NOUN
amwa-17	46	358	is	be	AUX
amwa-17	46	359	appropriate	appropriate	ADJ
amwa-17	46	360	,	,	PUNCT
amwa-17	46	361	in	in	ADP
amwa-17	46	362	a	a	DET
amwa-17	46	363	critical	critical	ADJ
amwa-17	46	364	care	care	NOUN
amwa-17	46	365	setting	set	VERB
amwa-17	46	366	may	may	AUX
amwa-17	46	367	8	8	NUM
amwa-17	46	368	,	,	PUNCT
amwa-17	46	369	2020	2020	NUM
amwa-17	46	370	propofol	propofol	NOUN
amwa-17	46	371	2	2	NUM
amwa-17	46	372	%	%	NOUN
amwa-17	46	373	sedative	sedative	NOUN
amwa-17	46	374	to	to	PART
amwa-17	46	375	maintain	maintain	VERB
amwa-17	46	376	sedation	sedation	NOUN
amwa-17	46	377	via	via	ADP
amwa-17	46	378	continuous	continuous	ADJ
amwa-17	46	379	infusion	infusion	NOUN
amwa-17	46	380	in	in	ADP
amwa-17	46	381	patients	patient	NOUN
amwa-17	46	382	>	>	PUNCT
amwa-17	46	383	16	16	NUM
amwa-17	46	384	years	year	NOUN
amwa-17	46	385	old	old	ADJ
amwa-17	46	386	with	with	ADP
amwa-17	46	387	suspected	suspect	VERB
amwa-17	46	388	or	or	CCONJ
amwa-17	46	389	confirmed	confirm	VERB
amwa-17	46	390	covid-19	covid-19	PROPN
amwa-17	46	391	who	who	PRON
amwa-17	46	392	require	require	VERB
amwa-17	46	393	mechanical	mechanical	ADJ
amwa-17	46	394	ventilation	ventilation	NOUN
amwa-17	46	395	in	in	ADP
amwa-17	46	396	an	an	DET
amwa-17	46	397	icu	icu	NOUN
amwa-17	46	398	setting	setting	NOUN
amwa-17	46	399	may	may	AUX
amwa-17	46	400	1	1	NUM
amwa-17	46	401	,	,	PUNCT
amwa-17	46	402	2020	2020	NUM
amwa-17	46	403	(	(	PUNCT
amwa-17	46	404	reissued	reissue	VERB
amwa-17	46	405	october	october	PROPN
amwa-17	46	406	22	22	NUM
amwa-17	46	407	,	,	PUNCT
amwa-17	46	408	2020)a	2020)a	NUM
amwa-17	46	409	remdesivir	remdesivir	NOUN
amwa-17	46	410	for	for	ADP
amwa-17	46	411	certain	certain	ADJ
amwa-17	46	412	hospitalized	hospitalize	VERB
amwa-17	46	413	patients	patient	NOUN
amwa-17	46	414	with	with	ADP
amwa-17	46	415	covid-19	covid-19	PROPN
amwa-17	46	416	antiviral	antiviral	NOUN
amwa-17	46	417	for	for	ADP
amwa-17	46	418	emergency	emergency	NOUN
amwa-17	46	419	use	use	NOUN
amwa-17	46	420	by	by	ADP
amwa-17	46	421	licensed	license	VERB
amwa-17	46	422	health	health	NOUN
amwa-17	46	423	care	care	NOUN
amwa-17	46	424	providers	provider	NOUN
amwa-17	46	425	for	for	ADP
amwa-17	46	426	the	the	DET
amwa-17	46	427	treatment	treatment	NOUN
amwa-17	46	428	of	of	ADP
amwa-17	46	429	suspected	suspect	VERB
amwa-17	46	430	or	or	CCONJ
amwa-17	46	431	laboratory	laboratory	NOUN
amwa-17	46	432	-	-	PUNCT
amwa-17	46	433	confirmed	confirm	VERB
amwa-17	46	434	covid-19	covid-19	PROPN
amwa-17	46	435	in	in	ADP
amwa-17	46	436	hospitalized	hospitalize	VERB
amwa-17	46	437	pediatric	pediatric	ADJ
amwa-17	46	438	patients	patient	NOUN
amwa-17	46	439	weighing	weigh	VERB
amwa-17	46	440	3.5	3.5	NUM
amwa-17	46	441	kg	kg	NOUN
amwa-17	46	442	to	to	ADP
amwa-17	46	443	<	<	X
amwa-17	46	444	40	40	NUM
amwa-17	46	445	kg	kg	NOUN
amwa-17	46	446	or	or	CCONJ
amwa-17	46	447	hospitalized	hospitalize	VERB
amwa-17	46	448	pediatric	pediatric	ADJ
amwa-17	46	449	patients	patient	NOUN
amwa-17	46	450	<	<	X
amwa-17	46	451	12	12	NUM
amwa-17	46	452	years	year	NOUN
amwa-17	46	453	old	old	ADJ
amwa-17	46	454	weighing	weigh	VERB
amwa-17	46	455	at	at	ADV
amwa-17	46	456	least	least	ADV
amwa-17	46	457	3.5	3.5	NUM
amwa-17	46	458	kg	kg	NOUN
amwa-17	46	459	april	april	PROPN
amwa-17	46	460	30	30	NUM
amwa-17	46	461	,	,	PUNCT
amwa-17	46	462	2020	2020	NUM
amwa-17	46	463	potassium	potassium	NOUN
amwa-17	46	464	-	-	PUNCT
amwa-17	46	465	free	free	ADJ
amwa-17	46	466	and	and	CCONJ
amwa-17	46	467	2	2	NUM
amwa-17	46	468	,	,	PUNCT
amwa-17	46	469	3	3	NUM
amwa-17	46	470	,	,	PUNCT
amwa-17	46	471	and	and	CCONJ
amwa-17	46	472	4	4	NUM
amwa-17	46	473	mmol	mmol	NOUN
amwa-17	46	474	/	/	SYM
amwa-17	46	475	l	l	NOUN
amwa-17	46	476	potassium	potassium	NOUN
amwa-17	46	477	solution	solution	NOUN
amwa-17	46	478	for	for	ADP
amwa-17	46	479	hemodialysis	hemodialysis	NOUN
amwa-17	46	480	/	/	SYM
amwa-17	46	481	hemofiltration	hemofiltration	NOUN
amwa-17	46	482	replacement	replacement	NOUN
amwa-17	46	483	solution	solution	NOUN
amwa-17	46	484	for	for	ADP
amwa-17	46	485	crrt	crrt	NOUN
amwa-17	46	486	to	to	PART
amwa-17	46	487	provide	provide	VERB
amwa-17	46	488	crrt	crrt	NOUN
amwa-17	46	489	to	to	PART
amwa-17	46	490	treat	treat	VERB
amwa-17	46	491	patients	patient	NOUN
amwa-17	46	492	in	in	ADP
amwa-17	46	493	an	an	DET
amwa-17	46	494	acute	acute	NOUN
amwa-17	46	495	care	care	NOUN
amwa-17	46	496	environment	environment	NOUN
amwa-17	46	497	during	during	ADP
amwa-17	46	498	the	the	DET
amwa-17	46	499	covid-19	covid-19	PROPN
amwa-17	46	500	pandemic	pandemic	ADJ
amwa-17	46	501	source	source	NOUN
amwa-17	46	502	:	:	PUNCT
amwa-17	46	503	fda	fda	PROPN
amwa-17	46	504	2021.13	2021.13	NUM
amwa-17	46	505	ad26	ad26	PROPN
amwa-17	46	506	,	,	PUNCT
amwa-17	46	507	adenovirus	adenovirus	NOUN
amwa-17	46	508	serotype	serotype	NOUN
amwa-17	46	509	26	26	NUM
amwa-17	46	510	;	;	PUNCT
amwa-17	46	511	crrt	crrt	NOUN
amwa-17	46	512	,	,	PUNCT
amwa-17	46	513	continuous	continuous	ADJ
amwa-17	46	514	renal	renal	ADJ
amwa-17	46	515	replacement	replacement	NOUN
amwa-17	46	516	therapy	therapy	NOUN
amwa-17	46	517	;	;	PUNCT
amwa-17	46	518	ecmo	ecmo	NOUN
amwa-17	46	519	,	,	PUNCT
amwa-17	46	520	extracorporeal	extracorporeal	ADJ
amwa-17	46	521	membrane	membrane	NOUN
amwa-17	46	522	oxygenation	oxygenation	NOUN
amwa-17	46	523	;	;	PUNCT
amwa-17	46	524	icu	icu	PROPN
amwa-17	46	525	,	,	PUNCT
amwa-17	46	526	intensive	intensive	ADJ
amwa-17	46	527	care	care	NOUN
amwa-17	46	528	unit	unit	NOUN
amwa-17	46	529	;	;	PUNCT
amwa-17	46	530	mrna	mrna	PROPN
amwa-17	46	531	,	,	PUNCT
amwa-17	46	532	messenger	messenger	PROPN
amwa-17	46	533	rna	rna	PROPN
amwa-17	46	534	.	.	PUNCT
amwa-17	47	1	athe	athe	PROPN
amwa-17	47	2	original	original	PROPN
amwa-17	47	3	eua	eua	PROPN
amwa-17	47	4	for	for	ADP
amwa-17	47	5	remdesivir	remdesivir	NOUN
amwa-17	47	6	issued	issue	VERB
amwa-17	47	7	may	may	PROPN
amwa-17	47	8	1	1	NUM
amwa-17	47	9	,	,	PUNCT
amwa-17	47	10	2020	2020	NUM
amwa-17	47	11	,	,	PUNCT
amwa-17	47	12	was	be	AUX
amwa-17	47	13	for	for	ADP
amwa-17	47	14	the	the	DET
amwa-17	47	15	treatment	treatment	NOUN
amwa-17	47	16	of	of	ADP
amwa-17	47	17	suspected	suspect	VERB
amwa-17	47	18	or	or	CCONJ
amwa-17	47	19	laboratory	laboratory	NOUN
amwa-17	47	20	-	-	PUNCT
amwa-17	47	21	confirmed	confirm	VERB
amwa-17	47	22	covid-19	covid-19	PROPN
amwa-17	47	23	in	in	ADP
amwa-17	47	24	adult	adult	NOUN
amwa-17	47	25	and	and	CCONJ
amwa-17	47	26	pediatric	pediatric	ADJ
amwa-17	47	27	patients	patient	NOUN
amwa-17	47	28	hospitalized	hospitalize	VERB
amwa-17	47	29	with	with	ADP
amwa-17	47	30	severe	severe	ADJ
amwa-17	47	31	disease	disease	NOUN
amwa-17	47	32	.	.	PUNCT
amwa-17	48	1	the	the	DET
amwa-17	48	2	eua	eua	PROPN
amwa-17	48	3	was	be	AUX
amwa-17	48	4	expanded	expand	VERB
amwa-17	48	5	to	to	PART
amwa-17	48	6	include	include	VERB
amwa-17	48	7	adult	adult	NOUN
amwa-17	48	8	and	and	CCONJ
amwa-17	48	9	pediatric	pediatric	ADJ
amwa-17	48	10	patients	patient	NOUN
amwa-17	48	11	with	with	ADP
amwa-17	48	12	covid-19	covid-19	PROPN
amwa-17	48	13	irrespective	irrespective	ADV
amwa-17	48	14	of	of	ADP
amwa-17	48	15	severity	severity	NOUN
amwa-17	48	16	on	on	ADP
amwa-17	48	17	august	august	PROPN
amwa-17	48	18	28	28	NUM
amwa-17	48	19	,	,	PUNCT
amwa-17	48	20	2020	2020	NUM
amwa-17	48	21	.	.	PUNCT
amwa-17	49	1	remdesivir	remdesivir	PROPN
amwa-17	49	2	was	be	AUX
amwa-17	49	3	the	the	DET
amwa-17	49	4	first	first	ADJ
amwa-17	49	5	treatment	treatment	NOUN
amwa-17	49	6	to	to	PART
amwa-17	49	7	receive	receive	VERB
amwa-17	49	8	approval	approval	NOUN
amwa-17	49	9	under	under	ADP
amwa-17	49	10	coronavirus	coronavirus	NOUN
amwa-17	49	11	treatment	treatment	NOUN
amwa-17	49	12	acceleration	acceleration	NOUN
amwa-17	49	13	program	program	NOUN
amwa-17	49	14	on	on	ADP
amwa-17	49	15	october	october	PROPN
amwa-17	49	16	22	22	NUM
amwa-17	49	17	,	,	PUNCT
amwa-17	49	18	2020	2020	NUM
amwa-17	49	19	,	,	PUNCT
amwa-17	49	20	for	for	ADP
amwa-17	49	21	use	use	NOUN
amwa-17	49	22	in	in	ADP
amwa-17	49	23	adults	adult	NOUN
amwa-17	49	24	and	and	CCONJ
amwa-17	49	25	pediatric	pediatric	ADJ
amwa-17	49	26	patients	patient	NOUN
amwa-17	49	27	with	with	ADP
amwa-17	49	28	covid-19	covid-19	PROPN
amwa-17	49	29	who	who	PRON
amwa-17	49	30	are	be	AUX
amwa-17	49	31	≥12	≥12	ADP
amwa-17	49	32	years	year	NOUN
amwa-17	49	33	old	old	ADJ
amwa-17	49	34	and	and	CCONJ
amwa-17	49	35	weigh	weigh	VERB
amwa-17	49	36	≥40	≥40	PROPN
amwa-17	49	37	kg	kg	NOUN
amwa-17	49	38	requiring	require	VERB
amwa-17	49	39	hospitalization	hospitalization	NOUN
amwa-17	49	40	;	;	PUNCT
amwa-17	49	41	the	the	DET
amwa-17	49	42	eua	eua	PROPN
amwa-17	49	43	was	be	AUX
amwa-17	49	44	reissued	reissue	VERB
amwa-17	49	45	to	to	PART
amwa-17	49	46	allow	allow	VERB
amwa-17	49	47	for	for	ADP
amwa-17	49	48	continued	continued	ADJ
amwa-17	49	49	access	access	NOUN
amwa-17	49	50	to	to	ADP
amwa-17	49	51	a	a	DET
amwa-17	49	52	subset	subset	NOUN
amwa-17	49	53	of	of	ADP
amwa-17	49	54	hospitalized	hospitalize	VERB
amwa-17	49	55	pediatric	pediatric	ADJ
amwa-17	49	56	patients	patient	NOUN
amwa-17	49	57	with	with	ADP
amwa-17	49	58	suspected	suspect	VERB
amwa-17	49	59	or	or	CCONJ
amwa-17	49	60	laboratory	laboratory	NOUN
amwa-17	49	61	-	-	PUNCT
amwa-17	49	62	confirmed	confirm	VERB
amwa-17	49	63	covid-19	covid-19	PROPN
amwa-17	49	64	who	who	PRON
amwa-17	49	65	weigh	weigh	VERB
amwa-17	49	66	3.5	3.5	NUM
amwa-17	49	67	kg	kg	NOUN
amwa-17	49	68	to	to	ADP
amwa-17	49	69	<	<	X
amwa-17	49	70	40	40	NUM
amwa-17	49	71	kg	kg	NOUN
amwa-17	49	72	or	or	CCONJ
amwa-17	49	73	who	who	PRON
amwa-17	49	74	are	be	AUX
amwa-17	49	75	<	<	X
amwa-17	49	76	12	12	NUM
amwa-17	49	77	years	year	NOUN
amwa-17	49	78	old	old	ADJ
amwa-17	49	79	and	and	CCONJ
amwa-17	49	80	weigh	weigh	VERB
amwa-17	49	81	at	at	ADV
amwa-17	49	82	least	least	ADV
amwa-17	49	83	3.5	3.5	NUM
amwa-17	49	84	kg	kg	NOUN
amwa-17	49	85	.	.	PROPN
amwa-17	49	86	amwa	amwa	PROPN
amwa-17	49	87	journal	journal	PROPN
amwa-17	49	88	/	/	SYM
amwa-17	49	89	v36	v36	PROPN
amwa-17	49	90	n2	n2	PROPN
amwa-17	49	91	/	/	SYM
amwa-17	49	92	2021	2021	NUM
amwa-17	49	93	/	/	SYM
amwa-17	49	94	amwa.org	amwa.org	PROPN
amwa-17	49	95	69	69	NUM
amwa-17	49	96	•	•	NUM
amwa-17	49	97	supply	supply	NOUN
amwa-17	49	98	chain	chain	NOUN
amwa-17	49	99	considerations	consideration	NOUN
amwa-17	49	100	,	,	PUNCT
amwa-17	49	101	such	such	ADJ
amwa-17	49	102	as	as	ADP
amwa-17	49	103	direct	direct	ADJ
amwa-17	49	104	-	-	PUNCT
amwa-17	49	105	to	to	ADP
amwa-17	49	106	-	-	PUNCT
amwa-17	49	107	patient	patient	NOUN
amwa-17	49	108	shipping	shipping	NOUN
amwa-17	49	109	,	,	PUNCT
amwa-17	49	110	administration	administration	NOUN
amwa-17	49	111	by	by	ADP
amwa-17	49	112	a	a	DET
amwa-17	49	113	home	home	NOUN
amwa-17	49	114	nurse	nurse	NOUN
amwa-17	49	115	,	,	PUNCT
amwa-17	49	116	and	and	CCONJ
amwa-17	49	117	disposal	disposal	NOUN
amwa-17	49	118	of	of	ADP
amwa-17	49	119	the	the	DET
amwa-17	49	120	investigational	investigational	ADJ
amwa-17	49	121	product	product	NOUN
amwa-17	49	122	•	•	ADP
amwa-17	49	123	remote	remote	ADJ
amwa-17	49	124	site	site	NOUN
amwa-17	49	125	monitoring	monitor	VERB
amwa-17	49	126	considerations	consideration	NOUN
amwa-17	49	127	,	,	PUNCT
amwa-17	49	128	including	include	VERB
amwa-17	49	129	prioritization	prioritization	NOUN
amwa-17	49	130	of	of	ADP
amwa-17	49	131	monitoring	monitor	VERB
amwa-17	49	132	activities	activity	NOUN
amwa-17	49	133	in	in	ADP
amwa-17	49	134	the	the	DET
amwa-17	49	135	circumstance	circumstance	NOUN
amwa-17	49	136	of	of	ADP
amwa-17	49	137	clinical	clinical	ADJ
amwa-17	49	138	trial	trial	NOUN
amwa-17	49	139	site	site	NOUN
amwa-17	49	140	closures	closure	NOUN
amwa-17	49	141	,	,	PUNCT
amwa-17	49	142	infectious	infectious	ADJ
amwa-17	49	143	disease	disease	NOUN
amwa-17	49	144	control	control	NOUN
amwa-17	49	145	restrictions	restriction	NOUN
amwa-17	49	146	,	,	PUNCT
amwa-17	49	147	or	or	CCONJ
amwa-17	49	148	local	local	ADJ
amwa-17	49	149	travel	travel	NOUN
amwa-17	49	150	constraints	constraint	NOUN
amwa-17	49	151	•	•	ADP
amwa-17	49	152	serious	serious	ADJ
amwa-17	49	153	adverse	adverse	ADJ
amwa-17	49	154	event	event	NOUN
amwa-17	49	155	(	(	PUNCT
amwa-17	49	156	sae	sae	PROPN
amwa-17	49	157	)	)	PUNCT
amwa-17	49	158	reporting	reporting	NOUN
amwa-17	49	159	,	,	PUNCT
amwa-17	49	160	including	include	VERB
amwa-17	49	161	reporting	reporting	NOUN
amwa-17	49	162	of	of	ADP
amwa-17	49	163	cases	case	NOUN
amwa-17	49	164	of	of	ADP
amwa-17	49	165	covid-19	covid-19	PROPN
amwa-17	49	166	on	on	ADP
amwa-17	49	167	non	non	ADJ
amwa-17	49	168	-	-	ADJ
amwa-17	49	169	covid-19	covid-19	ADJ
amwa-17	49	170	clinical	clinical	ADJ
amwa-17	49	171	trials	trial	NOUN
amwa-17	49	172	and	and	CCONJ
amwa-17	49	173	cross	cross	NOUN
amwa-17	49	174	-	-	NOUN
amwa-17	49	175	reporting	reporting	NOUN
amwa-17	49	176	of	of	ADP
amwa-17	49	177	saes	saes	PROPN
amwa-17	49	178	in	in	ADP
amwa-17	49	179	the	the	DET
amwa-17	49	180	case	case	NOUN
amwa-17	49	181	of	of	ADP
amwa-17	49	182	multiple	multiple	ADJ
amwa-17	49	183	inds	ind	VERB
amwa-17	49	184	a	a	DET
amwa-17	49	185	key	key	ADJ
amwa-17	49	186	takeaway	takeaway	NOUN
amwa-17	49	187	of	of	ADP
amwa-17	49	188	the	the	DET
amwa-17	49	189	guidance	guidance	NOUN
amwa-17	49	190	is	be	AUX
amwa-17	49	191	to	to	PART
amwa-17	49	192	ensure	ensure	VERB
amwa-17	49	193	collection	collection	NOUN
amwa-17	49	194	of	of	ADP
amwa-17	49	195	information	information	NOUN
amwa-17	49	196	on	on	ADP
amwa-17	49	197	when	when	SCONJ
amwa-17	49	198	and	and	CCONJ
amwa-17	49	199	how	how	SCONJ
amwa-17	49	200	any	any	DET
amwa-17	49	201	mitigations	mitigation	NOUN
amwa-17	49	202	were	be	AUX
amwa-17	49	203	implemented	implement	VERB
amwa-17	49	204	in	in	ADP
amwa-17	49	205	a	a	DET
amwa-17	49	206	clinical	clinical	ADJ
amwa-17	49	207	trial	trial	NOUN
amwa-17	49	208	to	to	PART
amwa-17	49	209	facilitate	facilitate	VERB
amwa-17	49	210	subsequent	subsequent	ADJ
amwa-17	49	211	reporting	reporting	NOUN
amwa-17	49	212	on	on	ADP
amwa-17	49	213	the	the	DET
amwa-17	49	214	impact	impact	NOUN
amwa-17	49	215	of	of	ADP
amwa-17	49	216	covid-19	covid-19	PROPN
amwa-17	49	217	on	on	ADP
amwa-17	49	218	the	the	DET
amwa-17	49	219	trial	trial	NOUN
amwa-17	49	220	objectives	objective	NOUN
amwa-17	49	221	.	.	PUNCT
amwa-17	50	1	in	in	ADP
amwa-17	50	2	addition	addition	NOUN
amwa-17	50	3	,	,	PUNCT
amwa-17	50	4	the	the	DET
amwa-17	50	5	biotech	biotech	NOUN
amwa-17	50	6	and	and	CCONJ
amwa-17	50	7	pharmaceutical	pharmaceutical	NOUN
amwa-17	50	8	industry	industry	NOUN
amwa-17	50	9	has	have	AUX
amwa-17	50	10	contributed	contribute	VERB
amwa-17	50	11	to	to	ADP
amwa-17	50	12	the	the	DET
amwa-17	50	13	discussion	discussion	NOUN
amwa-17	50	14	of	of	ADP
amwa-17	50	15	clinical	clinical	ADJ
amwa-17	50	16	trial	trial	NOUN
amwa-17	50	17	mitigations	mitigation	NOUN
amwa-17	50	18	necessitated	necessitate	VERB
amwa-17	50	19	by	by	ADP
amwa-17	50	20	covid-19	covid-19	PROPN
amwa-17	50	21	.	.	PUNCT
amwa-17	50	22	transcelerate	transcelerate	PROPN
amwa-17	50	23	biopharma	biopharma	PROPN
amwa-17	50	24	,	,	PUNCT
amwa-17	50	25	a	a	DET
amwa-17	50	26	collection	collection	NOUN
amwa-17	50	27	of	of	ADP
amwa-17	50	28	member	member	NOUN
amwa-17	50	29	biotech	biotech	NOUN
amwa-17	50	30	and	and	CCONJ
amwa-17	50	31	pharmaceutical	pharmaceutical	NOUN
amwa-17	50	32	companies	company	NOUN
amwa-17	50	33	working	work	VERB
amwa-17	50	34	to	to	PART
amwa-17	50	35	standardize	standardize	VERB
amwa-17	50	36	key	key	ADJ
amwa-17	50	37	clinical	clinical	ADJ
amwa-17	50	38	trial	trial	NOUN
amwa-17	50	39	activities	activity	NOUN
amwa-17	50	40	,	,	PUNCT
amwa-17	50	41	released	release	VERB
amwa-17	50	42	a	a	DET
amwa-17	50	43	number	number	NOUN
amwa-17	50	44	of	of	ADP
amwa-17	50	45	covid-19	covid-19	PROPN
amwa-17	50	46	–	–	PUNCT
amwa-17	50	47	related	relate	VERB
amwa-17	50	48	initiatives	initiative	NOUN
amwa-17	50	49	,	,	PUNCT
amwa-17	50	50	including	include	VERB
amwa-17	50	51	a	a	DET
amwa-17	50	52	data	data	NOUN
amwa-17	50	53	-	-	PUNCT
amwa-17	50	54	sharing	share	VERB
amwa-17	50	55	platform	platform	NOUN
amwa-17	50	56	called	call	VERB
amwa-17	50	57	datacelerate	datacelerate	NOUN
amwa-17	50	58	for	for	ADP
amwa-17	50	59	covid-19	covid-19	PROPN
amwa-17	50	60	research	research	NOUN
amwa-17	50	61	,	,	PUNCT
amwa-17	50	62	tools	tool	NOUN
amwa-17	50	63	for	for	ADP
amwa-17	50	64	riskbased	riskbase	VERB
amwa-17	50	65	monitoring	monitoring	NOUN
amwa-17	50	66	and	and	CCONJ
amwa-17	50	67	protocol	protocol	NOUN
amwa-17	50	68	deviation	deviation	NOUN
amwa-17	50	69	management	management	NOUN
amwa-17	50	70	,	,	PUNCT
amwa-17	50	71	and	and	CCONJ
amwa-17	50	72	a	a	DET
amwa-17	50	73	clinical	clinical	ADJ
amwa-17	50	74	study	study	NOUN
amwa-17	50	75	report	report	NOUN
amwa-17	50	76	template	template	NOUN
amwa-17	50	77	for	for	ADP
amwa-17	50	78	outlining	outline	VERB
amwa-17	50	79	details	detail	NOUN
amwa-17	50	80	on	on	ADP
amwa-17	50	81	covid19	covid19	NOUN
amwa-17	50	82	–	–	PUNCT
amwa-17	50	83	related	relate	VERB
amwa-17	50	84	clinical	clinical	ADJ
amwa-17	50	85	trial	trial	NOUN
amwa-17	50	86	impact.34,35	impact.34,35	NOUN
amwa-17	50	87	with	with	ADP
amwa-17	50	88	information	information	NOUN
amwa-17	50	89	changing	change	VERB
amwa-17	50	90	regularly	regularly	ADV
amwa-17	50	91	because	because	SCONJ
amwa-17	50	92	of	of	ADP
amwa-17	50	93	the	the	DET
amwa-17	50	94	dynamic	dynamic	ADJ
amwa-17	50	95	nature	nature	NOUN
amwa-17	50	96	of	of	ADP
amwa-17	50	97	the	the	DET
amwa-17	50	98	pandemic	pandemic	ADJ
amwa-17	50	99	and	and	CCONJ
amwa-17	50	100	its	its	PRON
amwa-17	50	101	regionally	regionally	ADV
amwa-17	50	102	varied	varied	ADJ
amwa-17	50	103	effects	effect	NOUN
amwa-17	50	104	,	,	PUNCT
amwa-17	50	105	and	and	CCONJ
amwa-17	50	106	with	with	ADP
amwa-17	50	107	ongoing	ongoing	ADJ
amwa-17	50	108	updates	update	NOUN
amwa-17	50	109	from	from	ADP
amwa-17	50	110	global	global	ADJ
amwa-17	50	111	health	health	NOUN
amwa-17	50	112	agencies	agency	NOUN
amwa-17	50	113	,	,	PUNCT
amwa-17	50	114	however	however	ADV
amwa-17	50	115	,	,	PUNCT
amwa-17	50	116	it	it	PRON
amwa-17	50	117	is	be	AUX
amwa-17	50	118	clear	clear	ADJ
amwa-17	50	119	that	that	SCONJ
amwa-17	50	120	any	any	DET
amwa-17	50	121	such	such	ADJ
amwa-17	50	122	tool	tool	NOUN
amwa-17	50	123	will	will	AUX
amwa-17	50	124	be	be	AUX
amwa-17	50	125	a	a	DET
amwa-17	50	126	work	work	NOUN
amwa-17	50	127	in	in	ADP
amwa-17	50	128	progress	progress	NOUN
amwa-17	50	129	rather	rather	ADV
amwa-17	50	130	than	than	ADP
amwa-17	50	131	a	a	DET
amwa-17	50	132	static	static	ADJ
amwa-17	50	133	guideline	guideline	NOUN
amwa-17	50	134	and	and	CCONJ
amwa-17	50	135	that	that	SCONJ
amwa-17	50	136	medical	medical	ADJ
amwa-17	50	137	writers	writer	NOUN
amwa-17	50	138	will	will	AUX
amwa-17	50	139	need	need	VERB
amwa-17	50	140	to	to	PART
amwa-17	50	141	stay	stay	VERB
amwa-17	50	142	informed	informed	ADJ
amwa-17	50	143	on	on	ADP
amwa-17	50	144	any	any	DET
amwa-17	50	145	updates	update	NOUN
amwa-17	50	146	over	over	ADP
amwa-17	50	147	time	time	NOUN
amwa-17	50	148	.	.	PUNCT
amwa-17	51	1	it	it	PRON
amwa-17	51	2	is	be	AUX
amwa-17	51	3	unclear	unclear	ADJ
amwa-17	51	4	as	as	ADP
amwa-17	51	5	of	of	ADP
amwa-17	51	6	yet	yet	ADV
amwa-17	51	7	what	what	DET
amwa-17	51	8	impact	impact	NOUN
amwa-17	51	9	these	these	DET
amwa-17	51	10	mitigations	mitigation	NOUN
amwa-17	51	11	have	have	AUX
amwa-17	51	12	had	have	VERB
amwa-17	51	13	on	on	ADP
amwa-17	51	14	the	the	DET
amwa-17	51	15	overall	overall	ADJ
amwa-17	51	16	continuation	continuation	NOUN
amwa-17	51	17	of	of	ADP
amwa-17	51	18	non	non	ADJ
amwa-17	51	19	-	-	ADJ
amwa-17	51	20	covid-19	covid-19	ADJ
amwa-17	51	21	clinical	clinical	ADJ
amwa-17	51	22	trials	trial	NOUN
amwa-17	51	23	during	during	ADP
amwa-17	51	24	the	the	DET
amwa-17	51	25	pandemic	pandemic	NOUN
amwa-17	51	26	.	.	PUNCT
amwa-17	52	1	the	the	DET
amwa-17	52	2	success	success	NOUN
amwa-17	52	3	of	of	ADP
amwa-17	52	4	the	the	DET
amwa-17	52	5	mitigations	mitigation	NOUN
amwa-17	52	6	will	will	AUX
amwa-17	52	7	need	need	VERB
amwa-17	52	8	to	to	PART
amwa-17	52	9	be	be	AUX
amwa-17	52	10	analyzed	analyze	VERB
amwa-17	52	11	and	and	CCONJ
amwa-17	52	12	reported	report	VERB
amwa-17	52	13	on	on	ADP
amwa-17	52	14	at	at	ADP
amwa-17	52	15	an	an	DET
amwa-17	52	16	individual	individual	ADJ
amwa-17	52	17	study	study	NOUN
amwa-17	52	18	level	level	NOUN
amwa-17	52	19	,	,	PUNCT
amwa-17	52	20	depending	depend	VERB
amwa-17	52	21	on	on	ADP
amwa-17	52	22	the	the	DET
amwa-17	52	23	company	company	NOUN
amwa-17	52	24	’s	’s	PART
amwa-17	52	25	assessment	assessment	NOUN
amwa-17	52	26	of	of	ADP
amwa-17	52	27	what	what	PRON
amwa-17	52	28	measures	measure	NOUN
amwa-17	52	29	were	be	AUX
amwa-17	52	30	needed	need	VERB
amwa-17	52	31	at	at	ADP
amwa-17	52	32	the	the	DET
amwa-17	52	33	time	time	NOUN
amwa-17	52	34	the	the	DET
amwa-17	52	35	pandemic	pandemic	NOUN
amwa-17	52	36	affected	affect	VERB
amwa-17	52	37	the	the	DET
amwa-17	52	38	trial	trial	NOUN
amwa-17	52	39	,	,	PUNCT
amwa-17	52	40	with	with	SCONJ
amwa-17	52	41	any	any	DET
amwa-17	52	42	publications	publication	NOUN
amwa-17	52	43	based	base	VERB
amwa-17	52	44	on	on	ADP
amwa-17	52	45	the	the	DET
amwa-17	52	46	trial	trial	NOUN
amwa-17	52	47	footnoted	footnote	VERB
amwa-17	52	48	accordingly	accordingly	ADV
amwa-17	52	49	with	with	ADP
amwa-17	52	50	this	this	DET
amwa-17	52	51	context	context	NOUN
amwa-17	52	52	.	.	PUNCT
amwa-17	53	1	based	base	VERB
amwa-17	53	2	on	on	ADP
amwa-17	53	3	regional	regional	ADJ
amwa-17	53	4	variation	variation	NOUN
amwa-17	53	5	on	on	ADP
amwa-17	53	6	how	how	SCONJ
amwa-17	53	7	the	the	DET
amwa-17	53	8	measures	measure	NOUN
amwa-17	53	9	could	could	AUX
amwa-17	53	10	be	be	AUX
amwa-17	53	11	implemented	implement	VERB
amwa-17	53	12	,	,	PUNCT
amwa-17	53	13	it	it	PRON
amwa-17	53	14	is	be	AUX
amwa-17	53	15	also	also	ADV
amwa-17	53	16	possible	possible	ADJ
amwa-17	53	17	that	that	SCONJ
amwa-17	53	18	some	some	DET
amwa-17	53	19	mitigations	mitigation	NOUN
amwa-17	53	20	will	will	AUX
amwa-17	53	21	be	be	AUX
amwa-17	53	22	successful	successful	ADJ
amwa-17	53	23	in	in	ADP
amwa-17	53	24	some	some	DET
amwa-17	53	25	regions	region	NOUN
amwa-17	53	26	but	but	CCONJ
amwa-17	53	27	not	not	PART
amwa-17	53	28	others	other	NOUN
amwa-17	53	29	or	or	CCONJ
amwa-17	53	30	that	that	SCONJ
amwa-17	53	31	some	some	DET
amwa-17	53	32	mitigations	mitigation	NOUN
amwa-17	53	33	were	be	AUX
amwa-17	53	34	successful	successful	ADJ
amwa-17	53	35	overall	overall	ADV
amwa-17	53	36	,	,	PUNCT
amwa-17	53	37	whereas	whereas	SCONJ
amwa-17	53	38	other	other	ADJ
amwa-17	53	39	planned	plan	VERB
amwa-17	53	40	mitigations	mitigation	NOUN
amwa-17	53	41	were	be	AUX
amwa-17	53	42	unsuccessful	unsuccessful	ADJ
amwa-17	53	43	because	because	SCONJ
amwa-17	53	44	of	of	ADP
amwa-17	53	45	local	local	ADJ
amwa-17	53	46	circumstances	circumstance	NOUN
amwa-17	53	47	.	.	PUNCT
amwa-17	54	1	it	it	PRON
amwa-17	54	2	is	be	AUX
amwa-17	54	3	clear	clear	ADJ
amwa-17	54	4	that	that	SCONJ
amwa-17	54	5	properly	properly	ADV
amwa-17	54	6	contextualizing	contextualize	VERB
amwa-17	54	7	and	and	CCONJ
amwa-17	54	8	reporting	report	VERB
amwa-17	54	9	out	out	ADP
amwa-17	54	10	the	the	DET
amwa-17	54	11	results	result	NOUN
amwa-17	54	12	of	of	ADP
amwa-17	54	13	any	any	DET
amwa-17	54	14	such	such	ADJ
amwa-17	54	15	mitigations	mitigation	NOUN
amwa-17	54	16	will	will	AUX
amwa-17	54	17	be	be	AUX
amwa-17	54	18	a	a	DET
amwa-17	54	19	time	time	NOUN
amwa-17	54	20	-	-	PUNCT
amwa-17	54	21	consuming	consume	VERB
amwa-17	54	22	effort	effort	NOUN
amwa-17	54	23	that	that	PRON
amwa-17	54	24	requires	require	VERB
amwa-17	54	25	complete	complete	ADJ
amwa-17	54	26	source	source	NOUN
amwa-17	54	27	documentation	documentation	NOUN
amwa-17	54	28	and	and	CCONJ
amwa-17	54	29	follow	follow	VERB
amwa-17	54	30	-	-	PUNCT
amwa-17	54	31	up	up	NOUN
amwa-17	54	32	on	on	ADP
amwa-17	54	33	details	detail	NOUN
amwa-17	54	34	with	with	ADP
amwa-17	54	35	cro	cro	NOUN
amwa-17	54	36	and	and	CCONJ
amwa-17	54	37	site	site	NOUN
amwa-17	54	38	partners	partner	NOUN
amwa-17	54	39	.	.	PUNCT
amwa-17	55	1	looking	look	VERB
amwa-17	55	2	forward	forward	ADV
amwa-17	55	3	for	for	ADP
amwa-17	55	4	medical	medical	ADJ
amwa-17	55	5	writers	writer	NOUN
amwa-17	55	6	,	,	PUNCT
amwa-17	55	7	the	the	DET
amwa-17	55	8	pandemic	pandemic	NOUN
amwa-17	55	9	has	have	AUX
amwa-17	55	10	provided	provide	VERB
amwa-17	55	11	both	both	DET
amwa-17	55	12	opportunities	opportunity	NOUN
amwa-17	55	13	,	,	PUNCT
amwa-17	55	14	such	such	ADJ
amwa-17	55	15	as	as	ADP
amwa-17	55	16	the	the	DET
amwa-17	55	17	opportunity	opportunity	NOUN
amwa-17	55	18	to	to	PART
amwa-17	55	19	work	work	VERB
amwa-17	55	20	on	on	ADP
amwa-17	55	21	the	the	DET
amwa-17	55	22	surge	surge	NOUN
amwa-17	55	23	of	of	ADP
amwa-17	55	24	covid19	covid19	NOUN
amwa-17	55	25	–	–	PUNCT
amwa-17	55	26	related	relate	VERB
amwa-17	55	27	clinical	clinical	ADJ
amwa-17	55	28	study	study	NOUN
amwa-17	55	29	protocols	protocol	NOUN
amwa-17	55	30	and	and	CCONJ
amwa-17	55	31	manuscripts	manuscript	NOUN
amwa-17	55	32	,	,	PUNCT
amwa-17	55	33	and	and	CCONJ
amwa-17	55	34	challenges	challenge	NOUN
amwa-17	55	35	,	,	PUNCT
amwa-17	55	36	such	such	ADJ
amwa-17	55	37	as	as	ADP
amwa-17	55	38	the	the	DET
amwa-17	55	39	interruption	interruption	NOUN
amwa-17	55	40	of	of	ADP
amwa-17	55	41	some	some	DET
amwa-17	55	42	non	non	ADJ
amwa-17	55	43	-	-	ADJ
amwa-17	55	44	covid-19	covid-19	ADJ
amwa-17	55	45	studies	study	NOUN
amwa-17	55	46	or	or	CCONJ
amwa-17	55	47	research	research	NOUN
amwa-17	55	48	and	and	CCONJ
amwa-17	55	49	the	the	DET
amwa-17	55	50	need	need	NOUN
amwa-17	55	51	to	to	PART
amwa-17	55	52	work	work	VERB
amwa-17	55	53	with	with	ADP
amwa-17	55	54	urgency	urgency	NOUN
amwa-17	55	55	to	to	PART
amwa-17	55	56	produce	produce	VERB
amwa-17	55	57	communication	communication	NOUN
amwa-17	55	58	for	for	ADP
amwa-17	55	59	various	various	ADJ
amwa-17	55	60	purposes	purpose	NOUN
amwa-17	55	61	.	.	PUNCT
amwa-17	56	1	as	as	SCONJ
amwa-17	56	2	we	we	PRON
amwa-17	56	3	pass	pass	VERB
amwa-17	56	4	the	the	DET
amwa-17	56	5	1	1	NUM
amwa-17	56	6	-	-	PUNCT
amwa-17	56	7	year	year	NOUN
amwa-17	56	8	mark	mark	NOUN
amwa-17	56	9	from	from	ADP
amwa-17	56	10	when	when	SCONJ
amwa-17	56	11	the	the	DET
amwa-17	56	12	first	first	ADJ
amwa-17	56	13	cases	case	NOUN
amwa-17	56	14	of	of	ADP
amwa-17	56	15	covid-19	covid-19	PROPN
amwa-17	56	16	were	be	AUX
amwa-17	56	17	reported	report	VERB
amwa-17	56	18	,	,	PUNCT
amwa-17	56	19	with	with	ADP
amwa-17	56	20	the	the	DET
amwa-17	56	21	recent	recent	ADJ
amwa-17	56	22	approval	approval	NOUN
amwa-17	56	23	of	of	ADP
amwa-17	56	24	vaccines	vaccine	NOUN
amwa-17	56	25	,	,	PUNCT
amwa-17	56	26	some	some	DET
amwa-17	56	27	aspects	aspect	NOUN
amwa-17	56	28	of	of	ADP
amwa-17	56	29	the	the	DET
amwa-17	56	30	medical	medical	ADJ
amwa-17	56	31	writing	writing	NOUN
amwa-17	56	32	profession	profession	NOUN
amwa-17	56	33	and	and	CCONJ
amwa-17	56	34	the	the	DET
amwa-17	56	35	industry	industry	NOUN
amwa-17	56	36	in	in	ADP
amwa-17	56	37	general	general	ADJ
amwa-17	56	38	may	may	AUX
amwa-17	56	39	start	start	VERB
amwa-17	56	40	to	to	PART
amwa-17	56	41	return	return	VERB
amwa-17	56	42	to	to	ADP
amwa-17	56	43	normal	normal	ADJ
amwa-17	56	44	.	.	PUNCT
amwa-17	57	1	time	time	NOUN
amwa-17	57	2	will	will	AUX
amwa-17	57	3	tell	tell	VERB
amwa-17	57	4	how	how	SCONJ
amwa-17	57	5	biotech	biotech	ADJ
amwa-17	57	6	and	and	CCONJ
amwa-17	57	7	pharmaceutical	pharmaceutical	NOUN
amwa-17	57	8	companies	company	NOUN
amwa-17	57	9	,	,	PUNCT
amwa-17	57	10	which	which	PRON
amwa-17	57	11	are	be	AUX
amwa-17	57	12	reliant	reliant	ADJ
amwa-17	57	13	on	on	ADP
amwa-17	57	14	raising	raise	VERB
amwa-17	57	15	capital	capital	NOUN
amwa-17	57	16	for	for	ADP
amwa-17	57	17	operational	operational	ADJ
amwa-17	57	18	costs	cost	NOUN
amwa-17	57	19	,	,	PUNCT
amwa-17	57	20	will	will	AUX
amwa-17	57	21	fare	fare	VERB
amwa-17	57	22	with	with	ADP
amwa-17	57	23	the	the	DET
amwa-17	57	24	delay	delay	NOUN
amwa-17	57	25	of	of	ADP
amwa-17	57	26	important	important	ADJ
amwa-17	57	27	milestone	milestone	NOUN
amwa-17	57	28	reporting	reporting	NOUN
amwa-17	57	29	that	that	PRON
amwa-17	57	30	helps	help	VERB
amwa-17	57	31	raise	raise	VERB
amwa-17	57	32	those	those	DET
amwa-17	57	33	funds	fund	NOUN
amwa-17	57	34	.	.	PUNCT
amwa-17	58	1	trials	trial	NOUN
amwa-17	58	2	of	of	ADP
amwa-17	58	3	preventive	preventive	ADJ
amwa-17	58	4	and	and	CCONJ
amwa-17	58	5	therapeutic	therapeutic	ADJ
amwa-17	58	6	products	product	NOUN
amwa-17	58	7	for	for	ADP
amwa-17	58	8	covid-19	covid-19	PROPN
amwa-17	58	9	will	will	AUX
amwa-17	58	10	continue	continue	VERB
amwa-17	58	11	,	,	PUNCT
amwa-17	58	12	including	include	VERB
amwa-17	58	13	those	those	PRON
amwa-17	58	14	in	in	ADP
amwa-17	58	15	nonhospitalized	nonhospitalize	VERB
amwa-17	58	16	settings36	settings36	NOUN
amwa-17	58	17	and	and	CCONJ
amwa-17	58	18	in	in	ADP
amwa-17	58	19	different	different	ADJ
amwa-17	58	20	age	age	NOUN
amwa-17	58	21	groups	group	NOUN
amwa-17	58	22	and	and	CCONJ
amwa-17	58	23	populations	population	NOUN
amwa-17	58	24	;	;	PUNCT
amwa-17	58	25	sequelae	sequelae	NOUN
amwa-17	58	26	of	of	ADP
amwa-17	58	27	covid-19	covid-19	PROPN
amwa-17	58	28	will	will	AUX
amwa-17	58	29	also	also	ADV
amwa-17	58	30	require	require	VERB
amwa-17	58	31	treatment	treatment	NOUN
amwa-17	58	32	.	.	PUNCT
amwa-17	59	1	viral	viral	ADJ
amwa-17	59	2	mutations	mutation	NOUN
amwa-17	59	3	and	and	CCONJ
amwa-17	59	4	their	their	PRON
amwa-17	59	5	implications	implication	NOUN
amwa-17	59	6	on	on	ADP
amwa-17	59	7	available	available	ADJ
amwa-17	59	8	treatments	treatment	NOUN
amwa-17	59	9	and	and	CCONJ
amwa-17	59	10	vaccines	vaccine	NOUN
amwa-17	59	11	will	will	AUX
amwa-17	59	12	require	require	VERB
amwa-17	59	13	monitoring,37	monitoring,37	PRON
amwa-17	59	14	and	and	CCONJ
amwa-17	59	15	new	new	ADJ
amwa-17	59	16	waves	wave	NOUN
amwa-17	59	17	of	of	ADP
amwa-17	59	18	lockdowns	lockdown	NOUN
amwa-17	59	19	may	may	AUX
amwa-17	59	20	cause	cause	VERB
amwa-17	59	21	continued	continue	VERB
amwa-17	59	22	clinical	clinical	ADJ
amwa-17	59	23	trial	trial	NOUN
amwa-17	59	24	enrollment	enrollment	NOUN
amwa-17	59	25	and	and	CCONJ
amwa-17	59	26	execution	execution	NOUN
amwa-17	59	27	challenges	challenge	NOUN
amwa-17	59	28	as	as	ADP
amwa-17	59	29	certain	certain	ADJ
amwa-17	59	30	regions	region	NOUN
amwa-17	59	31	with	with	ADP
amwa-17	59	32	increased	increase	VERB
amwa-17	59	33	case	case	NOUN
amwa-17	59	34	counts	count	VERB
amwa-17	59	35	return	return	VERB
amwa-17	59	36	to	to	ADP
amwa-17	59	37	lockdown	lockdown	NOUN
amwa-17	59	38	.	.	PUNCT
amwa-17	60	1	it	it	PRON
amwa-17	60	2	remains	remain	VERB
amwa-17	60	3	to	to	PART
amwa-17	60	4	be	be	AUX
amwa-17	60	5	determined	determine	VERB
amwa-17	60	6	how	how	SCONJ
amwa-17	60	7	some	some	PRON
amwa-17	60	8	of	of	ADP
amwa-17	60	9	the	the	DET
amwa-17	60	10	efficiencies	efficiency	NOUN
amwa-17	60	11	gained	gain	VERB
amwa-17	60	12	during	during	ADP
amwa-17	60	13	the	the	DET
amwa-17	60	14	pandemic	pandemic	NOUN
amwa-17	60	15	will	will	AUX
amwa-17	60	16	be	be	AUX
amwa-17	60	17	applied	apply	VERB
amwa-17	60	18	as	as	ADP
amwa-17	60	19	learning	learn	VERB
amwa-17	60	20	for	for	ADP
amwa-17	60	21	future	future	ADJ
amwa-17	60	22	processes	process	NOUN
amwa-17	60	23	in	in	ADP
amwa-17	60	24	a	a	DET
amwa-17	60	25	sustainable	sustainable	ADJ
amwa-17	60	26	way	way	NOUN
amwa-17	60	27	.	.	PUNCT
amwa-17	61	1	author	author	NOUN
amwa-17	61	2	declaration	declaration	NOUN
amwa-17	61	3	and	and	CCONJ
amwa-17	61	4	disclosures	disclosure	NOUN
amwa-17	61	5	:	:	PUNCT
amwa-17	61	6	jeanette	jeanette	PROPN
amwa-17	61	7	towles	towles	PROPN
amwa-17	61	8	has	have	AUX
amwa-17	61	9	received	receive	VERB
amwa-17	61	10	funds	fund	NOUN
amwa-17	61	11	from	from	ADP
amwa-17	61	12	several	several	ADJ
amwa-17	61	13	biotech	biotech	ADJ
amwa-17	61	14	and	and	CCONJ
amwa-17	61	15	pharmaceutical	pharmaceutical	NOUN
amwa-17	61	16	companies	company	NOUN
amwa-17	61	17	for	for	ADP
amwa-17	61	18	regulatory	regulatory	ADJ
amwa-17	61	19	writing	writing	NOUN
amwa-17	61	20	services	service	NOUN
amwa-17	61	21	on	on	ADP
amwa-17	61	22	covid-19	covid-19	PROPN
amwa-17	61	23	clinical	clinical	ADJ
amwa-17	61	24	trials	trial	NOUN
amwa-17	61	25	.	.	PUNCT
amwa-17	62	1	author	author	NOUN
amwa-17	62	2	contact	contact	PROPN
amwa-17	62	3	:	:	PUNCT
amwa-17	63	1	jtowles@synterex.com	jtowles@synterex.com	PROPN
amwa-17	63	2	references	reference	NOUN
amwa-17	63	3	1	1	X
amwa-17	63	4	.	.	PUNCT
amwa-17	64	1	middle	middle	PROPN
amwa-17	64	2	east	east	PROPN
amwa-17	64	3	respiratory	respiratory	ADJ
amwa-17	64	4	syndrome	syndrome	NOUN
amwa-17	64	5	coronavirus	coronavirus	NOUN
amwa-17	64	6	(	(	PUNCT
amwa-17	64	7	mers	mer	NOUN
amwa-17	64	8	-	-	PUNCT
amwa-17	64	9	cov	cov	NOUN
amwa-17	64	10	)	)	PUNCT
amwa-17	64	11	.	.	PUNCT
amwa-17	65	1	world	world	PROPN
amwa-17	65	2	health	health	PROPN
amwa-17	65	3	organization	organization	PROPN
amwa-17	65	4	.	.	PUNCT
amwa-17	66	1	published	publish	VERB
amwa-17	66	2	march	march	PROPN
amwa-17	66	3	11	11	NUM
amwa-17	66	4	,	,	PUNCT
amwa-17	66	5	2019	2019	NUM
amwa-17	66	6	.	.	PUNCT
amwa-17	67	1	accessed	access	VERB
amwa-17	67	2	december	december	PROPN
amwa-17	67	3	6	6	NUM
amwa-17	67	4	,	,	PUNCT
amwa-17	67	5	2020	2020	NUM
amwa-17	67	6	.	.	PUNCT
amwa-17	68	1	https://www.who.int/news-room/fact-sheets/detail/middle-eastrespiratory-syndrome-coronavirus-(mers-cov	https://www.who.int/news-room/fact-sheets/detail/middle-eastrespiratory-syndrome-coronavirus-(mers-cov	PROPN
amwa-17	68	2	)	)	PUNCT
amwa-17	69	1	2	2	NUM
amwa-17	69	2	.	.	X
amwa-17	69	3	severe	severe	ADJ
amwa-17	69	4	acute	acute	ADJ
amwa-17	69	5	respiratory	respiratory	ADJ
amwa-17	69	6	syndrome	syndrome	NOUN
amwa-17	69	7	(	(	PUNCT
amwa-17	69	8	sars	sars	PROPN
amwa-17	69	9	)	)	PUNCT
amwa-17	69	10	.	.	PUNCT
amwa-17	70	1	world	world	PROPN
amwa-17	70	2	health	health	PROPN
amwa-17	70	3	organization	organization	PROPN
amwa-17	70	4	.	.	PUNCT
amwa-17	71	1	published	publish	VERB
amwa-17	71	2	2020	2020	NUM
amwa-17	71	3	.	.	PUNCT
amwa-17	72	1	accessed	access	VERB
amwa-17	72	2	december	december	PROPN
amwa-17	72	3	6	6	NUM
amwa-17	72	4	,	,	PUNCT
amwa-17	72	5	2020	2020	NUM
amwa-17	72	6	.	.	PUNCT
amwa-17	73	1	https://www.who.int/	https://www.who.int/	NOUN
amwa-17	73	2	health	health	NOUN
amwa-17	73	3	-	-	PUNCT
amwa-17	73	4	topics	topic	NOUN
amwa-17	73	5	/	/	SYM
amwa-17	73	6	severe	severe	ADJ
amwa-17	73	7	-	-	PUNCT
amwa-17	73	8	acute	acute	ADJ
amwa-17	73	9	-	-	PUNCT
amwa-17	73	10	respiratory	respiratory	ADJ
amwa-17	73	11	-	-	PUNCT
amwa-17	73	12	syndrome#tab	syndrome#tab	NOUN
amwa-17	73	13	=	=	NOUN
amwa-17	73	14	tab_1	tab_1	PRON
amwa-17	73	15	3	3	NUM
amwa-17	73	16	.	.	PUNCT
amwa-17	73	17	emergencies	emergency	NOUN
amwa-17	73	18	preparedness	preparedness	NOUN
amwa-17	73	19	,	,	PUNCT
amwa-17	73	20	response	response	NOUN
amwa-17	73	21	.	.	PUNCT
amwa-17	74	1	novel	novel	ADJ
amwa-17	74	2	coronavirus	coronavirus	NOUN
amwa-17	74	3	–	–	PUNCT
amwa-17	74	4	china	china	PROPN
amwa-17	74	5	.	.	PUNCT
amwa-17	75	1	world	world	PROPN
amwa-17	75	2	health	health	PROPN
amwa-17	75	3	organization	organization	PROPN
amwa-17	75	4	.	.	PUNCT
amwa-17	76	1	published	publish	VERB
amwa-17	76	2	january	january	PROPN
amwa-17	76	3	12	12	NUM
amwa-17	76	4	,	,	PUNCT
amwa-17	76	5	2020	2020	NUM
amwa-17	76	6	.	.	PUNCT
amwa-17	77	1	accessed	access	VERB
amwa-17	77	2	december	december	PROPN
amwa-17	77	3	6	6	NUM
amwa-17	77	4	,	,	PUNCT
amwa-17	77	5	2020	2020	NUM
amwa-17	77	6	.	.	PUNCT
amwa-17	78	1	https://www.who.int/emergencies/disease-outbreak-news/	https://www.who.int/emergencies/disease-outbreak-news/	PRON
amwa-17	78	2	item/2020	item/2020	NOUN
amwa-17	78	3	-	-	PUNCT
amwa-17	78	4	don229	don229	PROPN
amwa-17	78	5	4	4	NUM
amwa-17	78	6	.	.	PUNCT
amwa-17	78	7	timeline	timeline	NOUN
amwa-17	78	8	of	of	ADP
amwa-17	78	9	who	who	PRON
amwa-17	78	10	’s	’	VERB
amwa-17	78	11	response	response	NOUN
amwa-17	78	12	to	to	ADP
amwa-17	78	13	covid-19	covid-19	PROPN
amwa-17	78	14	.	.	PUNCT
amwa-17	79	1	world	world	PROPN
amwa-17	79	2	health	health	PROPN
amwa-17	79	3	organization	organization	PROPN
amwa-17	79	4	.	.	PUNCT
amwa-17	80	1	accessed	access	VERB
amwa-17	80	2	january	january	PROPN
amwa-17	80	3	31	31	NUM
amwa-17	80	4	,	,	PUNCT
amwa-17	80	5	2021	2021	NUM
amwa-17	80	6	.	.	PUNCT
amwa-17	81	1	https://www.who.int/emergencies/	https://www.who.int/emergencies/	PROPN
amwa-17	81	2	diseases	disease	NOUN
amwa-17	81	3	/	/	SYM
amwa-17	81	4	novel	novel	NOUN
amwa-17	81	5	-	-	PUNCT
amwa-17	81	6	coronavirus-2019	coronavirus-2019	VERB
amwa-17	81	7	/	/	SYM
amwa-17	81	8	interactive	interactive	ADJ
amwa-17	81	9	-	-	PUNCT
amwa-17	81	10	timeline#event-22	timeline#event-22	DET
amwa-17	81	11	5	5	NUM
amwa-17	81	12	.	.	PUNCT
amwa-17	81	13	basavaraju	basavaraju	PROPN
amwa-17	81	14	sv	sv	PROPN
amwa-17	81	15	,	,	PUNCT
amwa-17	81	16	patton	patton	PROPN
amwa-17	81	17	me	i	PRON
amwa-17	81	18	,	,	PUNCT
amwa-17	81	19	grimm	grimm	PROPN
amwa-17	81	20	k	k	PROPN
amwa-17	81	21	,	,	PUNCT
amwa-17	81	22	et	et	PROPN
amwa-17	81	23	al	al	PROPN
amwa-17	81	24	.	.	PROPN
amwa-17	81	25	serologic	serologic	PROPN
amwa-17	81	26	testing	testing	NOUN
amwa-17	81	27	of	of	ADP
amwa-17	81	28	us	us	PROPN
amwa-17	81	29	blood	blood	NOUN
amwa-17	81	30	donations	donation	NOUN
amwa-17	81	31	to	to	PART
amwa-17	81	32	identify	identify	VERB
amwa-17	81	33	severe	severe	ADJ
amwa-17	81	34	acute	acute	ADJ
amwa-17	81	35	respiratory	respiratory	ADJ
amwa-17	81	36	syndrome	syndrome	NOUN
amwa-17	81	37	coronavirus	coronavirus	NOUN
amwa-17	81	38	2	2	NUM
amwa-17	81	39	(	(	PUNCT
amwa-17	81	40	sars	sar	NOUN
amwa-17	81	41	-	-	PUNCT
amwa-17	81	42	cov-2)–reactive	cov-2)–reactive	PROPN
amwa-17	81	43	antibodies	antibodie	VERB
amwa-17	81	44	:	:	PUNCT
amwa-17	81	45	december	december	PROPN
amwa-17	81	46	2019	2019	NUM
amwa-17	81	47	–	–	PUNCT
amwa-17	81	48	january	january	PROPN
amwa-17	81	49	2020	2020	NUM
amwa-17	81	50	.	.	PUNCT
amwa-17	82	1	clin	clin	PROPN
amwa-17	82	2	infect	infect	PROPN
amwa-17	82	3	dis	dis	PROPN
amwa-17	82	4	.	.	PUNCT
amwa-17	82	5	published	publish	VERB
amwa-17	82	6	online	online	ADV
amwa-17	82	7	november	november	PROPN
amwa-17	82	8	30	30	NUM
amwa-17	82	9	,	,	PUNCT
amwa-17	82	10	2020	2020	NUM
amwa-17	82	11	.	.	PUNCT
amwa-17	83	1	doi:10.1093	doi:10.1093	NOUN
amwa-17	83	2	/	/	SYM
amwa-17	83	3	cid/	cid/	ADJ
amwa-17	83	4	ciaa1785	ciaa1785	PROPN
amwa-17	83	5	6	6	NUM
amwa-17	83	6	.	.	PUNCT
amwa-17	83	7	holshue	holshue	PROPN
amwa-17	83	8	ml	ml	PROPN
amwa-17	83	9	,	,	PUNCT
amwa-17	83	10	debolt	debolt	NOUN
amwa-17	83	11	c	c	PROPN
amwa-17	83	12	,	,	PUNCT
amwa-17	83	13	lindquist	lindquist	PROPN
amwa-17	83	14	s	s	PROPN
amwa-17	83	15	,	,	PUNCT
amwa-17	83	16	et	et	PROPN
amwa-17	83	17	al	al	PROPN
amwa-17	83	18	.	.	PROPN
amwa-17	83	19	;	;	PUNCT
amwa-17	83	20	for	for	ADP
amwa-17	83	21	the	the	DET
amwa-17	83	22	washington	washington	PROPN
amwa-17	83	23	state	state	PROPN
amwa-17	83	24	2019	2019	NUM
amwa-17	83	25	-	-	PUNCT
amwa-17	83	26	ncov	ncov	NOUN
amwa-17	83	27	case	case	NOUN
amwa-17	83	28	investigation	investigation	NOUN
amwa-17	83	29	team	team	NOUN
amwa-17	83	30	.	.	PUNCT
amwa-17	84	1	first	first	ADJ
amwa-17	84	2	case	case	NOUN
amwa-17	84	3	of	of	ADP
amwa-17	84	4	2019	2019	NUM
amwa-17	84	5	novel	novel	ADJ
amwa-17	84	6	coronavirus	coronavirus	NOUN
amwa-17	84	7	in	in	ADP
amwa-17	84	8	the	the	DET
amwa-17	84	9	united	united	PROPN
amwa-17	84	10	states	states	PROPN
amwa-17	84	11	.	.	PUNCT
amwa-17	85	1	n	n	PROPN
amwa-17	85	2	engl	engl	PROPN
amwa-17	85	3	j	j	PROPN
amwa-17	85	4	med	med	PROPN
amwa-17	85	5	.	.	PUNCT
amwa-17	86	1	2020;382(10):929	2020;382(10):929	PROPN
amwa-17	86	2	-	-	SYM
amwa-17	86	3	936	936	NUM
amwa-17	86	4	.	.	PUNCT
amwa-17	87	1	7	7	NUM
amwa-17	87	2	.	.	X
amwa-17	87	3	lemieux	lemieux	PROPN
amwa-17	87	4	j	j	PROPN
amwa-17	87	5	,	,	PUNCT
amwa-17	87	6	siddle	siddle	PROPN
amwa-17	87	7	kj	kj	PROPN
amwa-17	87	8	,	,	PUNCT
amwa-17	87	9	shaw	shaw	PROPN
amwa-17	87	10	bm	bm	PROPN
amwa-17	87	11	,	,	PUNCT
amwa-17	87	12	et	et	PROPN
amwa-17	87	13	al	al	PROPN
amwa-17	87	14	.	.	PUNCT
amwa-17	88	1	phylogenetic	phylogenetic	ADJ
amwa-17	88	2	analysis	analysis	NOUN
amwa-17	88	3	of	of	ADP
amwa-17	88	4	sarscov-2	sarscov-2	NUM
amwa-17	88	5	in	in	ADP
amwa-17	88	6	boston	boston	PROPN
amwa-17	88	7	highlights	highlight	VERB
amwa-17	88	8	the	the	DET
amwa-17	88	9	impact	impact	NOUN
amwa-17	88	10	of	of	ADP
amwa-17	88	11	superspreading	superspreade	VERB
amwa-17	88	12	events	event	NOUN
amwa-17	88	13	.	.	PUNCT
amwa-17	89	1	science	science	NOUN
amwa-17	89	2	.	.	PUNCT
amwa-17	90	1	2021;371(6529):eabe3261	2021;371(6529):eabe3261	NUM
amwa-17	90	2	.	.	NOUN
amwa-17	90	3	8	8	NUM
amwa-17	90	4	.	.	PUNCT
amwa-17	91	1	cordeiro	cordeiro	PROPN
amwa-17	91	2	j.	j.	PROPN
amwa-17	91	3	the	the	DET
amwa-17	91	4	impact	impact	NOUN
amwa-17	91	5	of	of	ADP
amwa-17	91	6	the	the	DET
amwa-17	91	7	massachusetts	massachusetts	PROPN
amwa-17	91	8	life	life	PROPN
amwa-17	91	9	sciences	sciences	PROPN
amwa-17	91	10	emergency	emergency	NOUN
amwa-17	91	11	supplyhub	supplyhub	PROPN
amwa-17	91	12	.	.	PUNCT
amwa-17	92	1	massbio	massbio	PROPN
amwa-17	92	2	.	.	PUNCT
amwa-17	93	1	published	publish	VERB
amwa-17	93	2	march	march	PROPN
amwa-17	93	3	25	25	NUM
amwa-17	93	4	,	,	PUNCT
amwa-17	93	5	2020	2020	NUM
amwa-17	93	6	.	.	PUNCT
amwa-17	94	1	accessed	access	VERB
amwa-17	94	2	january	january	PROPN
amwa-17	94	3	31	31	NUM
amwa-17	94	4	,	,	PUNCT
amwa-17	94	5	2021	2021	NUM
amwa-17	94	6	.	.	PUNCT
amwa-17	95	1	https://www.massbio.org/news/recent-news/the-impact-of-themassachusetts-life-sciences-supplyhub/	https://www.massbio.org/news/recent-news/the-impact-of-themassachusetts-life-sciences-supplyhub/	NOUN
amwa-17	95	2	mailto:jtowles@synterex.com	mailto:jtowles@synterex.com	PROPN
amwa-17	95	3	https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirushttps://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov	https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirushttps://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov	PROPN
amwa-17	95	4	)	)	PUNCT
amwa-17	95	5	https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1	https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1	VERB
amwa-17	95	6	https://www.who.int/emergencies/disease-outbreak-news/item/2020-don229	https://www.who.int/emergencies/disease-outbreak-news/item/2020-don229	PROPN
amwa-17	95	7	https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/	https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/	NOUN
amwa-17	95	8	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#event-22	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#event-22	NOUN
amwa-17	95	9	https://www.massbio.org/news/recent-news/the-impact-of-the-massachusetts-life-sciences-supplyhub/	https://www.massbio.org/news/recent-news/the-impact-of-the-massachusetts-life-sciences-supplyhub/	NOUN
amwa-17	95	10	https://www.massbio.org/news/recent-news/the-impact-of-the-massachusetts-life-sciences-supplyhub/	https://www.massbio.org/news/recent-news/the-impact-of-the-massachusetts-life-sciences-supplyhub/	NOUN
amwa-17	95	11	70	70	NUM
amwa-17	95	12	amwa	amwa	PROPN
amwa-17	95	13	journal	journal	PROPN
amwa-17	95	14	/	/	SYM
amwa-17	95	15	v36	v36	PROPN
amwa-17	95	16	n2	n2	PROPN
amwa-17	95	17	/	/	SYM
amwa-17	95	18	2021	2021	NUM
amwa-17	95	19	/	/	SYM
amwa-17	95	20	amwa.org	amwa.org	PROPN
amwa-17	95	21	9	9	NUM
amwa-17	95	22	.	.	PUNCT
amwa-17	96	1	kwon	kwon	PROPN
amwa-17	96	2	d.	d.	PROPN
amwa-17	97	1	how	how	SCONJ
amwa-17	97	2	the	the	DET
amwa-17	97	3	pharma	pharma	PROPN
amwa-17	97	4	industry	industry	NOUN
amwa-17	97	5	pulled	pull	VERB
amwa-17	97	6	off	off	ADP
amwa-17	97	7	the	the	DET
amwa-17	97	8	pivot	pivot	NOUN
amwa-17	97	9	to	to	ADP
amwa-17	97	10	covid-19	covid-19	PROPN
amwa-17	97	11	.	.	PUNCT
amwa-17	98	1	the	the	DET
amwa-17	98	2	scientist	scientist	NOUN
amwa-17	98	3	.	.	PUNCT
amwa-17	99	1	published	publish	VERB
amwa-17	99	2	july	july	PROPN
amwa-17	99	3	13	13	NUM
amwa-17	99	4	,	,	PUNCT
amwa-17	99	5	2020	2020	NUM
amwa-17	99	6	.	.	PUNCT
amwa-17	100	1	accessed	access	VERB
amwa-17	100	2	january	january	PROPN
amwa-17	100	3	31	31	NUM
amwa-17	100	4	,	,	PUNCT
amwa-17	100	5	2021	2021	NUM
amwa-17	100	6	.	.	PUNCT
amwa-17	101	1	https://www.the-scientist.com/bio-business/how-the-pharmaindustry-pulled-off-the-pivot-to-covid-19-67719	https://www.the-scientist.com/bio-business/how-the-pharmaindustry-pulled-off-the-pivot-to-covid-19-67719	NOUN
amwa-17	101	2	10	10	NUM
amwa-17	101	3	.	.	PUNCT
amwa-17	102	1	who	who	PRON
amwa-17	102	2	director	director	NOUN
amwa-17	102	3	-	-	PUNCT
amwa-17	102	4	general	general	NOUN
amwa-17	102	5	's	's	PART
amwa-17	102	6	opening	opening	NOUN
amwa-17	102	7	remarks	remark	NOUN
amwa-17	102	8	at	at	ADP
amwa-17	102	9	the	the	DET
amwa-17	102	10	media	medium	NOUN
amwa-17	102	11	briefing	briefing	NOUN
amwa-17	102	12	on	on	ADP
amwa-17	102	13	covid-19	covid-19	PROPN
amwa-17	102	14	11	11	NUM
amwa-17	102	15	march	march	NOUN
amwa-17	102	16	2020	2020	NUM
amwa-17	102	17	.	.	PUNCT
amwa-17	103	1	world	world	PROPN
amwa-17	103	2	health	health	PROPN
amwa-17	103	3	organization	organization	PROPN
amwa-17	103	4	.	.	PUNCT
amwa-17	104	1	published	publish	VERB
amwa-17	104	2	march	march	PROPN
amwa-17	104	3	11	11	NUM
amwa-17	104	4	,	,	PUNCT
amwa-17	104	5	2020	2020	NUM
amwa-17	104	6	.	.	PUNCT
amwa-17	105	1	accessed	access	VERB
amwa-17	105	2	december	december	PROPN
amwa-17	105	3	6	6	NUM
amwa-17	105	4	,	,	PUNCT
amwa-17	105	5	2020	2020	NUM
amwa-17	105	6	.	.	PUNCT
amwa-17	106	1	https://www.who.int/	https://www.who.int/	NOUN
amwa-17	106	2	director	director	NOUN
amwa-17	106	3	-	-	PUNCT
amwa-17	106	4	general	general	NOUN
amwa-17	106	5	/	/	SYM
amwa-17	106	6	speeches	speech	NOUN
amwa-17	106	7	/	/	SYM
amwa-17	106	8	detail	detail	NOUN
amwa-17	106	9	/	/	SYM
amwa-17	106	10	who	who	PRON
amwa-17	106	11	-	-	PUNCT
amwa-17	106	12	director	director	NOUN
amwa-17	106	13	-	-	PUNCT
amwa-17	106	14	general	general	ADJ
amwa-17	106	15	-	-	PUNCT
amwa-17	106	16	s	s	NOUN
amwa-17	106	17	-	-	PUNCT
amwa-17	106	18	openingremarks	openingremarks	NOUN
amwa-17	106	19	-	-	PUNCT
amwa-17	106	20	at	at	ADP
amwa-17	106	21	-	-	PUNCT
amwa-17	106	22	the	the	DET
amwa-17	106	23	-	-	PUNCT
amwa-17	106	24	media	media	NOUN
amwa-17	106	25	-	-	PUNCT
amwa-17	106	26	briefing	briefing	NOUN
amwa-17	106	27	-	-	PUNCT
amwa-17	106	28	on	on	ADP
amwa-17	106	29	-	-	PUNCT
amwa-17	106	30	covid-19	covid-19	NOUN
amwa-17	106	31	-	-	PUNCT
amwa-17	106	32	--11	--11	ADJ
amwa-17	106	33	-	-	PUNCT
amwa-17	106	34	march-2020	march-2020	ADJ
amwa-17	106	35	11	11	NUM
amwa-17	106	36	.	.	PUNCT
amwa-17	107	1	severe	severe	ADJ
amwa-17	107	2	acute	acute	ADJ
amwa-17	107	3	respiratory	respiratory	ADJ
amwa-17	107	4	syndrome	syndrome	NOUN
amwa-17	107	5	coronavirus	coronavirus	NOUN
amwa-17	107	6	2	2	NUM
amwa-17	107	7	isolate	isolate	VERB
amwa-17	107	8	wuhan	wuhan	PROPN
amwa-17	107	9	-	-	PUNCT
amwa-17	107	10	hu-1	hu-1	PROPN
amwa-17	107	11	,	,	PUNCT
amwa-17	107	12	complete	complete	ADJ
amwa-17	107	13	genome	genome	NOUN
amwa-17	107	14	.	.	PUNCT
amwa-17	108	1	genbank	genbank	NOUN
amwa-17	108	2	:	:	PUNCT
amwa-17	108	3	mn908947.1	mn908947.1	NUM
amwa-17	108	4	,	,	PUNCT
amwa-17	108	5	mn908947.2	mn908947.2	NOUN
amwa-17	108	6	,	,	PUNCT
amwa-17	108	7	mn908947.3	mn908947.3	NOUN
amwa-17	108	8	.	.	PUNCT
amwa-17	109	1	national	national	ADJ
amwa-17	109	2	center	center	NOUN
amwa-17	109	3	for	for	ADP
amwa-17	109	4	biotechnology	biotechnology	NOUN
amwa-17	109	5	information	information	NOUN
amwa-17	109	6	.	.	PUNCT
amwa-17	110	1	accessed	access	VERB
amwa-17	110	2	december	december	PROPN
amwa-17	110	3	6	6	NUM
amwa-17	110	4	,	,	PUNCT
amwa-17	110	5	2020	2020	NUM
amwa-17	110	6	.	.	PUNCT
amwa-17	111	1	https://www.ncbi.nlm.nih.gov/nuccore/mn908947	https://www.ncbi.nlm.nih.gov/nuccore/mn908947	NOUN
amwa-17	111	2	12	12	NUM
amwa-17	111	3	.	.	PUNCT
amwa-17	112	1	fda	fda	PROPN
amwa-17	112	2	announces	announce	VERB
amwa-17	112	3	key	key	ADJ
amwa-17	112	4	actions	action	NOUN
amwa-17	112	5	to	to	PART
amwa-17	112	6	advance	advance	VERB
amwa-17	112	7	development	development	NOUN
amwa-17	112	8	of	of	ADP
amwa-17	112	9	novel	novel	ADJ
amwa-17	112	10	coronavirus	coronavirus	NOUN
amwa-17	112	11	medical	medical	ADJ
amwa-17	112	12	countermeasures	countermeasure	NOUN
amwa-17	112	13	.	.	PUNCT
amwa-17	113	1	us	we	PRON
amwa-17	113	2	food	food	NOUN
amwa-17	113	3	and	and	CCONJ
amwa-17	113	4	drug	drug	PROPN
amwa-17	113	5	administration	administration	NOUN
amwa-17	113	6	.	.	PUNCT
amwa-17	114	1	published	publish	VERB
amwa-17	114	2	january	january	PROPN
amwa-17	114	3	27	27	NUM
amwa-17	114	4	,	,	PUNCT
amwa-17	114	5	2020	2020	NUM
amwa-17	114	6	.	.	PUNCT
amwa-17	115	1	accessed	access	VERB
amwa-17	115	2	december	december	PROPN
amwa-17	115	3	6	6	NUM
amwa-17	115	4	,	,	PUNCT
amwa-17	115	5	2020	2020	NUM
amwa-17	115	6	.	.	PUNCT
amwa-17	116	1	https://www.fda.gov/news-events/press-announcements/fdaannounces-key-actions-advance-development-novel-coronavirusmedical-countermeasures	https://www.fda.gov/news-events/press-announcements/fdaannounces-key-actions-advance-development-novel-coronavirusmedical-countermeasure	NOUN
amwa-17	116	2	13	13	NUM
amwa-17	116	3	.	.	PUNCT
amwa-17	117	1	emergency	emergency	NOUN
amwa-17	117	2	use	use	NOUN
amwa-17	117	3	authorization	authorization	NOUN
amwa-17	117	4	.	.	PUNCT
amwa-17	118	1	us	we	PRON
amwa-17	118	2	food	food	NOUN
amwa-17	118	3	and	and	CCONJ
amwa-17	118	4	drug	drug	PROPN
amwa-17	118	5	administration	administration	NOUN
amwa-17	118	6	.	.	PUNCT
amwa-17	119	1	published	publish	VERB
amwa-17	119	2	december	december	PROPN
amwa-17	119	3	11	11	NUM
amwa-17	119	4	,	,	PUNCT
amwa-17	119	5	2020	2020	NUM
amwa-17	119	6	.	.	PUNCT
amwa-17	120	1	accessed	access	VERB
amwa-17	120	2	january	january	PROPN
amwa-17	120	3	2	2	NUM
amwa-17	120	4	,	,	PUNCT
amwa-17	120	5	2021	2021	NUM
amwa-17	120	6	.	.	PUNCT
amwa-17	121	1	https://www	https://www	PROPN
amwa-17	121	2	.	.	PUNCT
amwa-17	121	3	fda.gov/emergency-preparedness-and-response/mcm-legal-regulatoryand-policy-framework/emergency-use-authorization	fda.gov/emergency-preparedness-and-response/mcm-legal-regulatoryand-policy-framework/emergency-use-authorization	PROPN
amwa-17	121	4	14	14	NUM
amwa-17	121	5	.	.	PUNCT
amwa-17	122	1	emergency	emergency	NOUN
amwa-17	122	2	use	use	NOUN
amwa-17	122	3	authorization	authorization	NOUN
amwa-17	122	4	of	of	ADP
amwa-17	122	5	medical	medical	ADJ
amwa-17	122	6	products	product	NOUN
amwa-17	122	7	and	and	CCONJ
amwa-17	122	8	related	related	ADJ
amwa-17	122	9	authorities	authority	NOUN
amwa-17	122	10	:	:	PUNCT
amwa-17	122	11	guidance	guidance	NOUN
amwa-17	122	12	for	for	ADP
amwa-17	122	13	industry	industry	NOUN
amwa-17	122	14	and	and	CCONJ
amwa-17	122	15	other	other	ADJ
amwa-17	122	16	stakeholders	stakeholder	NOUN
amwa-17	122	17	.	.	PUNCT
amwa-17	123	1	us	we	PRON
amwa-17	123	2	food	food	NOUN
amwa-17	123	3	and	and	CCONJ
amwa-17	123	4	drug	drug	PROPN
amwa-17	123	5	administration	administration	NOUN
amwa-17	123	6	.	.	PUNCT
amwa-17	124	1	published	publish	VERB
amwa-17	124	2	january	january	PROPN
amwa-17	124	3	2017	2017	NUM
amwa-17	124	4	.	.	PUNCT
amwa-17	125	1	accessed	access	VERB
amwa-17	125	2	december	december	PROPN
amwa-17	125	3	6	6	NUM
amwa-17	125	4	,	,	PUNCT
amwa-17	125	5	2020	2020	NUM
amwa-17	125	6	.	.	PUNCT
amwa-17	126	1	https://www.fda.gov/regulatory-information/search-fdaguidance-documents/emergency-use-authorization-medical-productsand-related-authorities	https://www.fda.gov/regulatory-information/search-fdaguidance-documents/emergency-use-authorization-medical-productsand-related-authoritie	NOUN
amwa-17	126	2	15	15	NUM
amwa-17	126	3	.	.	PUNCT
amwa-17	127	1	fda	fda	PROPN
amwa-17	127	2	takes	take	VERB
amwa-17	127	3	significant	significant	ADJ
amwa-17	127	4	step	step	NOUN
amwa-17	127	5	in	in	ADP
amwa-17	127	6	coronavirus	coronavirus	NOUN
amwa-17	127	7	response	response	NOUN
amwa-17	127	8	efforts	effort	NOUN
amwa-17	127	9	,	,	PUNCT
amwa-17	127	10	issues	issue	NOUN
amwa-17	127	11	emergency	emergency	NOUN
amwa-17	127	12	use	use	NOUN
amwa-17	127	13	authorization	authorization	NOUN
amwa-17	127	14	for	for	ADP
amwa-17	127	15	the	the	DET
amwa-17	127	16	first	first	ADJ
amwa-17	127	17	2019	2019	NUM
amwa-17	127	18	novel	novel	ADJ
amwa-17	127	19	coronavirus	coronavirus	NOUN
amwa-17	127	20	diagnostic	diagnostic	ADJ
amwa-17	127	21	:	:	PUNCT
amwa-17	127	22	critical	critical	ADJ
amwa-17	127	23	milestone	milestone	NOUN
amwa-17	127	24	reached	reach	VERB
amwa-17	127	25	in	in	ADP
amwa-17	127	26	response	response	NOUN
amwa-17	127	27	to	to	ADP
amwa-17	127	28	this	this	DET
amwa-17	127	29	outbreak	outbreak	NOUN
amwa-17	127	30	.	.	PUNCT
amwa-17	128	1	us	we	PRON
amwa-17	128	2	food	food	NOUN
amwa-17	128	3	and	and	CCONJ
amwa-17	128	4	drug	drug	NOUN
amwa-17	128	5	administration	administration	NOUN
amwa-17	128	6	.	.	PUNCT
amwa-17	129	1	published	publish	VERB
amwa-17	129	2	february	february	PROPN
amwa-17	129	3	4	4	NUM
amwa-17	129	4	,	,	PUNCT
amwa-17	129	5	2020	2020	NUM
amwa-17	129	6	.	.	PUNCT
amwa-17	130	1	accessed	access	VERB
amwa-17	130	2	december	december	PROPN
amwa-17	130	3	6	6	NUM
amwa-17	130	4	,	,	PUNCT
amwa-17	130	5	2020	2020	NUM
amwa-17	130	6	.	.	PUNCT
amwa-17	131	1	https://www.fda.gov/news-events/pressannouncements/fda-takes-significant-step-coronavirus-responseefforts-issues-emergency-use-authorization-first	https://www.fda.gov/news-events/pressannouncements/fda-takes-significant-step-coronavirus-responseefforts-issues-emergency-use-authorization-first	PROPN
amwa-17	131	2	16	16	NUM
amwa-17	131	3	.	.	PUNCT
amwa-17	132	1	policy	policy	NOUN
amwa-17	132	2	for	for	ADP
amwa-17	132	3	coronavirus	coronavirus	NOUN
amwa-17	132	4	disease-2019	disease-2019	ADJ
amwa-17	132	5	tests	test	NOUN
amwa-17	132	6	during	during	ADP
amwa-17	132	7	the	the	DET
amwa-17	132	8	public	public	ADJ
amwa-17	132	9	health	health	NOUN
amwa-17	132	10	emergency	emergency	NOUN
amwa-17	132	11	(	(	PUNCT
amwa-17	132	12	revised	revise	VERB
amwa-17	132	13	):	):	PUNCT
amwa-17	132	14	immediately	immediately	ADV
amwa-17	132	15	in	in	ADP
amwa-17	132	16	effect	effect	NOUN
amwa-17	132	17	guidance	guidance	NOUN
amwa-17	132	18	for	for	ADP
amwa-17	132	19	clinical	clinical	ADJ
amwa-17	132	20	laboratories	laboratory	NOUN
amwa-17	132	21	,	,	PUNCT
amwa-17	132	22	commercial	commercial	ADJ
amwa-17	132	23	manufacturers	manufacturer	NOUN
amwa-17	132	24	,	,	PUNCT
amwa-17	132	25	and	and	CCONJ
amwa-17	132	26	food	food	NOUN
amwa-17	132	27	and	and	CCONJ
amwa-17	132	28	drug	drug	PROPN
amwa-17	132	29	administration	administration	NOUN
amwa-17	132	30	staff	staff	NOUN
amwa-17	132	31	.	.	PUNCT
amwa-17	133	1	us	we	PRON
amwa-17	133	2	food	food	NOUN
amwa-17	133	3	and	and	CCONJ
amwa-17	133	4	drug	drug	PROPN
amwa-17	133	5	administration	administration	NOUN
amwa-17	133	6	.	.	PUNCT
amwa-17	134	1	published	publish	VERB
amwa-17	134	2	may	may	PROPN
amwa-17	134	3	2020	2020	NUM
amwa-17	134	4	.	.	PUNCT
amwa-17	135	1	accessed	access	VERB
amwa-17	135	2	december	december	PROPN
amwa-17	135	3	6	6	NUM
amwa-17	135	4	,	,	PUNCT
amwa-17	135	5	2020	2020	NUM
amwa-17	135	6	.	.	PUNCT
amwa-17	136	1	https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/policy-coronavirusdisease-2019-tests-during-public-health-emergency-revised	https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/policy-coronavirusdisease-2019-tests-during-public-health-emergency-revise	VERB
amwa-17	136	2	17	17	NUM
amwa-17	136	3	.	.	PUNCT
amwa-17	137	1	coronavirus	coronavirus	NOUN
amwa-17	137	2	(	(	PUNCT
amwa-17	137	3	covid-19	covid-19	PROPN
amwa-17	137	4	)	)	PUNCT
amwa-17	137	5	update	update	NOUN
amwa-17	137	6	:	:	PUNCT
amwa-17	137	7	fda	fda	PROPN
amwa-17	137	8	takes	take	VERB
amwa-17	137	9	new	new	ADJ
amwa-17	137	10	actions	action	NOUN
amwa-17	137	11	to	to	PART
amwa-17	137	12	accelerate	accelerate	VERB
amwa-17	137	13	development	development	NOUN
amwa-17	137	14	of	of	ADP
amwa-17	137	15	novel	novel	ADJ
amwa-17	137	16	prevention	prevention	NOUN
amwa-17	137	17	,	,	PUNCT
amwa-17	137	18	treatment	treatment	NOUN
amwa-17	137	19	options	option	NOUN
amwa-17	137	20	for	for	ADP
amwa-17	137	21	covid-19	covid-19	PROPN
amwa-17	137	22	.	.	PUNCT
amwa-17	138	1	us	us	PROPN
amwa-17	138	2	food	food	NOUN
amwa-17	138	3	and	and	CCONJ
amwa-17	138	4	drug	drug	PROPN
amwa-17	138	5	administration	administration	NOUN
amwa-17	138	6	.	.	PUNCT
amwa-17	139	1	published	publish	VERB
amwa-17	139	2	may	may	PROPN
amwa-17	139	3	11	11	NUM
amwa-17	139	4	,	,	PUNCT
amwa-17	139	5	2020	2020	NUM
amwa-17	139	6	.	.	PUNCT
amwa-17	140	1	accessed	access	VERB
amwa-17	140	2	december	december	PROPN
amwa-17	140	3	12	12	NUM
amwa-17	140	4	,	,	PUNCT
amwa-17	140	5	2020	2020	NUM
amwa-17	140	6	.	.	PUNCT
amwa-17	141	1	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-takes-new-actionsaccelerate-development-novel-prevention-treatment	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-takes-new-actionsaccelerate-development-novel-prevention-treatment	PRON
amwa-17	141	2	18	18	NUM
amwa-17	141	3	.	.	PUNCT
amwa-17	142	1	covid-19	covid-19	PROPN
amwa-17	142	2	public	public	ADJ
amwa-17	142	3	health	health	NOUN
amwa-17	142	4	emergency	emergency	NOUN
amwa-17	142	5	:	:	PUNCT
amwa-17	142	6	general	general	ADJ
amwa-17	142	7	considerations	consideration	NOUN
amwa-17	142	8	for	for	ADP
amwa-17	142	9	preind	preind	ADJ
amwa-17	142	10	meeting	meeting	NOUN
amwa-17	142	11	requests	request	NOUN
amwa-17	142	12	for	for	ADP
amwa-17	142	13	covid-19	covid-19	PROPN
amwa-17	142	14	related	relate	VERB
amwa-17	142	15	drugs	drug	NOUN
amwa-17	142	16	and	and	CCONJ
amwa-17	142	17	biological	biological	ADJ
amwa-17	142	18	products	product	NOUN
amwa-17	142	19	:	:	PUNCT
amwa-17	142	20	guidance	guidance	NOUN
amwa-17	142	21	for	for	ADP
amwa-17	142	22	industry	industry	NOUN
amwa-17	142	23	and	and	CCONJ
amwa-17	142	24	investigators	investigator	NOUN
amwa-17	142	25	.	.	PUNCT
amwa-17	143	1	us	we	PRON
amwa-17	143	2	food	food	NOUN
amwa-17	143	3	and	and	CCONJ
amwa-17	143	4	drug	drug	PROPN
amwa-17	143	5	administration	administration	NOUN
amwa-17	143	6	.	.	PUNCT
amwa-17	144	1	published	publish	VERB
amwa-17	144	2	may	may	PROPN
amwa-17	144	3	2020	2020	NUM
amwa-17	144	4	.	.	PUNCT
amwa-17	145	1	accessed	access	VERB
amwa-17	145	2	december	december	PROPN
amwa-17	145	3	12	12	NUM
amwa-17	145	4	,	,	PUNCT
amwa-17	145	5	2020	2020	NUM
amwa-17	145	6	.	.	PUNCT
amwa-17	146	1	https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/covid-19-public-health-emergency-general-considerationspre-ind-meeting-requests-covid-19-related	https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/covid-19-public-health-emergency-general-considerationspre-ind-meeting-requests-covid-19-relate	VERB
amwa-17	146	2	19	19	NUM
amwa-17	146	3	.	.	PUNCT
amwa-17	147	1	covid-19	covid-19	PROPN
amwa-17	147	2	:	:	PUNCT
amwa-17	147	3	developing	develop	VERB
amwa-17	147	4	drugs	drug	NOUN
amwa-17	147	5	and	and	CCONJ
amwa-17	147	6	biological	biological	ADJ
amwa-17	147	7	products	product	NOUN
amwa-17	147	8	for	for	ADP
amwa-17	147	9	treatment	treatment	NOUN
amwa-17	147	10	or	or	CCONJ
amwa-17	147	11	prevention	prevention	NOUN
amwa-17	147	12	:	:	PUNCT
amwa-17	147	13	guidance	guidance	NOUN
amwa-17	147	14	for	for	ADP
amwa-17	147	15	industry	industry	NOUN
amwa-17	147	16	.	.	PUNCT
amwa-17	148	1	us	we	PRON
amwa-17	148	2	food	food	NOUN
amwa-17	148	3	and	and	CCONJ
amwa-17	148	4	drug	drug	PROPN
amwa-17	148	5	administration	administration	NOUN
amwa-17	148	6	.	.	PUNCT
amwa-17	149	1	published	publish	VERB
amwa-17	149	2	may	may	PROPN
amwa-17	149	3	2020	2020	NUM
amwa-17	149	4	.	.	PUNCT
amwa-17	150	1	accessed	access	VERB
amwa-17	150	2	dec	dec	PROPN
amwa-17	150	3	12	12	NUM
amwa-17	150	4	,	,	PUNCT
amwa-17	150	5	2020	2020	NUM
amwa-17	150	6	.	.	PUNCT
amwa-17	151	1	https://www.fda.gov/	https://www.fda.gov/	PROPN
amwa-17	151	2	regulatory	regulatory	ADJ
amwa-17	151	3	-	-	PUNCT
amwa-17	151	4	information	information	NOUN
amwa-17	151	5	/	/	SYM
amwa-17	151	6	search	search	NOUN
amwa-17	151	7	-	-	PUNCT
amwa-17	151	8	fda	fda	NOUN
amwa-17	151	9	-	-	PUNCT
amwa-17	151	10	guidance	guidance	NOUN
amwa-17	151	11	-	-	PUNCT
amwa-17	151	12	documents	document	NOUN
amwa-17	151	13	/	/	SYM
amwa-17	151	14	covid-19developing	covid-19developing	NOUN
amwa-17	151	15	-	-	PUNCT
amwa-17	151	16	drugs	drug	NOUN
amwa-17	151	17	-	-	PUNCT
amwa-17	151	18	and	and	CCONJ
amwa-17	151	19	-	-	PUNCT
amwa-17	151	20	biological	biological	ADJ
amwa-17	151	21	-	-	PUNCT
amwa-17	151	22	products	product	NOUN
amwa-17	151	23	-	-	PUNCT
amwa-17	151	24	treatment	treatment	NOUN
amwa-17	151	25	-	-	PUNCT
amwa-17	151	26	or	or	CCONJ
amwa-17	151	27	-	-	PUNCT
amwa-17	151	28	prevention	prevention	NOUN
amwa-17	151	29	20	20	NUM
amwa-17	151	30	.	.	PUNCT
amwa-17	152	1	statistical	statistical	ADJ
amwa-17	152	2	considerations	consideration	NOUN
amwa-17	152	3	for	for	ADP
amwa-17	152	4	clinical	clinical	ADJ
amwa-17	152	5	trials	trial	NOUN
amwa-17	152	6	during	during	ADP
amwa-17	152	7	the	the	DET
amwa-17	152	8	covid-19	covid-19	PROPN
amwa-17	152	9	public	public	ADJ
amwa-17	152	10	health	health	NOUN
amwa-17	152	11	emergency	emergency	NOUN
amwa-17	152	12	:	:	PUNCT
amwa-17	152	13	guidance	guidance	NOUN
amwa-17	152	14	for	for	ADP
amwa-17	152	15	industry	industry	NOUN
amwa-17	152	16	.	.	PUNCT
amwa-17	153	1	us	we	PRON
amwa-17	153	2	food	food	NOUN
amwa-17	153	3	and	and	CCONJ
amwa-17	153	4	drug	drug	PROPN
amwa-17	153	5	administration	administration	NOUN
amwa-17	153	6	.	.	PUNCT
amwa-17	154	1	published	publish	VERB
amwa-17	154	2	june	june	PROPN
amwa-17	154	3	2020	2020	NUM
amwa-17	154	4	.	.	PUNCT
amwa-17	155	1	accessed	access	VERB
amwa-17	155	2	december	december	PROPN
amwa-17	155	3	12	12	NUM
amwa-17	155	4	,	,	PUNCT
amwa-17	155	5	2020	2020	NUM
amwa-17	155	6	.	.	PUNCT
amwa-17	156	1	https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/statistical-considerations-clinical-trials-during-covid-19public-health-emergency-guidance-industry	https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/statistical-considerations-clinical-trials-during-covid-19public-health-emergency-guidance-industry	PROPN
amwa-17	156	2	21	21	NUM
amwa-17	156	3	.	.	PUNCT
amwa-17	157	1	development	development	NOUN
amwa-17	157	2	and	and	CCONJ
amwa-17	157	3	licensure	licensure	NOUN
amwa-17	157	4	of	of	ADP
amwa-17	157	5	vaccines	vaccine	NOUN
amwa-17	157	6	to	to	PART
amwa-17	157	7	prevent	prevent	VERB
amwa-17	157	8	covid-19	covid-19	PROPN
amwa-17	157	9	:	:	PUNCT
amwa-17	157	10	guidance	guidance	NOUN
amwa-17	157	11	for	for	ADP
amwa-17	157	12	industry	industry	NOUN
amwa-17	157	13	.	.	PUNCT
amwa-17	158	1	us	we	PRON
amwa-17	158	2	food	food	NOUN
amwa-17	158	3	and	and	CCONJ
amwa-17	158	4	drug	drug	PROPN
amwa-17	158	5	administration	administration	NOUN
amwa-17	158	6	.	.	PUNCT
amwa-17	159	1	published	publish	VERB
amwa-17	159	2	june	june	PROPN
amwa-17	159	3	2020	2020	NUM
amwa-17	159	4	.	.	PUNCT
amwa-17	160	1	accessed	access	VERB
amwa-17	160	2	december	december	PROPN
amwa-17	160	3	13	13	NUM
amwa-17	160	4	,	,	PUNCT
amwa-17	160	5	2020	2020	NUM
amwa-17	160	6	.	.	PUNCT
amwa-17	161	1	https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/development-andlicensure-vaccines-prevent-covid-19	https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/development-andlicensure-vaccines-prevent-covid-19	PROPN
amwa-17	161	2	22	22	NUM
amwa-17	161	3	.	.	PUNCT
amwa-17	162	1	emergency	emergency	NOUN
amwa-17	162	2	use	use	NOUN
amwa-17	162	3	authorization	authorization	NOUN
amwa-17	162	4	for	for	ADP
amwa-17	162	5	vaccines	vaccine	NOUN
amwa-17	162	6	to	to	PART
amwa-17	162	7	prevent	prevent	VERB
amwa-17	162	8	covid-19	covid-19	PROPN
amwa-17	162	9	:	:	PUNCT
amwa-17	162	10	guidance	guidance	NOUN
amwa-17	162	11	for	for	ADP
amwa-17	162	12	industry	industry	NOUN
amwa-17	162	13	.	.	PUNCT
amwa-17	163	1	us	we	PRON
amwa-17	163	2	food	food	NOUN
amwa-17	163	3	and	and	CCONJ
amwa-17	163	4	drug	drug	NOUN
amwa-17	163	5	administration	administration	NOUN
amwa-17	163	6	.	.	PUNCT
amwa-17	164	1	published	publish	VERB
amwa-17	164	2	february	february	PROPN
amwa-17	164	3	22	22	NUM
amwa-17	164	4	,	,	PUNCT
amwa-17	164	5	2021	2021	NUM
amwa-17	164	6	.	.	PUNCT
amwa-17	165	1	accessed	access	VERB
amwa-17	165	2	april	april	PROPN
amwa-17	165	3	19	19	NUM
amwa-17	165	4	,	,	PUNCT
amwa-17	165	5	2021	2021	NUM
amwa-17	165	6	.	.	PUNCT
amwa-17	166	1	https://www.fda.gov/	https://www.fda.gov/	PROPN
amwa-17	166	2	media/142749	media/142749	PROPN
amwa-17	166	3	/	/	SYM
amwa-17	166	4	download	download	NOUN
amwa-17	166	5	23	23	NUM
amwa-17	166	6	.	.	PUNCT
amwa-17	167	1	pfizer	pfizer	NOUN
amwa-17	167	2	-	-	PUNCT
amwa-17	167	3	biontech	biontech	PROPN
amwa-17	167	4	covid	covid	PROPN
amwa-17	167	5	19	19	NUM
amwa-17	167	6	vaccine	vaccine	NOUN
amwa-17	167	7	.	.	PUNCT
amwa-17	168	1	us	we	PRON
amwa-17	168	2	food	food	NOUN
amwa-17	168	3	and	and	CCONJ
amwa-17	168	4	drug	drug	PROPN
amwa-17	168	5	administration	administration	NOUN
amwa-17	168	6	.	.	PUNCT
amwa-17	169	1	published	publish	VERB
amwa-17	169	2	december	december	PROPN
amwa-17	169	3	11	11	NUM
amwa-17	169	4	,	,	PUNCT
amwa-17	169	5	2020	2020	NUM
amwa-17	169	6	.	.	PUNCT
amwa-17	170	1	accessed	access	VERB
amwa-17	170	2	january	january	PROPN
amwa-17	170	3	31	31	NUM
amwa-17	170	4	,	,	PUNCT
amwa-17	170	5	2021	2021	NUM
amwa-17	170	6	.	.	PUNCT
amwa-17	171	1	https://www	https://www	PROPN
amwa-17	171	2	.	.	PROPN
amwa-17	171	3	fda.gov/emergency-preparedness-and-response/coronavirus-disease2019-covid-19/pfizer-biontech-covid-19-vaccine	fda.gov/emergency-preparedness-and-response/coronavirus-disease2019-covid-19/pfizer-biontech-covid-19-vaccine	PROPN
amwa-17	171	4	24	24	NUM
amwa-17	171	5	.	.	PUNCT
amwa-17	172	1	frequently	frequently	ADV
amwa-17	172	2	asked	ask	VERB
amwa-17	172	3	questions	question	NOUN
amwa-17	172	4	on	on	ADP
amwa-17	172	5	the	the	DET
amwa-17	172	6	revocation	revocation	NOUN
amwa-17	172	7	of	of	ADP
amwa-17	172	8	the	the	DET
amwa-17	172	9	emergency	emergency	NOUN
amwa-17	172	10	use	use	VERB
amwa-17	172	11	authorization	authorization	NOUN
amwa-17	172	12	for	for	ADP
amwa-17	172	13	hydroxychloroquine	hydroxychloroquine	ADJ
amwa-17	172	14	sulfate	sulfate	NOUN
amwa-17	172	15	and	and	CCONJ
amwa-17	172	16	chloroquine	chloroquine	NOUN
amwa-17	172	17	phosphate	phosphate	NOUN
amwa-17	172	18	.	.	PUNCT
amwa-17	173	1	us	we	PRON
amwa-17	173	2	food	food	NOUN
amwa-17	173	3	and	and	CCONJ
amwa-17	173	4	drug	drug	PROPN
amwa-17	173	5	administration	administration	NOUN
amwa-17	173	6	.	.	PUNCT
amwa-17	174	1	published	publish	VERB
amwa-17	174	2	june	june	PROPN
amwa-17	174	3	19	19	NUM
amwa-17	174	4	,	,	PUNCT
amwa-17	174	5	2020	2020	NUM
amwa-17	174	6	.	.	PUNCT
amwa-17	175	1	accessed	access	VERB
amwa-17	175	2	december	december	PROPN
amwa-17	175	3	6	6	NUM
amwa-17	175	4	,	,	PUNCT
amwa-17	175	5	2020	2020	NUM
amwa-17	175	6	.	.	PUNCT
amwa-17	176	1	https://www.fda.gov/media/138946/	https://www.fda.gov/media/138946/	PROPN
amwa-17	176	2	download	download	VERB
amwa-17	176	3	25	25	NUM
amwa-17	176	4	.	.	PUNCT
amwa-17	177	1	“	"	PUNCT
amwa-17	177	2	solidarity	solidarity	NOUN
amwa-17	177	3	”	"	PUNCT
amwa-17	177	4	clinical	clinical	ADJ
amwa-17	177	5	trial	trial	NOUN
amwa-17	177	6	for	for	ADP
amwa-17	177	7	covid-19	covid-19	PROPN
amwa-17	177	8	treatments	treatment	NOUN
amwa-17	177	9	.	.	PUNCT
amwa-17	178	1	world	world	NOUN
amwa-17	178	2	health	health	PROPN
amwa-17	178	3	organization	organization	PROPN
amwa-17	178	4	.	.	PUNCT
amwa-17	179	1	published	publish	VERB
amwa-17	179	2	2020	2020	NUM
amwa-17	179	3	.	.	PUNCT
amwa-17	180	1	accessed	access	VERB
amwa-17	180	2	december	december	PROPN
amwa-17	180	3	6	6	NUM
amwa-17	180	4	,	,	PUNCT
amwa-17	180	5	2020	2020	NUM
amwa-17	180	6	.	.	PUNCT
amwa-17	181	1	https://	https://	PROPN
amwa-17	181	2	www.who.int/emergencies/diseases/novel-coronavirus-2019/globalresearch-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-forcovid-19-treatments	www.who.int/emergencies/diseases/novel-coronavirus-2019/globalresearch-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-forcovid-19-treatment	VERB
amwa-17	181	3	26	26	NUM
amwa-17	181	4	.	.	PUNCT
amwa-17	182	1	clinicaltrials.gov	clinicaltrials.gov	X
amwa-17	182	2	.	.	PUNCT
amwa-17	182	3	https://www.clinicaltrials.gov	https://www.clinicaltrials.gov	PROPN
amwa-17	182	4	.	.	PUNCT
amwa-17	183	1	accessed	access	VERB
amwa-17	183	2	january	january	PROPN
amwa-17	183	3	2	2	NUM
amwa-17	183	4	,	,	PUNCT
amwa-17	183	5	2021	2021	NUM
amwa-17	183	6	.	.	PUNCT
amwa-17	184	1	27	27	NUM
amwa-17	184	2	.	.	PUNCT
amwa-17	185	1	fidler	fidler	PROPN
amwa-17	185	2	b.	b.	PROPN
amwa-17	185	3	a	a	DET
amwa-17	185	4	guide	guide	NOUN
amwa-17	185	5	to	to	ADP
amwa-17	185	6	clinical	clinical	ADJ
amwa-17	185	7	trials	trial	NOUN
amwa-17	185	8	disrupted	disrupt	VERB
amwa-17	185	9	by	by	ADP
amwa-17	185	10	the	the	DET
amwa-17	185	11	coronavirus	coronavirus	NOUN
amwa-17	185	12	pandemic	pandemic	ADJ
amwa-17	185	13	.	.	PUNCT
amwa-17	186	1	biopharma	biopharma	PROPN
amwa-17	186	2	dive	dive	PROPN
amwa-17	186	3	.	.	PUNCT
amwa-17	187	1	published	publish	VERB
amwa-17	187	2	may	may	AUX
amwa-17	187	3	15	15	NUM
amwa-17	187	4	,	,	PUNCT
amwa-17	187	5	2020	2020	NUM
amwa-17	187	6	.	.	PUNCT
amwa-17	188	1	accessed	access	VERB
amwa-17	188	2	december	december	PROPN
amwa-17	188	3	6	6	NUM
amwa-17	188	4	,	,	PUNCT
amwa-17	188	5	2020	2020	NUM
amwa-17	188	6	.	.	PUNCT
amwa-17	189	1	https://www.biopharmadive.com/news/	https://www.biopharmadive.com/news/	PUNCT
amwa-17	189	2	coronavirus	coronavirus	NOUN
amwa-17	189	3	-	-	PUNCT
amwa-17	189	4	clinical	clinical	ADJ
amwa-17	189	5	-	-	PUNCT
amwa-17	189	6	trial	trial	NOUN
amwa-17	189	7	-	-	PUNCT
amwa-17	189	8	disruption	disruption	NOUN
amwa-17	189	9	-	-	PUNCT
amwa-17	189	10	biotech	biotech	NOUN
amwa-17	189	11	-	-	PUNCT
amwa-17	189	12	pharma/574609/	pharma/574609/	PROPN
amwa-17	189	13	28	28	NUM
amwa-17	189	14	.	.	PUNCT
amwa-17	190	1	rees	rees	PROPN
amwa-17	190	2	v.	v.	CCONJ
amwa-17	190	3	impact	impact	NOUN
amwa-17	190	4	of	of	ADP
amwa-17	190	5	covid-19	covid-19	PROPN
amwa-17	190	6	on	on	ADP
amwa-17	190	7	clinical	clinical	ADJ
amwa-17	190	8	trials	trial	NOUN
amwa-17	190	9	continuing	continue	VERB
amwa-17	190	10	,	,	PUNCT
amwa-17	190	11	say	say	VERB
amwa-17	190	12	researchers	researcher	NOUN
amwa-17	190	13	.	.	PUNCT
amwa-17	191	1	european	european	ADJ
amwa-17	191	2	pharmaceutical	pharmaceutical	PROPN
amwa-17	191	3	review	review	PROPN
amwa-17	191	4	.	.	PUNCT
amwa-17	192	1	published	publish	VERB
amwa-17	192	2	september	september	PROPN
amwa-17	192	3	11	11	NUM
amwa-17	192	4	,	,	PUNCT
amwa-17	192	5	2020	2020	NUM
amwa-17	192	6	.	.	PUNCT
amwa-17	193	1	accessed	access	VERB
amwa-17	193	2	january	january	PROPN
amwa-17	193	3	2	2	NUM
amwa-17	193	4	,	,	PUNCT
amwa-17	193	5	2021	2021	NUM
amwa-17	193	6	.	.	PUNCT
amwa-17	194	1	https://www.europeanpharmaceuticalreview	https://www.europeanpharmaceuticalreview	NOUN
amwa-17	194	2	.	.	PUNCT
amwa-17	194	3	com	com	NOUN
amwa-17	194	4	/	/	SYM
amwa-17	194	5	news/128134	news/128134	PROPN
amwa-17	194	6	/	/	SYM
amwa-17	194	7	impact	impact	NOUN
amwa-17	194	8	-	-	PUNCT
amwa-17	194	9	of	of	ADP
amwa-17	194	10	-	-	PUNCT
amwa-17	194	11	covid-19	covid-19	NOUN
amwa-17	194	12	-	-	PUNCT
amwa-17	194	13	on	on	ADP
amwa-17	194	14	-	-	PUNCT
amwa-17	194	15	clinical	clinical	ADJ
amwa-17	194	16	-	-	PUNCT
amwa-17	194	17	trials	trial	NOUN
amwa-17	194	18	-	-	PUNCT
amwa-17	194	19	continuingsay	continuingsay	NOUN
amwa-17	194	20	-	-	PUNCT
amwa-17	194	21	researchers/	researchers/	NUM
amwa-17	194	22	29	29	NUM
amwa-17	194	23	.	.	PUNCT
amwa-17	195	1	van	van	PROPN
amwa-17	195	2	dorn	dorn	PROPN
amwa-17	195	3	a.	a.	PROPN
amwa-17	195	4	covid-19	covid-19	PROPN
amwa-17	195	5	and	and	CCONJ
amwa-17	195	6	readjusting	readjust	VERB
amwa-17	195	7	clinical	clinical	ADJ
amwa-17	195	8	trials	trial	NOUN
amwa-17	195	9	.	.	PUNCT
amwa-17	196	1	lancet	lancet	PROPN
amwa-17	196	2	.	.	PUNCT
amwa-17	197	1	2020;396	2020;396	NUM
amwa-17	197	2	(	(	PUNCT
amwa-17	197	3	10250):523	10250):523	NUM
amwa-17	197	4	-	-	SYM
amwa-17	197	5	524	524	NUM
amwa-17	197	6	.	.	PUNCT
amwa-17	198	1	30	30	NUM
amwa-17	198	2	.	.	PUNCT
amwa-17	199	1	asaad	asaad	PROPN
amwa-17	199	2	m	m	PROPN
amwa-17	199	3	,	,	PUNCT
amwa-17	199	4	habibullah	habibullah	PROPN
amwa-17	199	5	nk	nk	PROPN
amwa-17	199	6	,	,	PUNCT
amwa-17	199	7	butler	butler	PROPN
amwa-17	199	8	ce	ce	PROPN
amwa-17	199	9	.	.	PUNCT
amwa-17	200	1	the	the	DET
amwa-17	200	2	impact	impact	NOUN
amwa-17	200	3	of	of	ADP
amwa-17	200	4	covid-19	covid-19	PROPN
amwa-17	200	5	on	on	ADP
amwa-17	200	6	clinical	clinical	ADJ
amwa-17	200	7	trials	trial	NOUN
amwa-17	200	8	.	.	PUNCT
amwa-17	201	1	ann	ann	PROPN
amwa-17	201	2	surg	surg	PROPN
amwa-17	201	3	.	.	PUNCT
amwa-17	202	1	2020;272(3):e222	2020;272(3):e222	NUM
amwa-17	202	2	-	-	SYM
amwa-17	202	3	e223	e223	PROPN
amwa-17	202	4	.	.	PUNCT
amwa-17	203	1	31	31	NUM
amwa-17	203	2	.	.	PUNCT
amwa-17	204	1	certain	certain	ADJ
amwa-17	204	2	medical	medical	ADJ
amwa-17	204	3	conditions	condition	NOUN
amwa-17	204	4	and	and	CCONJ
amwa-17	204	5	risk	risk	NOUN
amwa-17	204	6	for	for	ADP
amwa-17	204	7	severe	severe	ADJ
amwa-17	204	8	covid-19	covid-19	PROPN
amwa-17	204	9	illness	illness	NOUN
amwa-17	204	10	.	.	PUNCT
amwa-17	205	1	centers	center	NOUN
amwa-17	205	2	for	for	ADP
amwa-17	205	3	disease	disease	NOUN
amwa-17	205	4	control	control	NOUN
amwa-17	205	5	and	and	CCONJ
amwa-17	205	6	prevention	prevention	NOUN
amwa-17	205	7	.	.	PUNCT
amwa-17	206	1	published	publish	VERB
amwa-17	206	2	december	december	PROPN
amwa-17	206	3	29	29	NUM
amwa-17	206	4	,	,	PUNCT
amwa-17	206	5	2020	2020	NUM
amwa-17	206	6	.	.	PUNCT
amwa-17	207	1	accessed	access	VERB
amwa-17	207	2	january	january	PROPN
amwa-17	207	3	2	2	NUM
amwa-17	207	4	,	,	PUNCT
amwa-17	207	5	2021	2021	NUM
amwa-17	207	6	.	.	PUNCT
amwa-17	208	1	https://www.cdc.gov/coronavirus/2019-ncov/	https://www.cdc.gov/coronavirus/2019-ncov/	PROPN
amwa-17	208	2	need	need	VERB
amwa-17	208	3	-	-	PUNCT
amwa-17	208	4	extra	extra	ADJ
amwa-17	208	5	-	-	PUNCT
amwa-17	208	6	precautions	precaution	NOUN
amwa-17	208	7	/	/	SYM
amwa-17	208	8	people	people	NOUN
amwa-17	208	9	-	-	PUNCT
amwa-17	208	10	with	with	ADP
amwa-17	208	11	-	-	PUNCT
amwa-17	208	12	medical	medical	ADJ
amwa-17	208	13	-	-	PUNCT
amwa-17	208	14	conditions.html	conditions.html	NUM
amwa-17	208	15	32	32	NUM
amwa-17	208	16	.	.	PUNCT
amwa-17	209	1	common	common	ADJ
amwa-17	209	2	questions	question	NOUN
amwa-17	209	3	about	about	ADP
amwa-17	209	4	the	the	DET
amwa-17	209	5	covid-19	covid-19	PROPN
amwa-17	209	6	outbreak	outbreak	NOUN
amwa-17	209	7	.	.	PUNCT
amwa-17	210	1	american	american	ADJ
amwa-17	210	2	cancer	cancer	NOUN
amwa-17	210	3	society	society	PROPN
amwa-17	210	4	.	.	PUNCT
amwa-17	211	1	published	publish	VERB
amwa-17	211	2	december	december	PROPN
amwa-17	211	3	21	21	NUM
amwa-17	211	4	,	,	PUNCT
amwa-17	211	5	2020	2020	NUM
amwa-17	211	6	.	.	PUNCT
amwa-17	212	1	accessed	access	VERB
amwa-17	212	2	january	january	PROPN
amwa-17	212	3	2	2	NUM
amwa-17	212	4	,	,	PUNCT
amwa-17	212	5	2021	2021	NUM
amwa-17	212	6	.	.	PUNCT
amwa-17	213	1	https://www.cancer.org/latest-news/common-questions-about-thenew-coronavirus-outbreak.html	https://www.cancer.org/latest-news/common-questions-about-thenew-coronavirus-outbreak.html	PROPN
amwa-17	213	2	33	33	NUM
amwa-17	213	3	.	.	PUNCT
amwa-17	214	1	coronavirus	coronavirus	NOUN
amwa-17	214	2	(	(	PUNCT
amwa-17	214	3	covid-19	covid-19	PROPN
amwa-17	214	4	)	)	PUNCT
amwa-17	214	5	update	update	NOUN
amwa-17	214	6	:	:	PUNCT
amwa-17	214	7	fda	fda	PROPN
amwa-17	214	8	issues	issue	NOUN
amwa-17	214	9	guidance	guidance	VERB
amwa-17	214	10	for	for	ADP
amwa-17	214	11	conducting	conduct	VERB
amwa-17	214	12	clinical	clinical	ADJ
amwa-17	214	13	trials	trial	NOUN
amwa-17	214	14	.	.	PUNCT
amwa-17	215	1	us	we	PRON
amwa-17	215	2	food	food	NOUN
amwa-17	215	3	and	and	CCONJ
amwa-17	215	4	drug	drug	PROPN
amwa-17	215	5	administration	administration	NOUN
amwa-17	215	6	.	.	PUNCT
amwa-17	216	1	published	publish	VERB
amwa-17	216	2	march	march	PROPN
amwa-17	216	3	18	18	NUM
amwa-17	216	4	,	,	PUNCT
amwa-17	216	5	2020	2020	NUM
amwa-17	216	6	.	.	PUNCT
amwa-17	217	1	accessed	access	VERB
amwa-17	217	2	december	december	PROPN
amwa-17	217	3	6	6	NUM
amwa-17	217	4	,	,	PUNCT
amwa-17	217	5	2020	2020	NUM
amwa-17	217	6	.	.	PUNCT
amwa-17	218	1	https://www.fda.gov/news-events/	https://www.fda.gov/news-events/	PROPN
amwa-17	218	2	press	press	NOUN
amwa-17	218	3	-	-	PUNCT
amwa-17	218	4	announcements	announcement	NOUN
amwa-17	218	5	/	/	SYM
amwa-17	218	6	coronavirus	coronavirus	NOUN
amwa-17	218	7	-	-	PUNCT
amwa-17	218	8	covid-19	covid-19	PROPN
amwa-17	218	9	-	-	PUNCT
amwa-17	218	10	update	update	NOUN
amwa-17	218	11	-	-	PUNCT
amwa-17	218	12	fda	fda	NOUN
amwa-17	218	13	-	-	PUNCT
amwa-17	218	14	issuesguidance	issuesguidance	NOUN
amwa-17	218	15	-	-	PUNCT
amwa-17	218	16	conducting	conducting	NOUN
amwa-17	218	17	-	-	PUNCT
amwa-17	218	18	clinical	clinical	NOUN
amwa-17	218	19	-	-	PUNCT
amwa-17	218	20	trials	trial	NOUN
amwa-17	218	21	34	34	NUM
amwa-17	218	22	.	.	PUNCT
amwa-17	219	1	covid-19	covid-19	PROPN
amwa-17	219	2	.	.	PUNCT
amwa-17	219	3	transcelerate	transcelerate	PROPN
amwa-17	219	4	biopharma	biopharma	PROPN
amwa-17	219	5	,	,	PUNCT
amwa-17	219	6	inc	inc	PROPN
amwa-17	219	7	.	.	PROPN
amwa-17	219	8	accessed	access	VERB
amwa-17	219	9	december	december	PROPN
amwa-17	219	10	13	13	NUM
amwa-17	219	11	,	,	PUNCT
amwa-17	219	12	2020	2020	NUM
amwa-17	219	13	.	.	PUNCT
amwa-17	220	1	https://www.transceleratebiopharmainc.com/covid-19/	https://www.transceleratebiopharmainc.com/covid-19/	PROPN
amwa-17	220	2	35	35	NUM
amwa-17	220	3	.	.	PUNCT
amwa-17	221	1	clinical	clinical	ADJ
amwa-17	221	2	content	content	NOUN
amwa-17	221	3	&	&	CCONJ
amwa-17	221	4	reuse	reuse	NOUN
amwa-17	221	5	solutions	solution	NOUN
amwa-17	221	6	.	.	PUNCT
amwa-17	222	1	clinical	clinical	ADJ
amwa-17	222	2	template	template	NOUN
amwa-17	222	3	suite	suite	NOUN
amwa-17	222	4	(	(	PUNCT
amwa-17	222	5	cts	cts	PROPN
amwa-17	222	6	)	)	PUNCT
amwa-17	222	7	;	;	PUNCT
amwa-17	222	8	template	template	NOUN
amwa-17	222	9	,	,	PUNCT
amwa-17	222	10	resources	resource	NOUN
amwa-17	222	11	,	,	PUNCT
amwa-17	222	12	and	and	CCONJ
amwa-17	222	13	use	use	VERB
amwa-17	222	14	guidance	guidance	NOUN
amwa-17	222	15	:	:	PUNCT
amwa-17	222	16	2020	2020	NUM
amwa-17	222	17	csr	csr	NOUN
amwa-17	222	18	updates	update	NOUN
amwa-17	222	19	.	.	PUNCT
amwa-17	223	1	csr	csr	NOUN
amwa-17	223	2	considerations	consideration	NOUN
amwa-17	223	3	for	for	ADP
amwa-17	223	4	studies	study	NOUN
amwa-17	223	5	disrupted	disrupt	VERB
amwa-17	223	6	by	by	ADP
amwa-17	223	7	the	the	DET
amwa-17	223	8	covid-19	covid-19	PROPN
amwa-17	223	9	pandemic	pandemic	NOUN
amwa-17	223	10	.	.	PUNCT
amwa-17	224	1	transcelerate	transcelerate	ADJ
amwa-17	224	2	biopharma	biopharma	PROPN
amwa-17	224	3	,	,	PUNCT
amwa-17	224	4	inc	inc	PROPN
amwa-17	224	5	.	.	PROPN
amwa-17	224	6	accessed	access	VERB
amwa-17	224	7	december	december	PROPN
amwa-17	224	8	13	13	NUM
amwa-17	224	9	,	,	PUNCT
amwa-17	224	10	2020	2020	NUM
amwa-17	224	11	.	.	PUNCT
amwa-17	225	1	https://	https://	PROPN
amwa-17	225	2	www.transceleratebiopharmainc.com/assets/clinical-content-reusesolutions/	www.transceleratebiopharmainc.com/assets/clinical-content-reusesolutions/	PROPN
amwa-17	225	3	36	36	NUM
amwa-17	225	4	.	.	PUNCT
amwa-17	226	1	assessing	assess	VERB
amwa-17	226	2	covid-19	covid-19	PROPN
amwa-17	226	3	-	-	PUNCT
amwa-17	226	4	related	relate	VERB
amwa-17	226	5	symptoms	symptom	NOUN
amwa-17	226	6	in	in	ADP
amwa-17	226	7	outpatient	outpatient	NOUN
amwa-17	226	8	adult	adult	NOUN
amwa-17	226	9	and	and	CCONJ
amwa-17	226	10	adolescent	adolescent	ADJ
amwa-17	226	11	subjects	subject	NOUN
amwa-17	226	12	in	in	ADP
amwa-17	226	13	clinical	clinical	ADJ
amwa-17	226	14	trials	trial	NOUN
amwa-17	226	15	of	of	ADP
amwa-17	226	16	drugs	drug	NOUN
amwa-17	226	17	and	and	CCONJ
amwa-17	226	18	biological	biological	ADJ
amwa-17	226	19	products	product	NOUN
amwa-17	226	20	for	for	ADP
amwa-17	226	21	covid-19	covid-19	PROPN
amwa-17	226	22	prevention	prevention	NOUN
amwa-17	226	23	or	or	CCONJ
amwa-17	226	24	treatment	treatment	NOUN
amwa-17	226	25	:	:	PUNCT
amwa-17	226	26	guidance	guidance	NOUN
amwa-17	226	27	for	for	ADP
amwa-17	226	28	industry	industry	NOUN
amwa-17	226	29	.	.	PUNCT
amwa-17	227	1	us	we	PRON
amwa-17	227	2	food	food	NOUN
amwa-17	227	3	and	and	CCONJ
amwa-17	227	4	drug	drug	PROPN
amwa-17	227	5	administration	administration	NOUN
amwa-17	227	6	.	.	PUNCT
amwa-17	228	1	published	publish	VERB
amwa-17	228	2	september	september	PROPN
amwa-17	228	3	2020	2020	NUM
amwa-17	228	4	.	.	PUNCT
amwa-17	229	1	accessed	access	VERB
amwa-17	229	2	december	december	PROPN
amwa-17	229	3	13	13	NUM
amwa-17	229	4	,	,	PUNCT
amwa-17	229	5	2020	2020	NUM
amwa-17	229	6	.	.	PUNCT
amwa-17	230	1	https://www.fda.gov/regulatory-information/searchfda-guidance-documents/assessing-covid-19-related-symptomsoutpatient-adult-and-adolescent-subjects-clinical-trials-drugs	https://www.fda.gov/regulatory-information/searchfda-guidance-documents/assessing-covid-19-related-symptomsoutpatient-adult-and-adolescent-subjects-clinical-trials-drug	NOUN
amwa-17	230	2	37	37	NUM
amwa-17	230	3	.	.	PUNCT
amwa-17	231	1	interim	interim	ADJ
amwa-17	231	2	:	:	PUNCT
amwa-17	231	3	implications	implication	NOUN
amwa-17	231	4	of	of	ADP
amwa-17	231	5	the	the	DET
amwa-17	231	6	emerging	emerge	VERB
amwa-17	231	7	sars	sar	NOUN
amwa-17	231	8	-	-	PUNCT
amwa-17	231	9	cov-2	cov-2	NOUN
amwa-17	231	10	variant	variant	ADJ
amwa-17	231	11	voc	voc	NOUN
amwa-17	231	12	202012/01	202012/01	NUM
amwa-17	231	13	.	.	PUNCT
amwa-17	232	1	centers	center	NOUN
amwa-17	232	2	for	for	ADP
amwa-17	232	3	disease	disease	NOUN
amwa-17	232	4	control	control	NOUN
amwa-17	232	5	and	and	CCONJ
amwa-17	232	6	prevention	prevention	NOUN
amwa-17	232	7	.	.	PUNCT
amwa-17	233	1	published	publish	VERB
amwa-17	233	2	https://www.the-scientist.com/bio-business/how-the-pharma-industry-pulled-off-the-pivot-to-covid-19-67719	https://www.the-scientist.com/bio-business/how-the-pharma-industry-pulled-off-the-pivot-to-covid-19-67719	X
amwa-17	233	3	https://www.the-scientist.com/bio-business/how-the-pharma-industry-pulled-off-the-pivot-to-covid-19-67719	https://www.the-scientist.com/bio-business/how-the-pharma-industry-pulled-off-the-pivot-to-covid-19-67719	PROPN
amwa-17	233	4	https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020	https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020	PROPN
amwa-17	233	5	https://www.ncbi.nlm.nih.gov/nuccore/mn908947	https://www.ncbi.nlm.nih.gov/nuccore/mn908947	PROPN
amwa-17	233	6	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasures	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasure	NOUN
amwa-17	233	7	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasures	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasure	NOUN
amwa-17	233	8	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasures	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasure	NOUN
amwa-17	233	9	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasures	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasure	NOUN
amwa-17	233	10	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasures	https://www.fda.gov/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasure	NOUN
amwa-17	233	11	https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization	https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization	NOUN
amwa-17	233	12	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authoritie	VERB
amwa-17	233	13	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities	PROPN
amwa-17	233	14	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	VERB
amwa-17	233	15	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	PROPN
amwa-17	234	1	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	PROPN
amwa-17	234	2	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	PROPN
amwa-17	234	3	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first	PROPN
amwa-17	234	4	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revise	VERB
amwa-17	234	5	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revise	VERB
amwa-17	234	6	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revise	VERB
amwa-17	234	7	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revise	VERB
amwa-17	234	8	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	PROPN
amwa-17	234	9	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	PROPN
amwa-17	234	10	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	PROPN
amwa-17	234	11	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	PROPN
amwa-17	234	12	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment	PROPN
amwa-17	234	13	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-related	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-relate	VERB
amwa-17	234	14	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-related	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-relate	VERB
amwa-17	234	15	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-related	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-relate	VERB
amwa-17	234	16	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-related	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-related	PROPN
amwa-17	234	17	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention	PROPN
amwa-17	234	18	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry	PROPN
amwa-17	234	19	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry	PROPN
amwa-17	234	20	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry	PROPN
amwa-17	234	21	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry	PROPN
amwa-17	234	22	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	PROPN
amwa-17	234	23	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	PROPN
amwa-17	234	24	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	PROPN
amwa-17	234	25	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	PROPN
amwa-17	234	26	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19	NOUN
amwa-17	234	27	https://www.fda.gov/media/142749/download	https://www.fda.gov/media/142749/download	X
amwa-17	234	28	https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine	https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine	NOUN
amwa-17	234	29	https://www.fda.gov/media/138946/download	https://www.fda.gov/media/138946/download	NUM
amwa-17	235	1	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatment	NOUN
amwa-17	235	2	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatment	NOUN
amwa-17	235	3	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatment	NOUN
amwa-17	235	4	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatment	NOUN
amwa-17	235	5	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatment	NOUN
amwa-17	235	6	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatment	NOUN
amwa-17	235	7	https://www.clinicaltrials.gov	https://www.clinicaltrials.gov	PROPN
amwa-17	235	8	https://www.biopharmadive.com/news/coronavirus-clinical-trial-disruption-biotech-pharma/574609/	https://www.biopharmadive.com/news/coronavirus-clinical-trial-disruption-biotech-pharma/574609/	PROPN
amwa-17	235	9	https://www.europeanpharmaceuticalreview.com/news/128134/impact-of-covid-19-on-clinical-trials-continuing-say-researchers/	https://www.europeanpharmaceuticalreview.com/news/128134/impact-of-covid-19-on-clinical-trials-continuing-say-researchers/	ADJ
amwa-17	235	10	https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html	https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html	PROPN
amwa-17	235	11	https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html	https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html	VERB
amwa-17	235	12	https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html	https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html	VERB
amwa-17	235	13	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-guidance-conducting-clinical-trials	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-guidance-conducting-clinical-trial	NOUN
amwa-17	235	14	https://www.transceleratebiopharmainc.com/covid-19/	https://www.transceleratebiopharmainc.com/covid-19/	ADJ
amwa-17	235	15	https://www.transceleratebiopharmainc.com/assets/clinical-content-reuse-solutions/36	https://www.transceleratebiopharmainc.com/assets/clinical-content-reuse-solutions/36	PROPN
amwa-17	235	16	https://www.transceleratebiopharmainc.com/assets/clinical-content-reuse-solutions/36	https://www.transceleratebiopharmainc.com/assets/clinical-content-reuse-solutions/36	VERB
amwa-17	235	17	https://www.transceleratebiopharmainc.com/assets/clinical-content-reuse-solutions/36	https://www.transceleratebiopharmainc.com/assets/clinical-content-reuse-solutions/36	PROPN
amwa-17	235	18	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drug	NOUN
amwa-17	235	19	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drug	NOUN
amwa-17	235	20	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drug	NOUN
amwa-17	235	21	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drug	NOUN
amwa-17	235	22	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drug	NOUN
amwa-17	235	23	amwa	amwa	PROPN
amwa-17	235	24	journal	journal	PROPN
amwa-17	235	25	/	/	SYM
amwa-17	235	26	v36	v36	PROPN
amwa-17	235	27	n2	n2	PROPN
amwa-17	235	28	/	/	SYM
amwa-17	235	29	2021	2021	NUM
amwa-17	235	30	/	/	SYM
amwa-17	235	31	amwa.org	amwa.org	X
amwa-17	235	32	71	71	NUM
amwa-17	235	33	december	december	PROPN
amwa-17	235	34	29	29	NUM
amwa-17	235	35	,	,	PUNCT
amwa-17	235	36	2020	2020	NUM
amwa-17	235	37	.	.	PUNCT
amwa-17	236	1	accessed	access	VERB
amwa-17	236	2	april	april	PROPN
amwa-17	236	3	19	19	NUM
amwa-17	236	4	,	,	PUNCT
amwa-17	236	5	2021	2021	NUM
amwa-17	236	6	.	.	PUNCT
amwa-17	237	1	https://stacks.cdc.gov/	https://stacks.cdc.gov/	PROPN
amwa-17	237	2	view	view	NOUN
amwa-17	237	3	/	/	SYM
amwa-17	237	4	cdc/99303	cdc/99303	VERB
amwa-17	237	5	38	38	NUM
amwa-17	237	6	.	.	PUNCT
amwa-17	238	1	global	global	ADJ
amwa-17	238	2	equitable	equitable	ADJ
amwa-17	238	3	access	access	NOUN
amwa-17	238	4	to	to	ADP
amwa-17	238	5	covid-19	covid-19	PROPN
amwa-17	238	6	vaccines	vaccine	NOUN
amwa-17	238	7	estimated	estimate	VERB
amwa-17	238	8	to	to	PART
amwa-17	238	9	generate	generate	VERB
amwa-17	238	10	economic	economic	ADJ
amwa-17	238	11	benefits	benefit	NOUN
amwa-17	238	12	of	of	ADP
amwa-17	238	13	at	at	ADV
amwa-17	238	14	least	least	ADV
amwa-17	238	15	us$	us$	SYM
amwa-17	238	16	153	153	NUM
amwa-17	238	17	billion	billion	NUM
amwa-17	238	18	in	in	ADP
amwa-17	238	19	2020–21	2020–21	NUM
amwa-17	238	20	,	,	PUNCT
amwa-17	238	21	and	and	CCONJ
amwa-17	238	22	us$	us$	SYM
amwa-17	238	23	466	466	NUM
amwa-17	238	24	billion	billion	NUM
amwa-17	238	25	by	by	ADP
amwa-17	238	26	2025	2025	NUM
amwa-17	238	27	,	,	PUNCT
amwa-17	238	28	in	in	ADP
amwa-17	238	29	10	10	NUM
amwa-17	238	30	major	major	ADJ
amwa-17	238	31	economies	economy	NOUN
amwa-17	238	32	,	,	PUNCT
amwa-17	238	33	according	accord	VERB
amwa-17	238	34	to	to	ADP
amwa-17	238	35	new	new	ADJ
amwa-17	238	36	report	report	NOUN
amwa-17	238	37	by	by	ADP
amwa-17	238	38	the	the	DET
amwa-17	238	39	eurasia	eurasia	PROPN
amwa-17	238	40	group	group	PROPN
amwa-17	238	41	.	.	PUNCT
amwa-17	239	1	world	world	PROPN
amwa-17	239	2	health	health	PROPN
amwa-17	239	3	organization	organization	PROPN
amwa-17	239	4	.	.	PUNCT
amwa-17	240	1	published	publish	VERB
amwa-17	240	2	december	december	PROPN
amwa-17	240	3	3	3	NUM
amwa-17	240	4	,	,	PUNCT
amwa-17	240	5	2020	2020	NUM
amwa-17	240	6	.	.	PUNCT
amwa-17	241	1	accessed	access	VERB
amwa-17	241	2	december	december	PROPN
amwa-17	241	3	6	6	NUM
amwa-17	241	4	,	,	PUNCT
amwa-17	241	5	2020	2020	NUM
amwa-17	241	6	.	.	PUNCT
amwa-17	242	1	https://www.who.int/news/item/0312-2020-global-access-to-covid-19-vaccines-estimated-to-generateeconomic-benefits-of-at-least-153-billion-in-2020-21	https://www.who.int/news/item/0312-2020-global-access-to-covid-19-vaccines-estimated-to-generateeconomic-benefits-of-at-least-153-billion-in-2020-21	PROPN
amwa-17	242	2	39	39	NUM
amwa-17	242	3	.	.	PUNCT
amwa-17	243	1	who	who	PRON
amwa-17	243	2	issues	issue	VERB
amwa-17	243	3	its	its	PRON
amwa-17	243	4	first	first	ADJ
amwa-17	243	5	emergency	emergency	NOUN
amwa-17	243	6	use	use	VERB
amwa-17	243	7	validation	validation	NOUN
amwa-17	243	8	for	for	ADP
amwa-17	243	9	a	a	DET
amwa-17	243	10	covid-19	covid-19	PROPN
amwa-17	243	11	vaccine	vaccine	NOUN
amwa-17	243	12	and	and	CCONJ
amwa-17	243	13	emphasizes	emphasize	VERB
amwa-17	243	14	need	need	NOUN
amwa-17	243	15	for	for	ADP
amwa-17	243	16	equitable	equitable	ADJ
amwa-17	243	17	global	global	ADJ
amwa-17	243	18	access	access	NOUN
amwa-17	243	19	.	.	PUNCT
amwa-17	244	1	world	world	NOUN
amwa-17	244	2	health	health	PROPN
amwa-17	244	3	organization	organization	PROPN
amwa-17	244	4	.	.	PUNCT
amwa-17	245	1	published	publish	VERB
amwa-17	245	2	december	december	PROPN
amwa-17	245	3	31	31	NUM
amwa-17	245	4	,	,	PUNCT
amwa-17	245	5	2020	2020	NUM
amwa-17	245	6	.	.	PUNCT
amwa-17	246	1	accessed	access	VERB
amwa-17	246	2	january	january	PROPN
amwa-17	246	3	2	2	NUM
amwa-17	246	4	,	,	PUNCT
amwa-17	246	5	2021	2021	NUM
amwa-17	246	6	.	.	PUNCT
amwa-17	247	1	https://www.who.int/news/item/31-12-2020-who-issues-its-firstemergency-use-validation-for-a-covid-19-vaccine-and-emphasizesneed-for-equitable-global-access	https://www.who.int/news/item/31-12-2020-who-issues-its-firstemergency-use-validation-for-a-covid-19-vaccine-and-emphasizesneed-for-equitable-global-access	NOUN
amwa-17	247	2	40	40	NUM
amwa-17	247	3	.	.	PUNCT
amwa-17	248	1	r&d	r&d	NOUN
amwa-17	248	2	blueprint	blueprint	NOUN
amwa-17	248	3	and	and	CCONJ
amwa-17	248	4	covid-19	covid-19	PROPN
amwa-17	248	5	.	.	PUNCT
amwa-17	248	6	world	world	PROPN
amwa-17	248	7	health	health	PROPN
amwa-17	248	8	organization	organization	PROPN
amwa-17	248	9	.	.	PUNCT
amwa-17	249	1	published	publish	VERB
amwa-17	249	2	2020	2020	NUM
amwa-17	249	3	.	.	PUNCT
amwa-17	250	1	accessed	access	VERB
amwa-17	250	2	december	december	PROPN
amwa-17	250	3	13	13	NUM
amwa-17	250	4	,	,	PUNCT
amwa-17	250	5	2020	2020	NUM
amwa-17	250	6	.	.	PUNCT
amwa-17	251	1	https://www.who.int/teams/	https://www.who.int/teams/	PROPN
amwa-17	251	2	blueprint	blueprint	VERB
amwa-17	251	3	/	/	SYM
amwa-17	251	4	covid-19	covid-19	PROPN
amwa-17	251	5	41	41	NUM
amwa-17	251	6	.	.	PUNCT
amwa-17	252	1	a	a	DET
amwa-17	252	2	coordinated	coordinate	VERB
amwa-17	252	3	global	global	ADJ
amwa-17	252	4	research	research	NOUN
amwa-17	252	5	roadmap	roadmap	NOUN
amwa-17	252	6	.	.	PUNCT
amwa-17	253	1	world	world	PROPN
amwa-17	253	2	health	health	PROPN
amwa-17	253	3	organization	organization	PROPN
amwa-17	253	4	.	.	PUNCT
amwa-17	254	1	published	publish	VERB
amwa-17	254	2	march	march	PROPN
amwa-17	254	3	12	12	NUM
amwa-17	254	4	,	,	PUNCT
amwa-17	254	5	2020	2020	NUM
amwa-17	254	6	.	.	PUNCT
amwa-17	255	1	accessed	access	VERB
amwa-17	255	2	december	december	PROPN
amwa-17	255	3	13	13	NUM
amwa-17	255	4	,	,	PUNCT
amwa-17	255	5	2020	2020	NUM
amwa-17	255	6	.	.	PUNCT
amwa-17	256	1	https://www	https://www	PROPN
amwa-17	256	2	.	.	PUNCT
amwa-17	256	3	who.int/publications/m/item/a-coordinated-global-research-roadmap	who.int/publications/m/item/a-coordinated-global-research-roadmap	NOUN
amwa-17	256	4	42	42	NUM
amwa-17	256	5	.	.	PUNCT
amwa-17	257	1	coronavirus	coronavirus	NOUN
amwa-17	257	2	disease	disease	NOUN
amwa-17	257	3	(	(	PUNCT
amwa-17	257	4	covid-19	covid-19	PROPN
amwa-17	257	5	)	)	PUNCT
amwa-17	257	6	technical	technical	ADJ
amwa-17	257	7	guidance	guidance	NOUN
amwa-17	257	8	:	:	PUNCT
amwa-17	257	9	the	the	DET
amwa-17	257	10	unity	unity	NOUN
amwa-17	257	11	studies	study	NOUN
amwa-17	257	12	:	:	PUNCT
amwa-17	257	13	early	early	ADJ
amwa-17	257	14	investigation	investigation	NOUN
amwa-17	257	15	protocols	protocol	NOUN
amwa-17	257	16	.	.	PUNCT
amwa-17	258	1	world	world	NOUN
amwa-17	258	2	health	health	PROPN
amwa-17	258	3	organization	organization	PROPN
amwa-17	258	4	.	.	PUNCT
amwa-17	259	1	published	publish	VERB
amwa-17	259	2	2020	2020	NUM
amwa-17	259	3	.	.	PUNCT
amwa-17	260	1	accessed	access	VERB
amwa-17	260	2	december	december	PROPN
amwa-17	260	3	13	13	NUM
amwa-17	260	4	,	,	PUNCT
amwa-17	260	5	2020	2020	NUM
amwa-17	260	6	.	.	PUNCT
amwa-17	261	1	https://www.who.int/	https://www.who.int/	NOUN
amwa-17	261	2	emergencies	emergency	NOUN
amwa-17	261	3	/	/	SYM
amwa-17	261	4	diseases	disease	NOUN
amwa-17	261	5	/	/	SYM
amwa-17	261	6	novel	novel	NOUN
amwa-17	261	7	-	-	PUNCT
amwa-17	261	8	coronavirus-2019	coronavirus-2019	VERB
amwa-17	261	9	/	/	SYM
amwa-17	261	10	technical	technical	NOUN
amwa-17	261	11	-	-	PUNCT
amwa-17	261	12	guidance/	guidance/	VERB
amwa-17	261	13	early	early	ADJ
amwa-17	261	14	-	-	PUNCT
amwa-17	261	15	investigations	investigation	NOUN
amwa-17	261	16	43	43	NUM
amwa-17	261	17	.	.	PUNCT
amwa-17	262	1	fact	fact	NOUN
amwa-17	262	2	sheet	sheet	NOUN
amwa-17	262	3	:	:	PUNCT
amwa-17	262	4	explaining	explain	VERB
amwa-17	262	5	operation	operation	NOUN
amwa-17	262	6	warp	warp	NOUN
amwa-17	262	7	speed	speed	NOUN
amwa-17	262	8	.	.	PUNCT
amwa-17	263	1	us	us	PROPN
amwa-17	263	2	department	department	PROPN
amwa-17	263	3	of	of	ADP
amwa-17	263	4	health	health	PROPN
amwa-17	263	5	and	and	CCONJ
amwa-17	263	6	human	human	ADJ
amwa-17	263	7	services	service	NOUN
amwa-17	263	8	.	.	PUNCT
amwa-17	264	1	published	publish	VERB
amwa-17	264	2	november	november	PROPN
amwa-17	264	3	30	30	NUM
amwa-17	264	4	,	,	PUNCT
amwa-17	264	5	2020	2020	NUM
amwa-17	264	6	.	.	PUNCT
amwa-17	265	1	accessed	access	VERB
amwa-17	265	2	december	december	PROPN
amwa-17	265	3	6	6	NUM
amwa-17	265	4	,	,	PUNCT
amwa-17	265	5	2020	2020	NUM
amwa-17	265	6	.	.	PUNCT
amwa-17	266	1	https://health.mo.gov/living/healthcondiseases/	https://health.mo.gov/living/healthcondiseases/	PROPN
amwa-17	266	2	communicable	communicable	NOUN
amwa-17	266	3	/	/	SYM
amwa-17	266	4	novel	novel	NOUN
amwa-17	266	5	-	-	PUNCT
amwa-17	266	6	coronavirus	coronavirus	NOUN
amwa-17	266	7	-	-	PUNCT
amwa-17	266	8	lpha	lpha	NOUN
amwa-17	266	9	/	/	SYM
amwa-17	266	10	pdf	pdf	NOUN
amwa-17	266	11	/	/	SYM
amwa-17	266	12	fact	fact	NOUN
amwa-17	266	13	-	-	PUNCT
amwa-17	266	14	sheet	sheet	NOUN
amwa-17	266	15	-	-	PUNCT
amwa-17	266	16	operationwarp	operationwarp	NOUN
amwa-17	266	17	-	-	PUNCT
amwa-17	266	18	speed.pdf	speed.pdf	PROPN
amwa-17	266	19	44	44	NUM
amwa-17	266	20	.	.	PUNCT
amwa-17	266	21	nih	nih	PROPN
amwa-17	266	22	to	to	PART
amwa-17	266	23	launch	launch	VERB
amwa-17	266	24	public	public	ADJ
amwa-17	266	25	-	-	PUNCT
amwa-17	266	26	private	private	ADJ
amwa-17	266	27	partnership	partnership	NOUN
amwa-17	266	28	to	to	PART
amwa-17	266	29	speed	speed	VERB
amwa-17	266	30	covid-19	covid-19	PROPN
amwa-17	266	31	vaccine	vaccine	NOUN
amwa-17	266	32	and	and	CCONJ
amwa-17	266	33	treatment	treatment	NOUN
amwa-17	266	34	options	option	NOUN
amwa-17	266	35	.	.	PUNCT
amwa-17	267	1	national	national	PROPN
amwa-17	267	2	institutes	institutes	PROPN
amwa-17	267	3	of	of	ADP
amwa-17	267	4	health	health	PROPN
amwa-17	267	5	.	.	PUNCT
amwa-17	268	1	published	publish	VERB
amwa-17	268	2	april	april	PROPN
amwa-17	268	3	17	17	NUM
amwa-17	268	4	,	,	PUNCT
amwa-17	268	5	2020	2020	NUM
amwa-17	268	6	.	.	PUNCT
amwa-17	269	1	accessed	access	VERB
amwa-17	269	2	december	december	PROPN
amwa-17	269	3	6	6	NUM
amwa-17	269	4	,	,	PUNCT
amwa-17	269	5	2020	2020	NUM
amwa-17	269	6	.	.	PUNCT
amwa-17	270	1	https://www.nih.gov/news-events/	https://www.nih.gov/news-events/	PROPN
amwa-17	270	2	news	news	NOUN
amwa-17	270	3	-	-	PUNCT
amwa-17	270	4	releases	release	NOUN
amwa-17	270	5	/	/	SYM
amwa-17	270	6	nih	nih	NOUN
amwa-17	270	7	-	-	PUNCT
amwa-17	270	8	launch	launch	NOUN
amwa-17	270	9	-	-	PUNCT
amwa-17	270	10	public	public	ADJ
amwa-17	270	11	-	-	PUNCT
amwa-17	270	12	private	private	ADJ
amwa-17	270	13	-	-	PUNCT
amwa-17	270	14	partnership	partnership	NOUN
amwa-17	270	15	-	-	PUNCT
amwa-17	270	16	speed	speed	NOUN
amwa-17	270	17	-	-	PUNCT
amwa-17	270	18	covid-19vaccine	covid-19vaccine	NOUN
amwa-17	270	19	-	-	PUNCT
amwa-17	270	20	treatment	treatment	NOUN
amwa-17	270	21	-	-	PUNCT
amwa-17	270	22	options	option	NOUN
amwa-17	270	23	45	45	NUM
amwa-17	270	24	.	.	PUNCT
amwa-17	271	1	nih	nih	PROPN
amwa-17	271	2	launches	launch	VERB
amwa-17	271	3	clinical	clinical	ADJ
amwa-17	271	4	trials	trial	NOUN
amwa-17	271	5	network	network	NOUN
amwa-17	271	6	to	to	PART
amwa-17	271	7	test	test	VERB
amwa-17	271	8	covid-19	covid-19	PROPN
amwa-17	271	9	vaccines	vaccine	NOUN
amwa-17	271	10	and	and	CCONJ
amwa-17	271	11	other	other	ADJ
amwa-17	271	12	prevention	prevention	NOUN
amwa-17	271	13	tools	tool	NOUN
amwa-17	271	14	.	.	PUNCT
amwa-17	272	1	national	national	PROPN
amwa-17	272	2	institutes	institutes	PROPN
amwa-17	272	3	of	of	ADP
amwa-17	272	4	health	health	PROPN
amwa-17	272	5	.	.	PUNCT
amwa-17	273	1	published	publish	VERB
amwa-17	273	2	july	july	PROPN
amwa-17	273	3	8	8	NUM
amwa-17	273	4	,	,	PUNCT
amwa-17	273	5	2020	2020	NUM
amwa-17	273	6	.	.	PUNCT
amwa-17	274	1	accessed	access	VERB
amwa-17	274	2	december	december	PROPN
amwa-17	274	3	6	6	NUM
amwa-17	274	4	,	,	PUNCT
amwa-17	274	5	2020	2020	NUM
amwa-17	274	6	.	.	PUNCT
amwa-17	275	1	https://www.nih.gov/news-events/	https://www.nih.gov/news-events/	PROPN
amwa-17	275	2	news	news	NOUN
amwa-17	275	3	-	-	PUNCT
amwa-17	275	4	releases	release	NOUN
amwa-17	275	5	/	/	SYM
amwa-17	275	6	nih	nih	NOUN
amwa-17	275	7	-	-	PUNCT
amwa-17	275	8	launches	launch	NOUN
amwa-17	275	9	-	-	PUNCT
amwa-17	275	10	clinical	clinical	NOUN
amwa-17	275	11	-	-	PUNCT
amwa-17	275	12	trials	trial	NOUN
amwa-17	275	13	-	-	PUNCT
amwa-17	275	14	network	network	NOUN
amwa-17	275	15	-	-	PUNCT
amwa-17	275	16	test	test	NOUN
amwa-17	275	17	-	-	PUNCT
amwa-17	275	18	covid-19vaccines	covid-19vaccine	NOUN
amwa-17	275	19	-	-	PUNCT
amwa-17	275	20	other	other	ADJ
amwa-17	275	21	-	-	PUNCT
amwa-17	275	22	prevention	prevention	NOUN
amwa-17	275	23	-	-	PUNCT
amwa-17	275	24	tools	tool	NOUN
amwa-17	275	25	46	46	NUM
amwa-17	275	26	.	.	PUNCT
amwa-17	276	1	coronavirus	coronavirus	NOUN
amwa-17	276	2	treatment	treatment	NOUN
amwa-17	276	3	acceleration	acceleration	NOUN
amwa-17	276	4	program	program	NOUN
amwa-17	276	5	(	(	PUNCT
amwa-17	276	6	ctap	ctap	NOUN
amwa-17	276	7	)	)	PUNCT
amwa-17	276	8	.	.	PUNCT
amwa-17	277	1	us	we	PRON
amwa-17	277	2	food	food	NOUN
amwa-17	277	3	and	and	CCONJ
amwa-17	277	4	drug	drug	PROPN
amwa-17	277	5	administration	administration	NOUN
amwa-17	277	6	.	.	PUNCT
amwa-17	278	1	published	publish	VERB
amwa-17	278	2	november	november	PROPN
amwa-17	278	3	17	17	NUM
amwa-17	278	4	,	,	PUNCT
amwa-17	278	5	2020	2020	NUM
amwa-17	278	6	.	.	PUNCT
amwa-17	279	1	accessed	access	VERB
amwa-17	279	2	december	december	PROPN
amwa-17	279	3	6	6	NUM
amwa-17	279	4	,	,	PUNCT
amwa-17	279	5	2020	2020	NUM
amwa-17	279	6	.	.	PUNCT
amwa-17	280	1	https://www.fda.gov/drugs/coronavirus-covid-19drugs/coronavirus-treatment-acceleration-program-ctap	https://www.fda.gov/drugs/coronavirus-covid-19drugs/coronavirus-treatment-acceleration-program-ctap	PROPN
amwa-17	280	2	47	47	NUM
amwa-17	280	3	.	.	PUNCT
amwa-17	281	1	coronavirus	coronavirus	NOUN
amwa-17	281	2	disease	disease	NOUN
amwa-17	281	3	2019	2019	NUM
amwa-17	281	4	(	(	PUNCT
amwa-17	281	5	covid-19	covid-19	PROPN
amwa-17	281	6	)	)	PUNCT
amwa-17	281	7	.	.	PUNCT
amwa-17	282	1	us	us	PROPN
amwa-17	282	2	food	food	NOUN
amwa-17	282	3	and	and	CCONJ
amwa-17	282	4	drug	drug	PROPN
amwa-17	282	5	administration	administration	NOUN
amwa-17	282	6	.	.	PUNCT
amwa-17	283	1	published	publish	VERB
amwa-17	283	2	december	december	PROPN
amwa-17	283	3	11	11	NUM
amwa-17	283	4	,	,	PUNCT
amwa-17	283	5	2020	2020	NUM
amwa-17	283	6	.	.	PUNCT
amwa-17	284	1	accessed	access	VERB
amwa-17	284	2	december	december	PROPN
amwa-17	284	3	13	13	NUM
amwa-17	284	4	,	,	PUNCT
amwa-17	284	5	2020	2020	NUM
amwa-17	284	6	.	.	PUNCT
amwa-17	285	1	https://www.fda.gov/emergency-preparedness-and-response/	https://www.fda.gov/emergency-preparedness-and-response/	NOUN
amwa-17	285	2	counterterrorism	counterterrorism	NOUN
amwa-17	285	3	-	-	PUNCT
amwa-17	285	4	and	and	CCONJ
amwa-17	285	5	-	-	PUNCT
amwa-17	285	6	emerging	emerge	VERB
amwa-17	285	7	-	-	PUNCT
amwa-17	285	8	threats	threat	NOUN
amwa-17	285	9	/	/	SYM
amwa-17	285	10	coronavirus	coronavirus	NOUN
amwa-17	285	11	-	-	PUNCT
amwa-17	285	12	disease-2019covid-19	disease-2019covid-19	PROPN
amwa-17	285	13	48	48	NUM
amwa-17	285	14	.	.	PUNCT
amwa-17	285	15	manufacturing	manufacturing	NOUN
amwa-17	285	16	,	,	PUNCT
amwa-17	285	17	supply	supply	NOUN
amwa-17	285	18	chain	chain	NOUN
amwa-17	285	19	,	,	PUNCT
amwa-17	285	20	and	and	CCONJ
amwa-17	285	21	drug	drug	NOUN
amwa-17	285	22	and	and	CCONJ
amwa-17	285	23	biological	biological	ADJ
amwa-17	285	24	product	product	NOUN
amwa-17	285	25	inspections	inspection	NOUN
amwa-17	285	26	during	during	ADP
amwa-17	285	27	covid-19	covid-19	PROPN
amwa-17	285	28	public	public	ADJ
amwa-17	285	29	health	health	NOUN
amwa-17	285	30	emergency	emergency	NOUN
amwa-17	285	31	questions	question	NOUN
amwa-17	285	32	and	and	CCONJ
amwa-17	285	33	answers	answer	NOUN
amwa-17	285	34	:	:	PUNCT
amwa-17	285	35	guidance	guidance	NOUN
amwa-17	285	36	for	for	ADP
amwa-17	285	37	industry	industry	NOUN
amwa-17	285	38	.	.	PUNCT
amwa-17	286	1	us	we	PRON
amwa-17	286	2	food	food	NOUN
amwa-17	286	3	and	and	CCONJ
amwa-17	286	4	drug	drug	PROPN
amwa-17	286	5	administration	administration	NOUN
amwa-17	286	6	.	.	PUNCT
amwa-17	287	1	published	publish	VERB
amwa-17	287	2	august	august	PROPN
amwa-17	287	3	2020	2020	NUM
amwa-17	287	4	.	.	PUNCT
amwa-17	288	1	accessed	access	VERB
amwa-17	288	2	december	december	PROPN
amwa-17	288	3	13	13	NUM
amwa-17	288	4	,	,	PUNCT
amwa-17	288	5	2020	2020	NUM
amwa-17	288	6	.	.	PUNCT
amwa-17	289	1	https://www.fda	https://www.fda	PROPN
amwa-17	289	2	.	.	PUNCT
amwa-17	289	3	gov	gov	PROPN
amwa-17	289	4	/	/	SYM
amwa-17	289	5	media/141312	media/141312	PROPN
amwa-17	289	6	/	/	SYM
amwa-17	289	7	download	download	NOUN
amwa-17	289	8	49	49	NUM
amwa-17	289	9	.	.	PUNCT
amwa-17	290	1	coronavirus	coronavirus	NOUN
amwa-17	290	2	(	(	PUNCT
amwa-17	290	3	covid-19	covid-19	PROPN
amwa-17	290	4	)	)	PUNCT
amwa-17	290	5	update	update	NOUN
amwa-17	290	6	:	:	PUNCT
amwa-17	290	7	fda	fda	PROPN
amwa-17	290	8	authorizes	authorize	VERB
amwa-17	290	9	first	first	ADJ
amwa-17	290	10	diagnostic	diagnostic	ADJ
amwa-17	290	11	test	test	NOUN
amwa-17	290	12	for	for	ADP
amwa-17	290	13	screening	screening	NOUN
amwa-17	290	14	of	of	ADP
amwa-17	290	15	people	people	NOUN
amwa-17	290	16	without	without	ADP
amwa-17	290	17	known	know	VERB
amwa-17	290	18	or	or	CCONJ
amwa-17	290	19	suspected	suspect	VERB
amwa-17	290	20	covid-19	covid-19	PROPN
amwa-17	290	21	infection	infection	NOUN
amwa-17	290	22	.	.	PUNCT
amwa-17	291	1	us	we	PRON
amwa-17	291	2	food	food	NOUN
amwa-17	291	3	and	and	CCONJ
amwa-17	291	4	drug	drug	PROPN
amwa-17	291	5	administration	administration	NOUN
amwa-17	291	6	.	.	PUNCT
amwa-17	292	1	published	publish	VERB
amwa-17	292	2	july	july	PROPN
amwa-17	292	3	24	24	NUM
amwa-17	292	4	,	,	PUNCT
amwa-17	292	5	2020	2020	NUM
amwa-17	292	6	.	.	PUNCT
amwa-17	293	1	accessed	access	VERB
amwa-17	293	2	december	december	PROPN
amwa-17	293	3	13	13	NUM
amwa-17	293	4	,	,	PUNCT
amwa-17	293	5	2020	2020	NUM
amwa-17	293	6	.	.	PUNCT
amwa-17	294	1	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-authorizes-firstdiagnostic-test-screening-people-without-known-or	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-authorizes-firstdiagnostic-test-screening-people-without-known-or	PROPN
amwa-17	294	2	get	get	VERB
amwa-17	294	3	fit	fit	ADJ
amwa-17	294	4	with	with	ADP
amwa-17	294	5	amwa	amwa	PROPN
amwa-17	294	6	f	f	PROPN
amwa-17	294	7	ast	ast	NOUN
amwa-17	295	1	i	i	PRON
amwa-17	295	2	nteractive	nteractive	ADJ
amwa-17	295	3	t	t	PROPN
amwa-17	295	4	raining	rain	VERB
amwa-17	295	5	amwa	amwa	PROPN
amwa-17	295	6	’s	’s	PROPN
amwa-17	295	7	fit	fit	ADJ
amwa-17	295	8	series	series	NOUN
amwa-17	295	9	helps	help	VERB
amwa-17	295	10	medical	medical	ADJ
amwa-17	295	11	communicators	communicator	NOUN
amwa-17	295	12	stay	stay	VERB
amwa-17	295	13	healthy	healthy	ADJ
amwa-17	295	14	.	.	PUNCT
amwa-17	296	1	in	in	ADP
amwa-17	296	2	only	only	ADV
amwa-17	296	3	15	15	NUM
amwa-17	296	4	minutes	minute	NOUN
amwa-17	296	5	—	—	PUNCT
amwa-17	296	6	jog	jog	VERB
amwa-17	296	7	your	your	PRON
amwa-17	296	8	memory	memory	NOUN
amwa-17	296	9	,	,	PUNCT
amwa-17	296	10	tone	tone	NOUN
amwa-17	296	11	your	your	PRON
amwa-17	296	12	writing	writing	NOUN
amwa-17	296	13	muscles	muscle	NOUN
amwa-17	296	14	,	,	PUNCT
amwa-17	296	15	build	build	VERB
amwa-17	296	16	your	your	PRON
amwa-17	296	17	core	core	NOUN
amwa-17	296	18	skills	skill	NOUN
amwa-17	296	19	,	,	PUNCT
amwa-17	296	20	and	and	CCONJ
amwa-17	296	21	stretch	stretch	VERB
amwa-17	296	22	your	your	PRON
amwa-17	296	23	knowledge	knowledge	NOUN
amwa-17	296	24	.	.	PUNCT
amwa-17	297	1	www.amwa.org/fit	www.amwa.org/fit	NUM
amwa-17	297	2	only	only	ADV
amwa-17	297	3	$	$	SYM
amwa-17	297	4	15	15	NUM
amwa-17	297	5	each	each	PRON
amwa-17	297	6	/	/	PUNCT
amwa-17	297	7	approved	approve	VERB
amwa-17	297	8	for	for	ADP
amwa-17	297	9	.5	.5	NUM
amwa-17	297	10	ce	ce	PROPN
amwa-17	297	11	topics	topic	NOUN
amwa-17	297	12	in	in	ADP
amwa-17	297	13	the	the	DET
amwa-17	297	14	series	series	NOUN
amwa-17	297	15	include	include	VERB
amwa-17	297	16	:	:	PUNCT
amwa-17	297	17	}	}	PUNCT
amwa-17	297	18	misplaced	misplaced	ADJ
amwa-17	297	19	modifiers	modifier	NOUN
amwa-17	297	20	}	}	PUNCT
amwa-17	297	21	mean	mean	VERB
amwa-17	297	22	,	,	PUNCT
amwa-17	297	23	median	median	ADJ
amwa-17	297	24	,	,	PUNCT
amwa-17	297	25	and	and	CCONJ
amwa-17	297	26	mode	mode	NOUN
amwa-17	297	27	}	}	PUNCT
amwa-17	297	28	dangling	dangle	VERB
amwa-17	297	29	participles	participle	NOUN
amwa-17	297	30	}	}	PUNCT
amwa-17	297	31	measures	measure	NOUN
amwa-17	297	32	of	of	ADP
amwa-17	297	33	variability	variability	NOUN
amwa-17	297	34	https://stacks.cdc.gov/view/cdc/99303	https://stacks.cdc.gov/view/cdc/99303	PROPN
amwa-17	297	35	https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21	https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21	PROPN
amwa-17	297	36	https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21	https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21	PROPN
amwa-17	297	37	https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21	https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21	PROPN
amwa-17	297	38	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	PROPN
amwa-17	297	39	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	PROPN
amwa-17	297	40	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	PROPN
amwa-17	297	41	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	PROPN
amwa-17	297	42	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	PROPN
amwa-17	298	1	https://www.who.int/teams/blueprint/covid-19	https://www.who.int/teams/blueprint/covid-19	PROPN
amwa-17	298	2	https://www.who.int/publications/m/item/a-coordinated-global-research-roadmap	https://www.who.int/publications/m/item/a-coordinated-global-research-roadmap	PROPN
amwa-17	298	3	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigation	NOUN
amwa-17	298	4	https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus-lpha/pdf/fact-sheet-operation-warp-speed.pdf	https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus-lpha/pdf/fact-sheet-operation-warp-speed.pdf	PROPN
amwa-17	298	5	https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options	https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-option	NOUN
amwa-17	298	6	https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trials-network-test-covid-19-vaccines-other-prevention-tools	https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trials-network-test-covid-19-vaccines-other-prevention-tool	VERB
amwa-17	298	7	https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap	https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap	PROPN
amwa-17	298	8	https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap	https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap	PROPN
amwa-17	298	9	https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19	https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19	PROPN
amwa-17	298	10	https://www.fda.gov/media/141312/download	https://www.fda.gov/media/141312/download	NOUN
amwa-17	298	11	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-screening-people-without-known-or	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-screening-people-without-known-or	PROPN
amwa-17	298	12	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-screening-people-without-known-or	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-screening-people-without-known-or	PROPN
amwa-17	299	1	http://www.amwa.org/fit	http://www.amwa.org/fit	PROPN